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The Acquired Immune Deficiency Syndrome (AIDS) is the final stage of a 
chronic infection with the human immunodeficiency virus (HIV) 1,2. The 
natural history of HIV infection is characterized by an insidious 
deterioration of the cellular immune system. The quantity and proportion of 
plasma CD4+ T-cells decrease steadily over a period of years to decades, and 
this progressive loss of CD4+ T-cells is associated with the development of 
AIDS in infected individuals 3-8. There are currently 40 million people 
living with AIDS worldwide and it is estimated that 68 million will die of 
AIDS by 2020 9. In the absence of an effective vaccine against HIV, a 
worldwide search has been made in the past two decades to develop small-
molecule inhibitors to target essential steps in the viral cycle 10. 
Highly Active Antiretroviral therapy (HAART) is one of the most used 
treatment regimen in our days. The regimen employs a combination of 
therapeutic agents that target the viral reverse transcriptase (RT) and 
protease enzymes (PR) 10-12. In the developed world, access to HAART has 
led to significant reductions in the morbidity and mortality attributed to 
HIV/AIDS. However, the emergence of drug-resistant virus isolates is 
causing an increasingly detrimental impact on treatment options and the 
disease outcome 13-15. As a result, there is a urgent need to identify and 
develop new drugs that can be effective against these highly resistant virus 
isolates. Ideally, these new drugs should target steps in the HIV-1 
replication cycle that are not blocked by the antiretroviral drugs currently in 
widespread use 10.  
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Integrase (IN), a third enzyme encoded in HIV-1, is currently the focus of 
an intense research effort to develop new anti-HIV-1 drugs 16-18. This 
enzyme catalyses the integration of HIV genome into the chromosome of 
the host cell, arguably the most insidious step in the infection process 19.  
Another HIV-1 protein that seems to be a potential target for HIV treatment 
is Vif 20,21. This protein overcomes the innate antiviral activity of a cytidine 
deaminase APOBEC3G that induces G to A hypermutation in the viral 
genome, resulting in enhancement of viral replication infectivity 22,23. 
In addition for developing new drugs that are effective against HIV-1, gene 
therapy has been highly regarded as a new form of molecular medicine in 
treatment of HIV/AIDS, either as an alternative or as a supplement to anti-
retroviral chemotherapy 24-26. Within this context, intracellular antibodies 
(intrabodies) represent a new class of neutralizing molecules with potential 
use in gene therapy approaches 27-29. An intrabody consists of an antibody 
designed to be expressed intracellularly and directed to different subcellular 
compartments where they can exert their function more effectively 30. The 
binding of an intrabody to an intracellular target protein has the potential to 
block, suppress, alter or even enhance the process mediated by that        
molecule 31-33. The strong inhibiting potential of intracellular antibodies in 
the context of HIV gene therapy will be the focus of this dissertation thesis.  
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The thesis will be divided in 5 Chapters: 
Chapter 1 will present a general introduction to HIV-1 virus biology and 
HIV/AIDS treatment. This part of the thesis will be used to describe in more 
detail the intracellular immunization (intrabodies) approach. In the end, 
HIV-1 IN protein will be presented as a potential target for HIV-1 
inhibition. A brief description of Vif protein as a candidate for antiviral 
therapy will be also presented is this last section.  
Chapter 2 will describe the selection and characterization of 5 rabbit anti-
IN single-chain antibody fragments (scFv) that present high binding activity 
and specificity against HIV-1 IN protein. Results will be presented showing 
that scFv intrabodies can be efficiently designed to block integrase function 
and consequently inhibit early and late stages of HIV-1 replication. 
Chapter 3 will present a study to show that rabbit VL single-domain can 
also be use as intrabodies. The VL single-domain analysed here was derived 
from an anti-Vif scFv that was recently developed from immunized rabbits 
to HIV-1 Vif protein.  
Chapter 4 presents a study to generate lentiviral-derived particles with 
specificity of gene delivery for CCR5-expressing cells. To achieved this 
aim, we developed a novel Sindbis pseudotyped lentiviral vector where the 
Sindbis receptor binding envelope protein was modified to directly encode a 
scFv against the CCR5 chemokine receptor.  
Chapter 5 will present a general conclusion. 
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Abstract 
The spread of HIV-1 has been dramatic since the early eighties, when the 
virus was discovered as the causative agent of AIDS. In the absence of an 
effective vaccine against HIV, a worldwide search has been made in the past 
two decades to develop small-molecule inhibitors to target essential steps in 
the viral cycle. Over the recent years, gene therapy has been highly regarded 
as a new form of molecular medicine in treatment of HIV/AIDS, either as 
an alternative or as a complement to anti-retroviral chemotherapy. An 
intrabody consists of an antibody designed to be expressed intracellularly 
and directed to different subcellular compartments where they can exert 
their function more effectively. The binding of an intrabody to its molecular 
target has the potential to block, suppress, alter or even enhance the process 
mediated by that molecule. Within this context, intracellular antibodies 
(intrabodies) represent a new class of neutralizing molecules with potential 
use in gene therapy approaches. 
 
The HIV-1 integrase (IN) protein is currently the focus of an intense 
research effort to develop new anti-HIV-1 drugs. This enzyme catalyses the 
integration of HIV genome into the chromosome of the host cell, arguably 
the most insidious step in the infection process. In the first project of this 
thesis (Chapter 2), we explored the intracellular immunization approach by 
developing rabbit intrabodies against the HIV-1 IN protein. We immunized 
rabbits with HIV-1 IN and developed a combinatorial scFv library against 
IN. We were able to identify 5 different scFv’s antibodies with high binding 
activity and specificity to IN. These scFv´s bound simultaneously to the 
 xxii 
 
catalytic and C-terminus domains of IN. In addition, these antibodies have 
the ability to inhibit the strand transfer processing. Intrabody-expressing 
cells, either in their cytoplasm or nuclear compartments, were highly 
resistant to HIV-1 infection. Importantly, when HIV-1 particles where 
produced in the presence of anti-IN scFv, the expression of intrabodies did 
not affect virion production significantly. However, it markedly reduced the 
infectivity of progeny virions due to the incorporation of anti-IN scFv into 
the viral particles. These findings provide proof-in-principle that rabbit anti-
IN intrabodies can be designed to block early and late stages of HIV-1 
replication. As a result, our intrabodies might be useful agents for 
"intracellular immunization"- and used as new tools to study the structure 
and function of HIV-1 IN due to their epitope binding characteristics. 
Another potential target for HIV-1 treatment is Vif. This viral protein 
overcomes the innate antiviral activity of a cytidine deaminase APOBEC3G 
that induces G to A hypermutation in the viral genome, resulting in 
enhancement of viral replication infectivity. We previously demonstrated 
that anti-Vif scFv and camelized VH intrabodies are an effective approach 
to inhibit this crucial step of the viral replication cycle. In the second project 
of this thesis (Chapter 3), we showed that the rabbit VL domain can also be 
very potentially used as an intrabody. Our results demonstrate that the anti-
Vif VL single-domain preserve the antigen-binding activity and specificity 
in the absence of the parent VH domain. In addition, the VL single-domain 
was highly expressed in microbial cell culture and show favourable 
biophysical properties. The expression of the VL intrabody in eukaryotic 
cells also showed that the rabbit VL was correctly folded as soluble protein 
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in the reducing environment and could strongly neutralize HIV-1 infectivity. 
Therefore, the present study suggests that rabbit VL single-domains have 
also an enormous value as intracellular antigen recognition units.  
Lentiviral vectors are among the most efficient tools for gene delivery into 
mammalian cells. A major goal of lentiviral gene delivery systems is to 
develop vectors that can efficiently target specific cell types. In the last 
project of this thesis (Chapter 4), we attempted to generate viral particles for 
targeting gene delivery. To achieve this goal we have used CCR5-positive 
cells as the target for our strategy. We designed a novel Sindbis 
pseudotyped vector where the Sindbis E2 receptor binding envelope protein 
was modified to directly encode a scFv against the CCR5 chemokine 
receptor. Targeting into specific cells was mediated by the anti-CCR5 scFv 
display, and viral titers were close to 106 EGFP transduction units/ml. Our 
data demonstrate that the length of the peptide linker that connects the 
heavy chain and light chain of anti-CCR5 scFv significantly affects the 
efficiency of infection. Infection levels obtained with Sindbis envelope 
displaying a scFv with a longer linker was consistently higher than that with 
Sindbis envelope displaying a scFv with a short linker. The results presented 
show that chimeric scFv-Sindbis pseudotyped lentiviral vectors have the 
potential to become an efficient and broadly applicable approach for 
targeting gene delivery to specific cells. Furthermore, this strategy has the 
potential to become a powerful approach for targeting gene delivery in anti-
HIV gene therapy due to the important role of CCR5 expression in disease 
progression.         
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Resumo 
O Síndrome da Imunodeficiência Adquirida (SIDA) representa hoje um dos 
principais problemas de Saúde Pública a nível mundial. Os agentes 
etiológicos responsáveis pela SIDA são os Vírus da Imunodeficiência 
Humana tipo-1 e tipo-2 (VIH-1 e VIH-2), ambos retrovírus pertencentes à 
família dos lentivírus. Segundo dados da Organização Mundial de Saúde 
(OMS), estima-se que cerca de 40 milhões de pessoas se encontrem 
infectadas com o VIH e que aproximadamente 20 milhões já morreram 
devido à doença, originando um número, com tendência crescente, de 68 
milhões de pessoas até 2020. As drogas disponíveis actualmente como 
fármacos anti-VIH actuam na inibição de duas proteínas virais – a 
transcriptase reversa (RT) e a protease (PR). A aplicação de combinações 
destes agentes antiretrovirais (HAART) mudou dramaticamente o decorrer 
da infecção em muitos indivíduos infectados, levando a um declínio 
substancial na incidência da SIDA e da mortalidade associada nos países 
desenvolvidos. No entanto, um dos principais problemas relacionados com a 
aplicação deste tipo de terapia é o desenvolvimento de resistências virais aos 
fármacos utilizados. Este aspecto da resistência viral é muito importante na 
medida em que a susceptibilidade às drogas diminui, reduzindo, 
progressivamente, a eficácia das combinações terapêuticas usadas. A 
percentagem de novos indivíduos infectados com o VIH, que possuem vírus 
resistentes a pelo menos uma medicação antiretroviral tem vindo a 
aumentar. Deste modo, a irradicação total do VIH parece impossível com as 
actuais estratégias terapêuticas. Novas terapias e outros alvos mais 
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promissores precisam surgir rapidamente, com o objectivo de combater as 
formas mais resistentes do VIH que já circulam pelo mundo.  
A terapia génica é uma nova estratégia de medicina molecular com enormes 
potencialidades na terapêutica de doenças infecciosas e cancerígenas. Esta 
forma de terapia pode ser complementar e adicionar eficácia à terapêutica 
farmacológica. A terapia génica apresenta-se de enorme importância no 
tratamento ao VIH e SIDA, captando nos últimos anos o interesse de muitos 
investigadores e empresas biotecnológicas. Neste contexto, os anticorpos 
intracelulares (intrabodies) representam uma nova classe de moléculas 
neutralizantes com um enorme potencial na terapia génica. Os anticorpos 
intracelulares consistem normalmente em fragmentos Fv de cadeia única 
(scFv) que têm como objectivo serem expressos dentro de células 
eucariontes. Estes anticorpos são desenvolvidos a partir de bibliotecas de 
genes de anticorpos contra determinado antigénio. Como tal, ao serem 
expressos apresentam a capacidade de neutralizar determinada proteína 
intracelular e/ou interferir com interacções proteína-proteína.  
 
A proteína integrase (IN) do VIH-1 é actualmente considerada um alvo de 
enorme interesse na pesquisa de novas moléculas terapêuticas na inibição da 
replicação do VIH-1. A IN é responsável por uma das etapas mais críticas e 
importantes da replicação do VIH-1 – a integração do genoma do VIH no 
genoma da célula hospedeira. Neste contexto, o primeiro projecto desta 
dissertação de Doutoramento (Capítulo 2), teve como objectivo explorar a 
imunização intracelular através da construção de anticorpos intracelulares 
contra a IN do VIH-1. Para tal, imunizaram-se dois coelhos com IN e 
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construísse uma biblioteca combinatória de scFvs. A partir desta biblioteca 
identificaram-se 5 scFv diferentes com uma elevada capacidade de 
reconhecimento e especificidade contra a IN. Estes scFv interagem 
simultaneamente com o domínio catalítico e C-terminal da IN e 
demonstraram ter a capacidade de inibir a reacção de strand transfer da IN 
in vitro. Os resultados apresentados demonstraram ainda que células que 
expressem intracelularmente scFv anti-IN localizados no citoplasma ou 
núcleo, têm a capacidade de ser resistentes à infecção pelo VHI-1. Os 
resultados obtidos permitiram ainda verificar que quando partículas VIH-1 
são produzidas na presença de anti-IN scFv, a expressão dos intrabodies não 
afecta a produção do virião. No entanto, a sua infeciosidade diminui 
drasticamente devido à incorporação dos scFv na partícula viral. Estes 
resultados sugerem assim que os scFv anti-IN têm a capacidade de inibir a 
replicação viral do VIH-1 durante a sua fase inicial e tardia. O presente 
estudo sugere assim que estes intrabodies anti-IN poderão ser moléculas 
bastantes promissoras a nível da terapia génica do VIH. Por outro lado, estes 
scFv poderão ainda ser usados como novas ferramentas para estudar a 
estrutura e função da proteína IN do VIH-1.   
Uma outra proteína do VIH-1 que é considerada um excelente alvo 
terapêutico na inibição da replicação do VIH-1 é o Vif (Factor de 
Infecciosidade Viral). O Vif é uma proteína acessória do VIH cuja função 
principal é bloquear a acção do Apobec3G, uma citidina deaminase que tem 
a capacidade de tornar o VIH-1 não infeccioso através da indução de 
hipermutações G para A durante a síntese do ADN viral. Recentemente 
demonstramos que intrabodies anti-Vif derivados de coelho e no formato 
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scFv ou VH camelizados são uma estratégia bastante eficaz na neutralização 
da proteína Vif e inibição da replicação do VIH-1. O segundo projecto desta 
dissertação (Capítulo 3), teve como objectivo demonstrar que o domínio VL 
anti-Vif pode também ser uma molécula eficaz como anticorpo intracelular. 
Os resultados obtidos permitiram demonstrar que na ausência do domínio 
parental VH, o VL apresentou do mesmo modo um reconhecimento 
específico da proteína Vif. O domínio VL apresentou ainda altos níveis de 
expressão em E. coli e demonstrou ter propriedades biofísicas óptimas, 
nomeadamente solubilidades e estabilidades elevadas. Os resultados de 
expressão em células animais permitiram verificar que o domínio VL anti-
Vif apresentou um folding correcto no ambiente redutor do citoplasma o que 
lhe permitiu deste modo inibir eficientemente a infeciosidade do HIV-1. O 
presente estudo sugere assim que domínios VL derivados de coelho poderão 
vir a ser uma abordagem bastante promissora para o desenvolvimento 
anticorpos intracelulares cada vez mais pequenos e robustos para futuras 
aplicações a nível da terapia génica.   
 
Actualmente os vectores lentivirais são um dos vectores mais utilizados na 
inserção de genes em células eucariontes. Um dos grandes obstáculos destes 
vectores é não permitir um direcionamento específico para células alvo. O 
último projecto desta dissertação (Capitulo 4), teve por objectivo a 
construção de partículas lentivirais que permitam um direcionamento 
específico para células CCR5+. Para tal, construímos um vector quimérico 
Sindbis/lentiviral onde foi inserido um scFv anti-CCR5 na região da 
proteína E2 do envelope do vírus Sindbis. Os resultados obtidos 
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demonstraram que o direcionamento obtido pelas partículas quiméricas foi 
mediado pelo scFv anti-CCR5 e que a sua transdução permitiu obter títulos 
de 106 EGFP TU/ml. O tamanho do linker que liga o domínio VH com o 
domínio VL demonstrou influenciar a eficiência de transdução. Estes níveis 
demonstraram ser superiores nas partículas que apresentam um scFv com 
linker grande. Os resultados obtidos permitiram assim demonstrar que este 
tipo de partículas quiméricas poderão tornar-se numa estratégia bastante 
promissora para desenvolver vectores lentivirais que permitam um 
direcionamento específico para células alvo. Por outro lado, a estratégia 
desenvolvida neste estudo poderá ainda ser bastante promissora para 
proceder à inserção de genes anti-VIH em células alvo no âmbito da terapia 
génica do VIH-1 devido ao papel importante da expressão CCR5 na 
progressão da doença. 
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1.0 Human Immunodeficiency Virus 
Great progress has been made with respect to our understanding of the
immunopathogenesis of AIDS and the infectious agent, HIV, which causes the
disease 1,2. The natural history of HIV infection is characterized by an 
insidious deterioration of the cellular immune system. The quantity and
proportion of plasma CD4+ T-cells decreases steadily over a period of years to 
decades, and this progressive loss of CD4+ T-cells is associated with the 
development of AIDS in infected individuals 3-6. There are two types of human 
immunodeficiency virus: HIV-1 and HIV-2 1,2,7. Both virus are associated with 
the same mode of transmission and cause similar opportunistic infections and
AIDS. However, HIV-2 often is less infectious early in the course of infection
and, compared to HIV-1, the duration of increased infectiousness is shorter 7. 
In addition, while HIV-2 is prevalent in West Africa and some countries in
Western Europe, HIV-1 is prevalent worldwide 7,8.  
1.1 HIV Structure and Genome 
HIV is a member of the genus Lentivirus, part of the family of Retroviridae. 
HIV genome is encoded by RNA, which is reverse-transcribed to viral DNA 
by the viral RT upon entering a new host cell 34. The general features of the 
mature HIV virion and the structurally characterized viral proteins are shown
in Figure 1.1.  
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Figure 1.1 - Schematic diagram of the HIV-1 virion particle and genome (adapted from 35). 
 
All lentiviruses are enveloped by a lipid bilayer that is derived from the 
membrane of the host cell. Exposed surface glycoproteins (SU,gp120) are 
anchored to the virus via interactions with the transmembrane protein (TM,
gp41) 35. The lipid bilayer also contains several cellular membrane proteins
derived from the host cell, including major histocompatibility antigens, actin
and ubiquitin 36. A matrix shell comprising approximately 2000 copies of the
matrix protein (MA, p17) lines the inner surface of the viral membrane, and a
conical capsid core particle comprising about 2000 copies of the capsid protein 
(CA, p24) is located in the center of the virus 34,35. The capsid particle 
encapsidates two copies of the unspliced viral genome, which is stabilized as a 
ribonucleoprotein complex with about 2000 copies of the nucleocapsid protein 
(NC, p7), and also contains three essential virally encoded enzymes: protease, 
reverse transcriptase and integrase. Virus particles also package the accessory 
proteins, Nef, Vif and Vpr. Three additional accessory proteins that function in
the host cell, Rev, Tat and Vpu, do not seem to be packaged 34,35. 
                                                                                                               Introduction 
 
 
5 
 
The HIV-1 genome is encoded by a two single-stranded RNA molecule 
approximately 9 kb (9,000 nucleotide bases) in length, and contains 9 open
reading frames (ORFs) 34. The ends of each strand of HIV RNA contain an 
RNA sequence called the long terminal repeat (LTR). Regions in the LTR act 
as “switches” to control production of new viruses and can be triggered by 
proteins from either HIV or the host cell. The largest three reading frames 
transcribe the Gag, Pol, and Env polyproteins, which are proteolytically
processed into proteins common to all members of the retrovirus family 34,35. 
Gag is processed into matrix (MA), capsid (CA), nucleocapsid (NC), and p6 -
proteins that make up the inner core of the viral particle. Derived from the Env
polyprotein, gp120 (surface, SU) and gp41 (transmembrane, TM) make up the
virus’s outer membrane proteins 35. The polyprotein Pol encodes all three viral 
enzymes – PR, RT and PR – which are translated together as a precursor and 
subsequently cleaved by the action of the HIV-1 PR. The six remaining genes, 
tat, rev, vif, vpu, vpr, and nef are regulatory genes for proteins that control the 
ability of HIV to infect cells, produce new copies of virus (replicate), or cause
disease 35. Tat and Rev regulate viral gene transcription and are essential for
HIV replication 37-40. The Vif protein overcomes the innate antiviral activity of
a cytidine deaminase APOBEC3G (CEM15) that induces G to A
hypermutation in the viral genome, resulting in enhancement of viral
replication infectivity 20-23. Vpu intervenes in the assembly process41 and Vpr 
in the nuclear transport of the viral genome 42,43. Nef might have multiple
functions, including acceleration of clinical disease, enhancement of virion
infectivity, downregulation of surface CD4 receptor and major 
histocompatibility class I molecules (MHC), modulation of signal 
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transduction, and the favoring of HIV entry into target cells by the CD4 and
chemokine-dependent route 44. 
 
1.2 HIV Tropism 
 
HIV enters T-lymphocytes and monocytes through cognate binding of the viral 
glycoprotein gp120 with the cell surface CD4 molecule and a chemokine 
receptor 45-48. Although a number of chemokine receptors have been associated
with viral entry in vitro, CCR5 and CXCR4 appear to be the most relevant
coreceptors used in vivo 48-50. The interaction of these proteins induces the 
binding of the viral gp41 to heparan sulfate on the host plasma membrane;
trigering the fusion of the viral envelope and the release of the capsid into the 
cytoplasm 34,51. On the basis of cell tropism, HIV strains can be broadly 
divided into 2 categories, macrophage-tropic (M-tropic) and T-cell tropic (T-
tropic) 48. M-tropic strains use CCR5 as a coreceptor and are referred as R5
viruses. They primarily infect macrophages and primary T-cells and infect 
poorly CD4+ T-cell lines 52. T-tropic strains use the CXCR4 coreceptor, which 
is most expressed in CD4+ T cells. Also referred as X4 viruses, they induce the 
formation of syncytia in the infected cells 53,54. Early in the course of HIV 
infection, the R5 strain viruses predominate, but eventually both X4 and R5 
strains are recovered 54,55,56.  
 
1.3 HIV-1 Replication Cycle 
 
The defining characteristic of retroviruses is their ability to generate a double-
stranded DNA copy of their double single-stranded RNA genome, the 
provirus, through the action of the viral RT 57,58. The provirus is subsequently 
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integrated into the host chromosome through the action of the viral IN 16-18. 
From this point on, proviral DNA is part of the host cell and cannot be
eliminated unless the cell dies. A unique feature of lentiviruses is their ability
to infect and integrate not just in actively dividing cells, but also into
nondividing cells such as resting T cells and macrophages 58. Creation of latent 
reservoirs occurs early in the course of HIV infection in humans, so that by the 
time of occurrence of an acute retroviral syndrome, HIV has disseminated 
widely and established a chronic infection in the host 59. The HIV replication 
proceeds in a series of events that can be divided into two overall phases:
“early” and “late” 34,58. The early phase begins with the recognition of the 
target cell by the mature virion and involves all processes leading to and
including integration of the genomic DNA into the chromosome of the host
cell. The late phase begins with the regulated expression of the integrated
proviral genome, and involves all processes up to and including virus budding
and maturation (Figure 2.1).  
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Figure 2.1 HIV-1 replication cycle. The viral replication cycle can be divided into two main
stages: early and late. The major steps of the early stage include viral fusion, reverse 
transcription, nuclear trafficking and, lastly, integration. The late stage of viral replication
begins with host-cell-mediated proviral gene transcription and translation followed by virion
assembly, virion budding and, finally, viral maturation into infectious progeny virion capable 
of another round of infection with a new target immune cell (adapted from 60). 
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1.3.1 Early phase 
 
1.3.1.1 Virus Entry 
 
HIV-1 enters the target cell through fusion of the virus envelope with the target 
cell membrane. The initial step of entry is believed to involve a high affinity
binding between the surface envelope glycoprotein gp120 and the cellular
receptor, CD4, which is present on the surface of a subset of T-lymphocytes 
and monocytes 45-49. Binding of the surface subunit gp120 to CD4 and a
coreceptor on the T-cell surface triggers conformational changes in the Env
complex, leading to the insertion of the hydrophobic N-terminal fusion peptide 
(FP) of gp41 into the target cell membrane 61-64.  
 
1.3.1.2 Reverse Transcription  
 
After virus entry, the viral capsid is disrupted and the viral RT enzyme is fully
activated. During reverse transcription, the two RNA molecules in the virion
are converted to a linear double-stranded DNA 65,66. The process of reverse 
transcription requires priming provided by the tRNAlys3, which is annealed to 
the primer-binding-site (PBS) at the 5´end of the viral genome during particle
formation. tRNAlys3 is selectively incorporated in the HIV-1 virion, which 
contains approximately eight molecules of tRNAlys3 per two copies of genomic 
RNA 67,68.  
 
1.3.1.3 Nuclear Transport and Integration 
 
After reverse transcription, the newly synthesized HIV-1 cDNA is transported 
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to the nucleus as part of a preintegration complex (PIC) 58. This complex 
contains linear viral DNA and several viral proteins including MA, RT, IN, 
Vpr and NC 69. Functional cellular proteins have also been identified 
functional in PICs 69. Vpr protein is thought to enhance the HIV-1 
preintegration complex transport to the nucleus 42,43. Once near the nuclear 
membrane, peptide sequences from Vpr and MA provide a nuclear localization 
signal to actively enter the nucleus. The proviral DNA is then integrated at
random sites throughout the cellular host genome by the action of the viral 
enzyme IN 19. The integration process is arguably one of the most insidious
steps in the infection process 17,70-72. As a result, HIV-1 IN is currently the 
focus of an intense research effort to develop new anti-HIV-1 drugs 73. In the 
present dissertation, IN was chosen as a potential target for HIV-1 gene 
therapy. Therefore, this HIV-1 enzyme will be described in more detail in a 
later section. 
 
1.3.2 Late Stage 
 
Following integration into the host chromosome, the integrated provirus serves 
as the template for the synthesis of the viral RNAs that ultimately encode the
full complement of structural, regulatory, and accessory proteins used to direct 
virus replication 34. 
 
1.3.2.1 HIV Transcription  
 
The integrated provirus flanked by the tandem LTRs is organized as a 
eukaryotic transcriptional unit 34. The 5’ LTR contains a strong 
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enhancer/promoter and the 3’ LTR contains an efficient polyadenylation site.
The HIV-1 promoter is highly regulated by both viral and cellular factors 74. Its 
activity varies greatly depending on the cell status. In many infected cells in
HIV-positive individuals, virus expression is undetectable. Thus, a state of 
viral latency exists in individual cells, although the infection is chronically 
active in a fraction of cells due to continue HIV expression 58.  
 
Transcription from the HIV-1 LTR leads to the generation of a large number 
(more than 30) of viral RNAs 75. These fall into three major classes: 1) 
unspliced RNAs, which function as the mRNAs for the Gag and Gag-Pol 
polyprotein precursors, and are packaged into progeny virions as genomic
RNA, 2) partially spliced mRNAs, which are around 5 kb in size and encode
the Env, Vif, Vpu, and Vpr proteins, and 3) small (1.7 to 2.0 kb), multiple
spliced mRNAs, which are translated into Rev, Tat, and Nef  58,75,76. After HIV 
mRNA is processed in the cell's nucleus, it is transported to the cytoplasm.  
 
1.3.2.2 HIV Translation, Assembly and Budding 
 
To assemble a virus, the structural proteins must be produced first 77. For HIV-
1, the genomic RNA is also the mRNA that codes for the Gag precursor (Pr
55Gag) and the Gag-Pol fusion protein (PR 160Gag-Pol).  Pr 55Gag is as 
polyprotein precursor that can be processed into MA (p17), CA (p24), NC (p7)
and p6 58. The gene encoding the viral enzymes PR, RT and IN are translated
as part of the fusion Gag-Pol polyprotein 78.  
 
The Env precursor polyprotein (gp160) is synthesized in the endoplasmic
reticulum (ER) using the spliced env mRNA gene as the message 77,78. Env is 
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posttranslationally modified in the ER and Golgi apparatus and is cleaved to
produce the two envelope glycoproteins gp41 and gp120 58. These are 
transported to the plasma membrane of the host cell where gp41 anchors the 
gp120 to the membrane of the infected cell. The Gag and Gag-Pol polyproteins
also associate with the inner surface of the plasma membrane along with the
HIV genomic RNA as the forming virion begins to bud from the host cell 79.  
 
1.3.2.3 Maturation 
 
As the particle buds and is released from the cell surface coated with gp120 
and gp41, the virion undergoes a morphologic change known as maturation.
This step involves proteolytic processing of the Gag and Gag-Pol polyproteins 
by PR. The mature virion is then ready to infect the next cell and initiate a new 
infection cycle 58 . 
1.4 HIV/AIDS Treatments 
The spread of HIV-1 has been dramatic since the early eighties, when the virus
was discovered as the causative agent of AIDS. In the absence of an effective 
vaccine against HIV, a worldwide search has been made in the past two
decades to develop small-molecule inhibitors to target essential steps in the
viral cycle 10. Currently, nearly 25 antiretroviral drugs (ARV) have been
licensed for the treatment of HIV-1: nine nucleoside reverse transcriptase 
inhibitors (NRTI), four nonnucleoside reverse transcriptase inhibitors
(NNRTI), nine protease inhibitors (PI), one fusion inhibitor, one CCR5
inhibitor, and one integrase inhibitor 80-87. The first CCR5 and integrase 
inhibitors were approved in the end of 2007, increasing the number of ARV 
                                                                                                               Introduction 
 
 
13 
 
classes from four to six 86,87.  
 
Anti-HIV drugs are most effective when taken in a combination. This
treatment regimen is called Highly Active Antiretroviral Therapy (HAART). 
Current HAART options use combinations consisting of at least three drugs
belonging to at least two types, or "classes," of antiretroviral agents. Typically, 
these classes are two nucleoside analogue reverse transcriptase inhibitors
(NRTIs) plus either a protease inhibitor (PI) or a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) (Table 1.1). New classes of drugs such as 
Entry and Integrase inhibitors provide treatment options for patients who are 
infected with viruses already resistant to common therapies, although they are
not widely available and not typically accessible in resource-limited settings 11. 
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Table 1.1 – Current Licensed antiretroviral drugs (adapted from 10) 
 
 
1.4.1 HIV-1 Drug Resistance and Emergence of new Approaches for AIDS 
         Treatment 
 
In the developed world, access to multi-drug combination regimens have 
reduced the viral count to undetectable levels in infected patients; which 
resulted in significant reductions in the morbidity and mortality attributed to
                                                                                                               Introduction 
 
 
15 
 
HIV/AIDS 10,11,13. However, full eradication of the infection has failed due to
the persistence of latent HIV-1 in resting memory CD4+ T-cells. Furthermore, 
the emergence of multi-drug-resistant viral strains in patients exposed to 
HAART regimens and the rapid escalation of infections in developing
countries pose an overwhelming challenge to the treatment strategies of
HIV/AIDS 13-15.  
 
The emergence of HIV strains resistant to antiretroviral drugs aimed at any 
viral target is an inevitable phenomenon following the initiation of treatment in
infected patients. The viral drug resistance occurs by at least two mechanisms.
First, the lack of an inherent proofreading mechanism in RT naturally causes a 
high rate of mutations in each replication cycle 88. Second, the pressure 
induced by an antiviral agent accelerates specific mutations in its target,
particularly in the region where it binds, eventually leading to a permanent loss 
in potency 12,14. The emergence of drug-resistant viral strains in combination 
with several other critical factors, such as a patient’s inability to adhere to
long-term treatment regimens, severe side effects associated with existing
drugs, and the high cost of medication have require a high demand for the 
development of new therapeutic approaches for AIDS treatment 10,14. Gene 
therapy is one such forward-looking strategy. 
 
1.5 Gene Therapy for HIV-1 
  
At the most basic level, gene therapy can be described as the intracellular 
delivery of genetic material to generate a therapeutic effect by correcting an
existing abnormality or providing cells with a new function. Initially inherited
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genetic disorders were the main focus of gene therapy but now a wide range of 
diseases, including cancer, vascular diseases, neurodegenerative disorders and 
other acquired diseases are being considered as targets. The ultimate goal of
gene therapy is the amelioration of disease upon a single administration of an
appropriate therapeutic gene. The genetic material considered for use intended
to replace a defective or missing gene, augment the functions of the genes
present, and instill a specified sensitivity to a normally inert prodrug or to
interfere with the life cycle of infectious agents 89.   
 
Gene therapy has gained special interest among AIDS researchers, since
conventional therapies have shown limited success 24-26. Alteration of the host 
cell could potentially confer permanent suppression of viral replication, after
infection, or could provide protection against viral infection. Over the past 10
years several different anti-HIV-1 gene therapy approaches have been 
developed and tested 26. These approaches can be classified into two main
categories: RNA-based agents and protein-based agents.  
 
RNA Strategies 
 
RNA approaches include antisense oligonucleotides, ribozymes, RNA 
aptamers and decoys, and RNA interference (RNAi).  
 
(1) Antisense oligonucleotides  
 
Antisense oligonucleotides are short sequences of nucleic acids
complementary to a given messenger nucleic acid (sense sequence) 89. 
Antisense oligonucleotides were shown by several groups to inhibit gene 
expression in HIV-1 infection in vitro when targeted to such critical HIV-1 
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genes such as tat, rev, and integrase 90. The problems associated with this type 
of therapy essentially derive from the short half-life of antisense 
oligonucleotides and the difficulty involved in accessing the inside of the
cell 89.  
 
(2) Ribozymes 
 
Ribozymes are antisense enzymatic RNAs molecules that can specifically 
recognize and cleave target RNAs, and prevent or significantly reduce
translation of proteins encoded by the sequences against which they are
targeted 89. The cleavage reaction is catalytic and no energy source is required.
Since the first demonstration that ribozymes can inhibit HIV replication,
several studies have demonstrated related ribozyme-based strategies for the 
treatment of HIV infection 91. Three separate clinical trials have used 
ribozymes targeting HIV genes, including tat, rev and the viral U5 region 92. 
Although these trials have not shown significant anti-HIV efficacy, they 
demonstrated that it is safe to mobilize stem cells or to collect peripheral blood
mononuclear cells from persons with HIV, genetically modify the cells with 
retroviral-ribozyme vectors and reinfuse them into patients 25,26,. 
 
(3) RNA aptamers and decoys 
 
Another group of RNA molecules, RNA aptamers, have been evolved in vitro 
to bind targeted ligands with high affinity 93. Although aptamers against HIV 
show promise, thus far there have been no clinical trials using anti-HIV 
aptamers 25. One potential problem is that aptamers selected in vitro may not 
form the required tertiary structure in cells to effectively bind target proteins.
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On the other hand, expressed RNA decoys have been more amenable to gene
therapy 94. RNA decoys employ short RNA oligonucleotides which mimic
critical regulatory sequences in HIV. The majority of the RNA decoys have
targeted the HIV regulatory gene products tat and rev 24-26,94.  
 
(4) RNA interference  
 
RNA interference (RNAi) was originally discovered in Caenorhabditis 
elegans as a biological response to exogenous double-stranded RNA molecules 
(dsRNA) which induce sequence-specific gene silencing 95. Subsequently, it 
was reported that RNAi could take place in a wide variety of organisms, such
as fungi, plants, invertebrates and vertebrates. In fact, RNAi serves as a 
safeguard for the preservation of genomic integrity. It protects the host from
viral infections and invasion by mobile genetic elements by degrading the 
exogenous genomic material (e.g. viral RNAs). In mammalian cells, it had 
been known that introduction of dsRNA activated the IFN pathway and RNA
binding protein kinase and induced non-specific degradation of RNA, 
translation inhibition and cell death 89. However, Elbashir et al succeeded in 
inducing RNAi machinery in mammalian cells by using small dsRNA (called
small interfering RNA; siRNA) without a non-specific response against the 
dsRNA 96. This finding was a major breakthrough for the application of RNAi. 
Thereafter, siRNA became a widespread tool for specific gene silencing. Small 
interfering RNAs (siRNA) are double-stranded RNA sequences, 
approximately 22 base pairs in length that bind cellular mRNAs in a sequence-
specific manner and cleave them at the center of the complementary
region 97,98. They achieve this through a series of steps involving the
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recruitment of RNAi factors, formation of an RNA induced silencing complex
(RISC), unwinding of the siRNA, and activation of RISC. RNAi triggers can 
also be produced by expressing short hairpin (shRNA) precursors that partly
resemble endogenous microRNA precursors, allowing them to be exported to
the cytoplasm and processed by the RNAi machinery 89. Expressing short 
hairpin precursors encoding siRNAs targeting viral or cellular sequences can
be readily accomplished from the backbone of viral vectors used in gene
therapy.  HIV-1 was one of the first infectious agents targeted by RNAi as a
result of the virus’ well-understood life cycle and pattern of gene expression 97. 
To date, small interfering RNAs have been used in vitro to target viral genes 
like tat and rev and cellular genes like CCR5 with great success 97,98. 
 
Protein-based strategies 
 
Similar to the RNA-based inhibitors of HIV, proteins can be directed to inhibit
either cellular or viral targets. The most relevant protein-based approaches 
include suicide genes, transdominant negative proteins, zinc finger 
transcription factors and intracellular intrabodies. 
 
(1) Introduction of suicide genes 
 
Generally, suicide genes code for enzymes that convert an inactive drug to a
toxic form, allowing for the potential killing of the modified cells. The idea of
using suicide genes was made popular as a potential approach for treating 
cancer 89. As an anti-HIV strategy this method was tried in vitro as proof-of-
concept in a study that used a retrovirus to transduce autologous CD8+ cells
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from HIV-infected patients; the suicide gene was thymidine kinase expressed
as a fusion protein with hygromycin phosphotransferase 99. As with other gene 
therapy approaches, specific targeting of desired HIV-infected cell populations 
would present a challenge for this approach to be successful in vivo. 
 
(2) Transdominant negative proteins 
 
Mutations in a specific gene expressed in a dominant fashion where the mutant
protein can interfere with the function normally carried out by the parent gene
product. If the protein is multimeric, the nonfunctional protein can multimerize
with the normal protein and the resultant complex is functionally inactive 89. 
Thus, the dominant negative protein can have a strong inhibitory effect on the
normal protein formation or function. Examples of this are HIV-1 Gag mutants 
and Rev M10 100,101. Rev M10 was the first transdominant negative protein 
used in clinical trials; it is a dominant negative mutant capable of binding the
Rev Responsive Element (RRE) and has the capability of forming multimers
101. 
(3) Polydactyl Zinc Finger Transcription Factors  
 
 
Recent advances in the design, selection, and engineering of DNA binding
proteins have led to the emerging field of designer transcription factors (TFs)
102. Modular DNA-binding protein domains can be assembled to recognize a
given sequence of a DNA in a regulatory region of a targeted gene. TFs can be 
readily prepared by linking the DNA-binding protein to a variety of effector 
domains that mediate transcriptional activation or repression. Furthermore, the
interaction between the TF and the genomic DNA can be regulated by several 
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approaches, including chemical regulation by a variety of small molecules.
Genome-wide single target specificity has been demonstrated using sequence-
specific zinc finger (ZF) domains 102. Any laboratory today can easily 
construct polydactyl ZF proteins by linkage of predefined ZF units that 
recognize specific triplets of DNA. Several laboratories are currently 
developing artificial transcription factors to inhibit HIV- replication 103. For 
instance, we have recently in collaboration with Dr. Carlos Barbas III inhibited 
the HIV-1 replication with artificial transcription factors targeting the highly
conserved primer-binding site 104.  
 
(4) Intracellular Intrabodies 
 
Intracellular antibodies (intrabodies) represent a new class of neutralizing
molecules with potential use in gene therapy approaches 27-29. An intrabody 
consists of an antibody designed to be expressed intracellularly and directed to
different subcellular compartments where it can exert its function more
effectively 30. The binding of an intrabody to an intracellular target protein has 
the potential to block, suppress, alter or even enhance the process mediated by
that molecule 31-33. The strong inhibiting potential of intracellular antibodies in 
the context of HIV gene therapy will be the focus of this thesis. This new gene 
therapy approach will be described in detail in the next section.   
 
1.6 Intracellular Antibodies as Specific Molecules for Gene Therapy  
 
Antibodies are prime recognition molecules: they possess a high specificity
and affinity for their target, and can be easily raised against virtually any 
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protein 105. For these reasons, antibodies have been extensively studied and
subjected to more modifications than any other type of molecule: antibodies
are being fragmented, remodeled, made part of chimeric molecules, or 
covalently linked to other compounds. Modified antibodies have now been
used for decades as tools for molecular biology, and as therapeutic
agents 106,107. 
 
One of the latest antibody applications involves intracellular antibodies 27-29. 
Early studies showed that the cDNA of an antibody (heavy and light chains)
against yeast alcohol dehydrogenase I (ADH I) could be expressed in the
cytoplasm of Saccharomyces cerevisiae and could neutralize the enzyme in 
vivo 108. Further studies verified that the assembly of an antibody could take
place in the reducing environment of a mammalian cytoplasm 109. Protein 
engineering of antibody binding sites demonstrated the feasibility of joining 
heavy chain and light-chain variable domains through a synthetic linker, 
maintaining binding specificity and affinity of the parent molecule 110,111. With 
these advances in the field and further improvements, intrabodies were shown 
to inhibit functions in mammalian cells and therefore represent now a new 
class of neutralizing molecules with a potential use in gene therapy 27-33. 
 
1.6.1 Antibody Structure and Function   
 
In vertebrates, there are five different classes of antibodies known as IgD, IgA,
IgM, IgE and IgG, which differ in their function in the immune system 105. 
IgGs are the most abundant immunoglobulins in the blood and currently are 
the intact format almost exclusively used as therapeutic antibody. This typical
antibody consists of two antigen-binding fragments (Fabs), which are linked 
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via a flexible region (hinge) to a constant Fc region (Figure 1.3A). IgG 
antibodies are usually "Y" shaped molecules comprising two identical light
chains (L) and two identical heavy chains (H) linked together by disulfide
bonds. The heavy chains contain a variable domain (VH domain) and three 
constant domains (CH1, CH2 and CH3). By contrast, the light chains contain a
variable domain (VL domain) and a single constant domain (CL domain). The
variable domains show three regions of hypervariability in sequence called the 
complementarity determining regions (CDRs) 105. They differ in length and 
sequence between different antibodies and are responsible for the specificity
(recognition) and affinity (binding) of the antibodies to the antigen. The
remaining V region amino acids act as a scaffold to support the CDRs loops
and are referred as framework residues (FR). On the other hand, the Fc 
constant region recruits cytotoxic effector functions through complement
and/or through interactions with γFc receptors. In addition, this non-antigen 
binding part of an antibody is also associated with serum half-life of 
antibodies. In this case, the Fc region binds to FcRn receptors on endothelial
cells and rescues antibody molecules from intracellular degradation 106,107.  
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Figure 1.3 - A - Schematic representation of the structure of a conventional IgG antibody. IgG 
antibodies comprise a pair of identical heavy and light chains linked by disulphide bonds.
Light chains contain one constant domain (CL) and one variable domain (VL), while heavy 
chains contain three constant domains (CH1, CH2 and CH3) and one variable domain (VH).
The variable domains of both the heavy and light chains are responsible for the antigen-
binding site of the molecule (Fv). The Fc constant region recruits effector functions of the 
immune system. Constant light (CL) and heavy (CH) chain domains are represented in yellow.
Variable light (VL) and heavy (VH) chain domains are represented in orange. B - Schematic 
representation of antibody constructs. The engineering of antibody fragments that can be 
generated from an intact conventional IgG: antigen-binding fragment (Fab), single-chain Fv 
fragment (scFv) and heavy and light chains only (V domains) (adapted from 112).  
 
1.6.2 Intrabody  Formats  
 
The most commonly used form of intrabody consists of engineered scFv in 
which the variable domain of the heavy chain (VH) is connected to the light
chain (VL) through a peptide linker, preserving the specificity and affinity of
the parent antibody (Figure 1.3B) 110,111. The most common peptide linker is a 
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flexible (Gly4Ser)3, but many other linker designs have been successfully
employed. A scFv antibody can have either VH–linker–VL or VL-linker-VH 
configuration 29. 
 
Single-chain Fv fragments are usually viewed as the smallest antibody units, 
which form complete antigen binding sites. However, early observations in the
late 1960s indicated that sometimes VH domains alone retained a significant 
part of the original binding activity 113-115. Based on this concept, in 1989 Greg 
Winter’s group at Medical Research Council, Cambridge-UK, isolated heavy 
chain variable domains with antigen affinity against lysozyme derived from an
immunized murine VH library 116. Despite such promising results, the efficient
expression of VH fragments is usually confronted with folding problems, low
solubility and high tendency for aggregation caused by the exposure of the
hydrophobic VH/VL interface upon removal of the VL domain. Nevertheless,
these problems seem to have been overcome, or at least greatly reduced for 
some mouse and rabbit VH domains by the identification and design of
mutations that minimize the hydrophobic interface and by direct selection of
highly stable single-domains from phage display libraries 117-126. In contrast, 
another promising alternative is the naturally heavy chain antibodies devoid of
light chain that were recently discovered in camelids (camels and llamas) 127. 
These heavy-chain antibodies recognize the antigen by one single variable
domain and can be obtained from either immunized or non-immunized 
animals. In camelids, the variable heavy chains are referred to VHH (~15 kDa)
and consist of four framework regions and three CDRs 128. In VHH the third 
antigen-binding loop (CDR3) is often stabilized by disulfide bonds and is, on 
average, longer than a human or mouse VH-CDR3 loop. These smaller 
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antibody molecules might, therefore, reach targets not easily accessible by 
currently marketed mAbs therapies, such as enzyme active sites and canyons
in viral and infectious disease biomarkers 129. 
 
Thus an intrabody can also be reduced in size to a single functional variable
domain. For this designed format, a single VH domain, known as an IDab,
possesses excellent solubility, stability and expression within eukaryotic cells. 
An ideal IDab should exhibit specific antigen recognition and neutralizing
activity. IDabs isolated for RAS protein have been shown to inhibit RAS-
dependent oncogenic transformation of NIH3T3 cells 130. We have also 
recently developed a minimal rabbit scaffold VH fragment with intrabody
properties derived from anti-Vif scFv that was engineered to mimic camelid 
antibody domains 121,131. These camelized VH single-domain intrabodies were 
highly expressed in reducing environments and exhibited a strong 
neutralization of HIV infectivity 121. Natural VHH antibodies have also been 
validated as intrabodies. In this case, several Bax-specific VHH intrabodies 
were stably expressed in mammalian cells and prevented mitochondrial
membrane potential collapse and apoptosis after oxidative stress in the host 
cells 132. Another format is the Fd fragment (VH-CH1) which has been shown 
to inhibit glucose-6-phosphate dehydrogenase in the cytoplasm of mammalian
cells 133. Recently, a VL-Dab and its disulfide bond-free derivative were also 
successfully utilized as an anti-huntingtin intrabody in Huntington’s disease 
134,135. The development of rabbit VL single domains as potential intrabodies
will be also evaluated in the present dissertation.  
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1.6.3 Molecular Mechanism of Intrabodies  
 
 
Intrabodies have been used to alter the functions of the target antigens by
modifying related cellular pathways or by redirecting the antigen to a new 
cellular compartment 29. The unique molecular characteristics of intrabodies
allow them to affect protein functions by:  
 
(1) Sequestration of a target protein from its normal subcellular
compartment of action. 
(2) Mediating enzyme function through blocking of the active site or
modulation of its conformation. 
(3) Disrupting biological or signal pathways via interfering normal 
protein– protein or protein–DNA interactions. 
(4) Inducing cell death via activation of the caspase-3-mediated apoptotic 
pathway. 
(5) Selective degradation via the ubiquitin–proteosome pathway. 
 
Firstly, intrabodies can be designed to be expressed in different subcellular 
compartments such as cytoplasm, nucleus, endoplasmic reticulum (ER), Golgi,
mitochondria, peroxisomes, plasma membrane and other locations 30. DNA 
recombinant techniques allow classical intracellular trafficking signals to be 
genetically fused to the N- or C-termini of antibodies to direct the intrabodies 
to specific subcellular localizations in order to block or interfere target antigen 
function 30. For instance, ER-retained intrabodies are designed with a signal 
leader peptide sequence at the N-terminus and a retention peptide, KDEL, at 
the C-terminus to tether intrabodies within the lumen of the ER. The 
engineered intrabody can then interact with targeted secretory-pathway 
proteins, sequestering them within the ER and inhibiting their natural 
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expression. Retention of antibodies in the ER can effectively down regulate its
target receptors or signaling molecules, such as reduction of cell surface 
expression of VEGF-R2 and epidermal growth factor receptor (EGFR) 136,137. 
Similar target protein retention in the trans-Golgi has been reported for 
intrabodies containing a trans-Golgi retention signal 138. For expression of 
cytoplasmic intrabodies, the signal sequences are removed and cytosolic
intrabodies are translated on free polysomes. Cytoplasmic intrabodies with an
intrinsically stable sequence that can fold properly in the absence of disulfide
bond formation are required to function appropriately 30.  
 
Secondly, intrabodies can modulate enzymatic function by blocking an 
enzyme active site, by sequestering substrate, or by modulating the
conformation of an enzyme catalytic site. It has been shown that cytoplasm-
expressed single-domain intrabodies targeting the protein kinase Etk could
inhibit its autophosphorylation and ability to phosphorylate its substrate. This 
activity resulted in a partial inhibition of cellular transformation in Src-
transformed cells 139.  
 
Thirdly, intrabodies can be used to disrupt biological signaling pathways of
target proteins by interfering with normal protein-protein or protein-DNA 
interactions. For example, a nuclear-targeted intrabody has been used to bind 
to cyclin-E resulting in the inhibition growth of a breast cancer cell line 140. 
Fourthly, when genetically fused to caspase-3, intrabodies can be used to 
promote death of target cells (e.g. cancer cells) by activating the caspase-3-
mediated apoptosis pathway 141. It is also possible to design intrabodies that 
can promote selective degradation of cellular protein targets via the ubiquitin-
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proteasome pathway by fusion with F-box 142,143. In addition, intrabodies also 
have the potential to cause gain-of-function after binding to their target 
proteins. For example, it has been demonstrated that certain anti-p53 scFv 
antibodies restored the transactivating activity of mutant p53 in p53 knockout
human tumor cells 144. 
 
The strong inhibiting potential of intracellular antibodies is well known in the 
field of cancer, HIV, transplantation, autoimmune and neurodegenerative
diseases 121,131,133-140,144-147. Despite such successful results obtained, the 
efficient cytoplasmic expression of intrabodies is generally confronted with
folding problems, low solubility, short protein half-life and high tendency for 
aggregation 29. These problems are most likely caused by the reducing 
environment of the cell cytoplasm. The preserved intrachain disulfide bridges 
of heavy and light chains is not formed in scFv’s expressed in the cytoplasm, 
thus resulting in unstable intrabodies that are non-functional inside the cell 30.
Therefore, only intrinsically very soluble and stable scFv fragments will be
able to fold correctly in sufficient amounts to be active as intrabodies 150.  At 
this time, no rules or consistent predictions can be established about
intrabodies that will tolerate the reducing cellular environments. Within this
context, there is a strong interest in the ability to express functional antibodies
in this environment and only recently several different approaches started to
emerge with such requirements 151,152. These approaches include in vivo
screening for intrabody-antigen interaction based on two hybrid screening 152-
154 and construction of antibody libraries using randomized CDRs on scFv
frameworks that have been selected for high solubility and stability in an 
intracellular environment 154-157. Several other strategies have also been 
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developed to address these same concerns. For example, stable and functional
cytoplasmic cysteine-free scFv have been generated by using DNA shuffling
and phage display 150,151. VH and VL single domain antibody libraries are
becoming a major strategy to be used to avoid disulfide bond requirement 
130,132,133,134. In addition, camelization strategies have also been used to 
improve the solubility and stability of rabbit VH domains 121. Finally, fusion of 
intrabodies with E. coli maltose binding protein were shown to enhance their
solubility and stability in bacteria and mammalian cell cytoplasm 158.  
 
1.6.4 Intrabody Gene Sources 
To obtain the variable domain sequences to construct an intrabody, two 
sources have commonly been used: hybridomas and antibody libraries.
Hybridomas producing either murine monoclonal 159-161 or human monoclonal 
antibodies 162 have been the source of VH and VL cDNA for those particular 
antibodies. Specific primer sequences can be used to amplify the
immunoglobulin chains that will be used to construct scFv’s. Two 
disadvantages of hybridoma technology are the length of time required to 
develop antibody candidates and the need to restart the antibody development 
process when unwanted characteristics such as cross reactivities are discovered
163. Currently antibody libraries are the main source to select intrabodies. In 
general, three types of antibody libraries may be used: immune, naïve and
synthetic 163,164. 
 Immune libraries are derived from the IgG mRNA of B-cells of an immune 
source, such as immunized animals or in some instances human B-cells. These 
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libraries result in more and sometimes higher affinity antibodies than those
rescued from hybridomas 163,165,166.  
 
The second type of libraries is obtained from large naïve repertoires of
antibody fragments which can be recovered from non-immunized donors. In 
this case, mRNA from B-cells is isolated from haematopoietic organs and IgM
variable regions are then amplified by PCR using degenerate oligonucleotide
primer sets and cloned directly into phage display vectors 167-170.   
 
Synthetic antibody libraries are constructed entirely in vitro using 
oligonucleotides that introduce areas of complete or tailored degeneracy into 
the CDRs of one or more V-genes 171. By introducing degeneracy in specific 
position codons of synthetic oligonucleotides, the degree of randomization can
be precisely controlled. There are examples of semisynthetic antibodies
libraries, which incorporate a balance of natural and synthetic repertoires and
are often created to increase natural diversity while maintaining a certain level
of functional diversity 172.  
1.6.5 Antibody Selection Methods 
  
Many methods can be used to obtain antibody genes for the construction of 
intrabodies. The most relevant selection platforms will be briefly described
below. 
1.6.5.1 Phage Display Technology 
Phage display technology had its beginnings in 1985 when George Smith 
cloned a fragment of the gene encoding the Eco RI endonuclease into the gene 
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III insertion site of filamentous phage f1 and created a fusion protein, which
was displayed on the virion surface 173. Following these studies, describing the 
display of peptides on the surface of filamentous phage, several laboratories 
simultaneously developed phage display systems for antibody fragments in the
early 1990s 174,175. In these systems, antibody genes are linked to the amino
terminus region of the phage minor coat protein pIII. When expressed, the 
encoded fusion product is incorporated into the mature phage particle during
normal phage biogenesis. The resulting phage particle expresses antibodies on
its surface and contains the antibody encoding gene. This linkage between
antibody genotype and phenotype allows the enrichment of antigen-specific 
phage antibodies, using immobilized or labelled antigen 176,177. The selection 
process by phage display can be divided into four main steps: (1) coating of 
antigen; (2) incubation of phage repertoire with antigen; (3) washing to remove 
non-specific phages; and (4) elution and reamplification of antigen-specific 
phages. Usually, three to six rounds of binding, elution and amplification are 
sufficient to generate antibodies with high affinity and specificity. Still, this 
selection success hinges on the combination of this display and enrichment
method, with the generation of large and highly diverse repertoires of phage
antibody libraries 178-180. Phage display technology is currently one of the most
well-established platforms used to identify intrabodies. 
1.6.5.2 Ribosome Display Technology 
Ribosome display, originally described by Mattheakis and co-workers 181, is a 
cell-free system for the in vitro selection of peptides and proteins from large 
libraries. It uses the principle of coupling individual nascent proteins
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(phenotypes) to their corresponding mRNA (genotypes), through the formation
of stable protein-ribosome-mRNA (PRM) complexes. This permits the 
simultaneous isolation of a functional nascent protein, through affinity for a 
ligand, together with the encoding mRNA, which is then converted and
amplified as DNA for further manipulation. Ribosome display has recently
been adapted to the screening of antibody libraries by Pluckthun182 and 
Taussig 183. 
Ribosome display has several potential advantages over phage display. Firstly,
larger libraries (1012–1014 members) can be constructed with ribosome display 
compared to phage display. Secondly, ribosome display avoids transformation
and cloning steps that can be laborious with large phage display libraries and 
may result in the loss of diversity. Finally, libraries can be further diversified 
during PCR steps in ribosome display using low-fidelity polymerases. Thus, 
high-affinity antibodies initially not present in libraries can be generated and 
selected against a large array of antigens 184. 
1.6.5.3 Cell Display Technology 
Before the advent of phage display systems, antibodies were displayed in 
bacterial cells, although isolation of specific clones was difficult due to
inefficient screening methods. The recent development of high-speed flow 
cytometers has re-activated the efforts in cell surface display, and several high-
affinity antibodies are now starting to be isolated by this method. For screening
purposes, a library of cells (e.g. E. coli or Saccharomyces cerevisiae), each 
displaying multiple copies of a different antibody variant, is incubated with a
fluorescently tagged antigen in buffer 185,186. Cells displaying antibodies that 
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specifically bind the ligand become fluorescently labeled and are easily 
isolated by fluorescence-activated cell sorting (FACS). With flow cytometry,
the binding of each clone in the library to a particular ligand is easily
determined quantitatively. Therefore, the brighter the fluorescent signal for 
antigen binding, the higher the affinity of the clone for the antigen. In addition,
parameters such as ligand concentration or time for the dissociation of
antibody-antigen complexes can be easily optimized. These features are
particularly significant for antibody affinity maturation, and in fact, the limited
data reported so far indicate that cell surface display may be a superior
screening technology for that purpose 187,188. 
1.6.5.4 Yeast Two-Hybrid System 
 
Intracellular interaction of antibody with target antigen in yeast could be 
evaluated by providing conditional cell growth advantage through controlled
expression of selected reporter genes 152,155. In such a system, the antigen is 
usually cloned in frame at C-terminus of the DNA binding domain of the E. 
coli protein LexA and scFv antibody fused at the N-terminus of the activation 
domain of the herpes virus 1 VP16 transcription factor. After cotransfection of 
these plasmids into the yeast or mammalian cells and upon interaction, the 
antibody-antigen complex binds to the promoter of reporter genes containing
relevant DNA binding sites and activates their transcription. For example,
activation of HIS3 gene controlled by a minimal transcription promoter with
LexA binding sites upon antigen-antibody interaction enables the host yeast to 
grow on plate without histidine and with 3-amino-triazole (3-AT) for 
selection 155. In addition, Auf der Maur et al. (2001) developed a related 
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procedure in which stable intrabodies could be selected independent of their 
antigens based on strong correlation between the degree of reporter gene
activation and the stability/solubility of the fused antibody 156. It should be 
noted that a library size of 10
7 
clones can be screened per assay in these yeast 
systems, which is at disadvantage as compared to >10
10 
clones that can be 
handled with relative ease using phage display. 
 
1.6.5.5 Protein Fragment Complementation Selection (PCA)  
 
Protein fragment complementation assay (PCA) has been adapted to screen for
antibody binding by reconstituting the activity of dihydrofolate reductase
(DHFR) that confers a survival advantage on transformed E. coli 190. In this 
method, antibodies and antigens are linked with dissected portions of mouse
DHFR (mDHFR). The interaction of antibody and antigen brings the two 
halves of dissected mDHFR together, thus restoring its enzyme activity and
allowing transformed E. coli to grow on minimal medium in the presence of 
antibiotic trimethoprim 190. Four different target antigens were tested by this
system, it was shown that there was about seven orders of magnitude more
colonies in antigen pool containing specific antigen as compared to few
colonies found in pool with only non-specific antigen 190. The procedure is 
relatively simple and fast and only involves the transformation of plasmids, 
functional expression of the fusion proteins and analysis of the grown bacterial
cells. Notably, it gives a very low background of false positive results. The
antigen does not need to be purified and immobilized. However, since the 
screening is performed in the cytoplasm of E. coli, antibodies with inherent 
stable framework can be isolated under reducing conditions but they would be
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lack of post-translational modification. 
 
1.6.6 Intrabody Delivery  
 
Currently, lentivirus vectors are the main gene delivery tool used to obtain 
high transduction efficiency and long-term expression of intrabodies.
Lentiviral vectors were developed by investigators at the Salk Institute in the
mid-1990s, using design strategies defined over the prior decade to optimize 
gamma-retroviral vectors for safety and effectiveness 191. Like the lentiviral 
subclass of Retroviridae from which they are derived, lentiviral vectors can
integrate in nondividing cells, making them more effective than retroviral 
vectors for gene transfer to postmitotic or slowly dividing cells, which may
include hematopoietic stem cells and T cells 191-196. Many of the lentivirus 
vectors used in gene therapy are based on the HIV-1. Typically, HIV vectors 
can accommodate fairly large gene inserts and can provide long-term 
expression through chromosomal integration 193. Today, the limitations of 
using lentivirus vectors in clinical trials are mainly due to the lack of sufficient 
methods for production of high-titer virus stocks and the safety concerns 
related to their origin from HIV, despite the engineering of packaging cell lines
and deletions of genes required for viral replication 193,197,198. One approach to 
address safety issues has been to develop lentivirus vectors incapable of 
replication in human cells 193. Another main challenge faced by lentiviral gene 
delivery systems is the development of vectors that can efficiently target
specific cell types. The most common approach developed to date changes the
tropism of envelope lentiviral receptor binding domain with a cell-specific 
ligand or a scFv that recognizes and binds to specific cell surface
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molecules 199-208. Some of these approaches have allowed some degree of cell-
type-specific viral entry, however, the envelope alterations in most strategies 
also affect viron assembly and lead to low fusion activity and viral titers
193,194,209. Within this context, there is strong interest in developing new and
improved strategies to allow lentiviral cell-specific targeting. The present 
dissertation thesis will also focus the development of lentiviral-derived vector 
that can efficiently target specific-cells. 
 
1.6.7 Comparison of intrabodies and other intracellular targeting  
         strategies 
 
Other strategies for the inactivation of specific intracellular molecules are also
being developed. These techniques include the use of antisense RNA 210 and 
RNA interference (RNAi) 211,212. Unlike intrabodies, which are targeted to 
specific protein domains, these methods act at the level of mRNA destruction 
or inhibition of protein synthesis, and can potentially entirely remove the
protein target from the cell. The use of RNAi has proven to be highly effective 
in the removal of target RNA. Stably expressing vector systems for the small
interfering RNA (siRNA) molecules have been developed, potentially allowing 
long-term expression in cells 213.   
 
In general, the RNAi strategy follows a simple design with well-defined 
algorithms and is less technically challenging than intrabody techniques; 
however, it has non-specific effects 211,212. This non-specificity takes the form 
of dsRNA-triggered responses mediated by interferon-associated pathways, 
which do not exist in invertebrates and plants 214-216. A gene expression 
profiling study indicated that >1,000 genes involved in diverse cellular
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functions are non-specifically stimulated or repressed in mammalian tissue-
culture cells treated with conventional 21-bp RNAi 215,217. Another limitation 
of the RNAi technique is the relatively short half-life of the desired 
knockdown effects unless stimulatory RNAs are expressed via transfected
recombinant DNA (which delays observation of the knockdown effect). In
contrast, it is useful to use intrabodies for a nearly instantaneous and durable
effect. Intrabodies can block particular binding interactions of target
molecules, by changing their structural conformation or by exerting positive
functions including catalytic functions, stabilization of protein-protein or 
protein-DNA interactions. 
 
1.6.8 Rabbit Antibodies as Intrabodies Source 
 
The rabbit antibody repertoire has been used for decades in diagnostic
applications in the form of polyclonal antibodies. Nowadays, it offers an
attractive alternative for the generation of therapeutic monoclonal antibodies
218,219. Humanized antibodies from immunized rabbits extend the accessible
epitope repertoire of a given antigen 220. Epitopes that are not immunogenic in 
human or mice might be immunogenic in rabbits. This is of particular interest
for the development of therapeutic scFv or single-domain antibodies that need 
to be evaluated in disease mouse models, and are required to recognize both
the human antigen and its mouse homologues. Moreover, as previously
demonstrated, rabbit antibodies can be converted to humanized antibodies that 
retain both high specificity and affinity for the antigen 220. In addition, we have 
already demonstrated that rabbit antibody fragments against viral proteins can 
be highly expressed in reducing environments of mammalian cells and 
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consequently block viral protein functions 121,131,221. Within this context, rabbit 
antibodies are used as intrabody source in the present thesis.  
 
1.7 HIV-1 IN protein as therapeutic target for intracellular immunization 
 
Each step of the HIV life cycle can be a potential target for inhibition. RT and 
PR were the initial targets for inhibition and subsequently, viral entry and
integration received considerable interest from the scientific community 82. As 
describe above, IN makes an attractive target for inhibition since is absolutely 
required for a stable and productive infection by HIV-1 222-224. Furthermore, IN 
is highly conserved among HIV-1 clinical isolates and no human homologue 
known of IN exists 16,19,224,225. During the last 10 years, several IN inhibitors 
have been designed to block this critical step in the HIV replication cycle 17,226. 
However, progress in the development of IN inhibitors have been slow, given 
that most of these compounds have not met the minimum standards required to
be defined as lead molecules in the search for clinically useful, or turned out to 
be toxic in cell cultures 17,18. Within this context, intracellular antibodies 
against IN protein might be a strong alternative approach to identify new 
therapeutic molecules that can efficiently block the integration process. 
Therefore, in the present thesis, IN of HIV-1 was chosen as a potential 
therapeutic target for our intracellular immunization strategy. Structure and 
function of IN will be therefore described in detail in the following section.  
 
 
1.7.1 HIV-1 IN  
 
The HIV-1 IN protein belongs to a protein superfamily of nucleotidyl
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transferases that include RNase H, Holliday junction resolvase RuvC, bacterial
Mu and Tn5 transposases, the recombination-activating gene (RAG) 1 subunit
of the RAG1/2 recombinase, and the Argonaute protein of the RNA-induced 
silencing complex (RISC) 227-229. These enzymes break and/or join nucleic 
acids via their phosphodiester backbones. The enzyme active-site domains 
adopt a similar protein fold (referred to as the RNase H fold) and harbour 
conserved Asp and Glu amino acid residues that coordinate Mg2+ metal ions to 
effect bimolecular in-line nucleophilic substitution (Sn2) reactions at the
scissile phosphoester bond 19. 
 
1.7.2 HIV-1 DNA Integration 
 
The process of retroviral integration has been divided as a two well-
characterized catalytic steps referred to as 3’ processing (the removal of two
terminal nucleotides from the 3’ends of the viral double-stranded DNA) and 
strand transfer (transfer of viral DNA to the human chromosomal 
DNA) 19,69,230,231. However, if HIV-1 integration is to be considered as possible 
drug target, it may be better described it as four unique processes that can be
targeted and potentially inhibited: (1) assembly of a stable complex between 
IN and specific viral DNA sequences at the end of the HIV-1 long terminal 
repeat regions (LTRs), (2) 3’-end processing, (3) strand transfer, and (4) DNA 
gap repair and ligation (Figure 1.4). 
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Figure 1.4 DNA cutting and joining steps in retroviral integration. The IN enzyme cleaves 
the viral DNA ends after a CA dinucleotide (3’end processing) and integration occurs in the 
nucleus (strand transfer). Viral DNA integration leads to a signature duplication of a short
stretch of cellular DNA, represented as ‘VWXYZ’. After integration, cellular enzymes repair
and ligate the viral/cellular DNA junction (adapted from 12 ). 
 
 
(1) IN binds to viral DNA 
 
After the viral RT enzyme creates a double-stranded DNA product, IN 
assemble at the ends of the viral DNA and binds to the HIV-1 LTR region. The 
viral LTR ends contain specific DNA sequences that are required for
recognition by IN resulting in a stable viral DNA-IN binding complex 19,69,232. 
This is a crucial initial step in the integration process. One class of INIs in 
preclinical development is the pyrano-dipyrimidines (PDPs). These 
compounds have been shown in vitro to prevent viral DNA binding to IN, thus 
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preventing proper assembly of viral DNA (step 1) and consequently any
further steps of integration 233. 
 
(2) First catalytic step - 3’end processing 
 
During 3’-end processing, IN removes a pGT dinucleotide at each end of the
viral DNA LTRs adjacent to a highly conserved CA dinucleotide from the 3’
end extremity of the linear viral genome producing new 3’ hydroxyl ends (CA-
3-OH) 19,230,231,234. This reaction takes place in the cytoplasm of the CD4+ T-
cell within the preintegration complex (PIC). This complex contains linear 
viral DNA and several viral proteins including MA, RT, IN, and NC 69,235. The 
HIV-1 PIC is a cytoplasmic nucleoprotein structure derived from the core of
the virion and is responsible for reverse transcription of viral RNA to DNA,
transport to the nucleus, and integration of the viral DNA into the genome of
the host cell 19,69. Another class of INIs in preclinical development is the
styrylquinolines. These agents have been described as potent in vitro 3’-end
processing inhibitors by directly competing for HIV LTR substrates 236. 
 
(3) Second catalytic step - strand transfer or “transesterification” 
 
Strand transfer is temporally and spatially separated from 3’ end processing
and occurs after the transport of the PIC from the cytoplasm through a nuclear
pore into the cell’s nucleus 19,237,238. After the PIC is transported, the processed 
viral DNA-IN complex is joined to the host DNA by IN. Both 3’ ends of the
viral DNA generated from the first reaction are processed simultaneously 239. 
In the nucleus, the IN binds to the host’s cellular DNA and mediates a
concerted nucleophilic attack by the 3’ hydroxyl residues of the viral DNA on
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phosphodiester bridges located on either side of the major groove in the target
DNA 19,239. Next the processed CA-3-OH viral DNA ends are ligated to the 5’-
O-phosphate ends of the target DNA, irreversibly binding the viral DNA to the 
cellular DNA 239,240. IN strand transfer inhibitors (STIs) can prevent this
catalytic reaction from taking place. The β diketo acids (DKAs) and their DKA 
derivatives are examples of strand transfer inhibitors that have been shown in 
vitro and in vivo to effectively stop this process 97,241. Oxadiazoles are another 
class of INIs in early development that are described as nuclear import 
inhibitors 242. These compounds have been shown in vitro to indirectly prevent 
the second catalytic step of integration by targeting and preventing the nuclear
translocation of the HIV-1 PIC 242. 
 
(4) Gap repair and ligation of viral DNA to host DNA 
 
After the strand transfer reaction, the new product (viral DNA-cellular DNA 
combination) is a gapped intermediate product in which the 5-phosphate ends 
of the viral DNA are not attached to the 3-OH ends of the host DNA 230. The 
integration reaction is completed by the removal of the two unpaired
nucleotides at the 5’ end of the viral DNA and the repair of the single-stranded 
gaps created between the viral and target DNA 243. Although IN may be 
involved in these repair reactions, it is not necessary because the host cell 
already has the machinery to carry out such processes. So repair is probably
accomplished by host cell DNA repair enzymes 230,243. Staggered strand 
transfer and gap repair result in the duplication of host cell sequences
immediately flanking the inserted proviral DNA. For the integration reaction,
no source of energy is needed and only divalent cations such as Mn2+ or Mg2+
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are required for the catalytic activity 239. 
 
1.7.3 HIV-1 IN structure 
 
The HIV-1 IN consists of a 288 amino acid protein (32 kDa) encoded at the 
3’end of the HIV pol gene, which contains three distinct domains: (1) N-
terminal, (2) catalytic core, and the (3) C-terminal (Figure 1.5A) 19,230,244,245. 
To date, the insolubility of HIV-1 IN has been the main barrier in obtaining a 
crystal structure of the full-length IN. However, the discovery of a single 
mutant, through site-directed mutagenesis, within the catalytic core of IN 
dramatically increased its solubility while retaining catalytic activity 246. The 
substitution of lysine 185 for phenylalanine enabled IN50-212 to be 
crystallized and its structure to be solved for the first time by Dyda et al 227. 
Since then other crystal structures of the isolated catalytic core and in complex 
with either the C-terminal or the N-terminal have been resolved (Figure 1.5B)
247-251. 
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Figure 1.5. Integrase protein domains and structures. (a) Domain organisation and amino 
acid residues conserved among retroviral integrase proteins. The enzyme comprises the N-
terminal domain (NTD, aa 1–49), catalytic core domain (CCD, aa 50–212) and C-terminal 
domain (CTD, aa 213–288). The H and C residues within the NTD are additionally conserved
among retrotransposon integrase proteins. The D and E residues in the CCD form the DDE
motif (red font). The K159 residue, which contributes to binding to the viral long terminal
repeat (LTR), is found among a smaller subset of transposase proteins. The W 235 in the CTD
is conserved only among the retroviral integrases. The function and fold of the protein 
domains are indicated below the domain organisation. (b) X-ray crystal structure of IN1–212 
[protein database code (PDB) 1K6Y](Ref. 250). Two NTD–CCD dimers (green/blue and 
yellow/magenta) are identified within the crystallographic asymmetric unit. Grey sphere, zinc 
atom; red side chains, DDE active-site residues. (c) X-ray structure of dimeric IN52 –288 
(PDB code 1EX4). The CTD of the blue monomer may help to position the LTR DNA end to
the DDE active site of the green monomer for catalysis (Ref 251) (adapted from 72). 
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(1) N-terminal domain - NTD 
 
The N-terminal domain (amino acids 1–49) is believed to be involved in 
protein multimerization and contains a histidine-histidine-cystine-cystine 
(HHCC) motif that coordinates zinc binding 244,252-255. The binding of zinc to 
the HHCC motif stabilizes the protein folding of IN and bound zinc is required
for optimal enzymatic activity 252. Point mutations of His or Cys residues 
abolish the zinc binding ability of IN and affect the 3’-processing and strand 
transfer activity but do not impair disintegration activity 256,257. These results 
confirm that the active site is not located in the NTD and that this domain is
not the single DNA binding domain in the protein 257-261. Further, chimeric 
experiments with HIV-1 IN and visna virus IN indicated that the NTD also 
does not contribute to viral DNA specificity 262. However, the NTD is 
proposed to interact with DNA in the context of the whole protein 257-260.  
 
The structures of the NTD of both HIV-1 and HIV-2 IN have been solved by 
multidimensional heteronuclear magnetic resonance 249,263. The HIV-1 IN N-
terminal domain is composed of four α helices. A hydrophobic core stabilizes
the lower region of the monomer, and coordination of zinc to the His and Cys
residues of the HHCC motif stabilizes the upper part of the monomer structure
249. The monomer of the N-terminal domain of HIV-2 integrase adopts the 
same structure 263. The N-terminal domain of HIV-1 IN is a dimer with an 
interface composed predominantly of hydrophobic residues, whereas that of
HIV-2 appears to be monomeric 19.  
 
 
                                                                                                               Introduction 
 
 
47 
 
(2) Catalytic core domain - CCD  
The central or catalytic core domain (amino acids 50–212), which is well 
conserved among retroviral IN and also shares significant sequence similarity 
with the transposase proteins of many mobile genetic elements, contains the
well-know DDE motif 19. These invariant residues, Asp64 (D64), Asp116
(D116), and Glu152 (E152) are key residues of the active site 257,264. In the 
context of full-length IN, the CCD has been assigned a direct role in carrying
out the 3’-processing and strand transfer reactions, in recognizing the 
conserved CA/TG base pairs near the viral DNA end and in recognizing target
DNA 264-269. Mutations of the conserved residues D116N, E152Q abolished
detectable activity in all three processes while the mutations D64E and D64N
retain barely detectable strand transfer and disintegration activity 244,264. 
Mutational studies on other residues within the CCD identified K159 as an
important residue for the recognition of the conserved CA dinucleotide of viral
DNA 270 and excluded other residues initially thought to be important for 
activity 271. The flexibility of the active site loop that consists of residues 141-
148 is important for integration. When residues G140 and G149 that act as 
conformational hinges for the loop are replaced with alanines the flexibility of 
the loop is diminished. These mutants loose catalytic activity but retain DNA
binding affinity. Based on this observation the loop is proposed to have a role
in a reaction step after the DNA binding step 272. The importance of the 
flexible loop 140-149 was also corroborated by molecular dynamics studies
273. 
The structure of the catalytic domain of HIV-1 IN has been determined by x-
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ray crystallography 227. It is a dimer that is spherical in shape, with each
monomer forming one hemisphere. The catalytic residues D64, D116, and 
E152 in the IN structure are in close proximity, coordinate divalent metal ion,
and define the active site 227. However, the residues comprising the active site
region exhibit considerable flexibility, suggesting that binding of DNA 
substrate is required to impose the precise configuration of residues that is 
required for catalysis.  
(3) C-terminal Domain – CTD 
 
The C-terminal domain (amino acids residues 213-288) is the least conserved 
domain of IN 19. The CTD is proposed to be involved in the multimerization of 
IN 274, in binding DNA nonspecifically and is required for 3’-processing and 
strand transfer activity 234,265,275. Mutational analysis identified residues in the 
CTD critical for oligomerization and DNA binding 276. Viral DNA specificity 
was mapped to both the CTD and CCD and CTD-DNA interactions were 
identified just inside the CAGT base pairs of the viral DNA. A similar function
for site-specific DNA binding is exhibited by transposases 277. Earlier studies 
attributed the interactions of the target DNA to the CTD however; the present
studies indicate that all three domains interact with the target DNA 19. 
Furthermore, experiments showed that CTD is involved in interactions with
HIV-1 RT 278,279. The structure of the C-terminal domain of HIV-1 IN was 
determined by two laboratories using multidimensional heteronuclear magnetic 
resonance 247,280. Both structures are dimeric, with each monomer composed of
five-stranded β barrel that is topologically very similar to solved structures of
Src homology 3 (SH3) domains. The dimer is formed by stacking of β strands
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2, 3, and 4 of each monomer, with the β sheets from the two subunits stacked 
in an antiparallel configuration to form the dimer interface 19,247,280.  
 
1.7.4 Multimeric Organization of HIV IN 
 
The active form of IN is believed to be a multimer although the degree of 
active multimer, has not been determined. The evidence for an active multimer 
is derived from domain deletion studies demonstrating that isolated domains of
HIV-1 IN do not possess activity 19. In contrast, independent domains of IN 
can complement each other and restore IN activity 281-284. The trans
interactions between the NTD and the CCD of HIV-1 IN mutant proteins 
indicated that an intact NTD and CCD must be part of different monomers
within the multimer. On the other hand, the CTD could function in both cis
and trans interactions with the CCD 285. Based on gel filtration experiments 
full-length IN exists in a dimer-tetramer equilibrium in solution. The isolated 
CCD and CTD and the two domain CCD-NTD complex exist as a dimer 19. On 
the other hand, the two domain CCD-CTD complex exists in a dimer-tetramer 
equilibrium. These results point to the CCD and CTD as the necessary
domains for multimerization 274. Nevertheless, Zn2+ was found to promote 
multimerization indicating that the NTD as well is important for protein-
protein interactions 252,286. Experimental data point towards a tetramer as the 
minimal active form of IN. Cross-linked tetramers could catalyze full-site 
integration in vitro while dimmers could integrate just one viral LTR end to the
target DNA 287. In detailed IN-DNA models DNA cross-links occurred in trans
to the active site 288,289. A reconstructed tetramer of HIV-1 IN was consistent 
with the cross-linking experiments and confirmed the observation that the
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F185K mutation disrupts complex formation in vivo by preventing the 
tetramerization of IN 290. 
 
1.7.5 Host Factors of Integration 
 
The exact mechanism of HIV-1 integration has not been established so far and 
studies support the idea that host factors are required to accomplish integration
of the viral DNA into the human genome in vivo. The disruption of key 
interactions between IN and direct cellular cofactors might provide a novel 
therapeutic approach for the design and development of new classes of anti-
retroviral agents 291. Therefore, a brief description of each IN-interacting 
cellular cofactor is shown below. 
 
LEDGF/p75 is the most recently identified cellular partner of HIV-1 IN. 
LEDGF/p75 is a nuclear protein that may act as a chromatin docking factor or
receptor for lentiviral pre-integration complexes. LEDGF/p75 tethers HIV-1
IN to chromatin, protects it from degradation, and strongly influences the
genome-wide pattern of HIV integration 292.  
 
BAF, a single polypeptide that consists of 89 amino acids was first identified 
as a host factor of MoMLV 293 and later as part of the PIC complex of HIV 294. 
BAF prevented autointegration in the MoMLV virus and a similar role has
been proposed for the HIV-1 virus 294.  
 
HMG-I(Y) was identified in PICs isolated from HIV-1 infected cells. In vitro 
depletion of HMG-I(Y) from PICs diminished activity that was restored upon 
back-implementing the protein 295. Mechanistic studies indicated that an 
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interaction between HMG-I(Y) and cDNA promotes the formation of active
IN-DNA complexes, presumably by bringing together DNA segments 295.  
 
INI1, identified in a yeast two-hybrid screen, is the first protein shown to 
directly interact with HIV-1 IN and stimulate its in vitro activity 296. The role 
of full-length INI1 in HIV-1 replication is not yet clarified and the lack of
strong experimental evidence makes it difficult to assign a function for INI1
during HIV-1 replication in vivo 296,297. 
 
The human polycomb group EED protein is another host factor of HIV-1 IN 
and may have a functional role at the early steps of infection. EED contains 
two discreet binding domains located at its N-terminal domain that binds at the 
CTD of IN 298. Another candidate co-factor is the yeast cellular protein HSP60 
that interacts with HIV-1 IN in vitro and stimulates processing and strand 
transfer activities 299.  
 
1.8 Vif protein as therapeutic target for intracellular immunization 
The Vif protein of HIV-1 plays a dramatic importance in viral infectivity 20,21. 
Vif is a basic protein of 23 kDa required in the virus-producing cells during the 
late stages of infection to enhance viral infectivity 10- to 1000-fold 300-303. 
HIV-1 vif-defective virus can replicate in permissive cells such as Jurkat and 
SupT1 cells, but cannot replicate in non-permissive cells such as macrophages,
primary human T cells, and some restrictive T cell lines 300-304. Previous studies 
found that non-permissive cells contain an anti-viral cellular factor capable of 
suppress the HIV infectivity, recently identified as APOBEC3G, for which the
antiviral action is overcome by Vif 22,23. APOBEC3G is a virion-encapsidated 
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cellular protein that deaminates dC to dU in minus-strand viral cDNA during 
reverse transcription, preferentially at CCCA sequences 22,23,305,306. The uracil-
containing cDNA may activate a cellular uracil-DNA-glycosylase causing the 
failure of reverse transcription, characteristic of vif-defective virus 307 and 
impair the integration of the provirus in the host genome 308. Furthermore, if 
the reverse transcription is completed at low efficiency and the resulting
proviral double-stranded cDNA is integrated in the cell genome, the massive
C-U conversion in the minus strand leads to a massive G to A hypermutation of 
the proviral plus-strand cDNA 305,306,309. The exact mechanism how Vif 
counteracts APOBEC3G action is not clear. It has been shown that Vif inhibits 
APOBEC3G translation or intracellular half-life 310,311. Recent evidences 
showed that Vif interacts with APOBEC3G as part of a Vif·Cul5·Sk-p1-Cullin-
F-box complex resulting in the polyubiquitination and proteasomal degradation
of APOBEC3G 312,313. The increase degradation and/or reduced level of 
APOBEC3G expression by Vif reduces its incorporation into virions and 
consequent absence during reverse transcription in the target cell, allowing the 
virus to replicate 311,314.Thus, Vif is an excellent target for therapeutic
intervention.  
Recently we developed a specific scFv from immunized rabbits to HIV-1 Vif 
protein that was expressed intracellularly and inhibited reverse transcription 
and viral replication 131. Moreover, we have also shown that anti-Vif camelized 
VH domains alone may be useful as intrabodies, with improved intracellular 
expression 121. In the present dissertation, we will now show that rabbit VL 
domains can also be potentially used as intrabodies. 
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Abstract 
Since the discovery of the HIV-1 as the causative agent of AIDS its spread 
has been dramatic. Current therapies use a combination of drugs targeted at 
the viral RT and PR enzymes. The clinical benefits of these therapies are 
considerable, although many multiple drug-resistant viral strains have 
arisen. The addition of new anti-HIV drugs targeting a third step of the viral 
replication may help in preventing resistance development. The HIV-1 IN 
protein establishes infection during the early stages of the retroviral life 
cycle and therefore is an attractive target for therapeutic intervention. Based 
on this, our strategy is to make susceptible CD4+ cells resistant to infection 
by expressing scFv intrabodies against HIV-1 IN. In the present study, we 
have for the first time immunized rabbits with HIV-1 IN and developed a 
combinatorial scFv library against IN. We were able to identify 5 different 
scFv antibodies with high binding activity and specificity to IN. These scFv 
bound simultaneously to the catalytic and C-terminus domains of IN. Cells 
expressing anti-IN scFvs localized in either cytoplasmic or nuclear 
compartment were highly resistant to HIV-1 infection. Furthermore, when 
HIV-1 particles where produced in the presence of anti-IN scFv, the 
expression of intrabodies did not affect virion production significantly. 
However, it markedly reduced the infectivity of progeny virions due to the 
incorporation of anti-IN scFvs into the viral particles. These results provide 
proof-in-principle that anti-IN scFv intrabodies can be designed to block 
early and late stages of HIV-1 replication without causing cellular toxicity, 
and as a result, they may be useful agents for "intracellular immunization"-
based on gene therapy strategies for HIV-1 infection.  
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2.1 Introduction  
The spread of HIV-1 has been dramatic since the early eighties, when the 
virus was discovered as the causative agent of AIDS 1,2. In the absence of an 
effective vaccine against HIV, a worldwide search has been made in the past 
two decades to develop small-molecule inhibitors to target essential steps in 
the viral cycle 10. Highly Active Antiretroviral Therapy (HAART) is one of 
the most used treatment regimens in our days. The regimen employs a 
combination of therapeutic agents that target the viral reverse transcriptase 
(RT) and protease enzymes (PR) 10-12. In the developed world, access to 
HAART has led to significant reductions in the morbidity and mortality 
attributed to HIV/AIDS. However, the emergence of drug-resistant virus 
isolates is causing an increasingly detrimental impact on treatment options 
and the disease outcome 13-15. As a result, there is a pressing need to identify 
and develop new drugs that can be effective against these highly resistant 
virus isolates.  
Integrase (IN) is currently the focus of an intense research effort to develop 
new anti-HIV-1 drugs 16-18. This enzyme catalyses the integration of the 
HIV genome into the chromosome of the host cell, arguably the most 
insidious step in the infection process 19. The HIV-1 IN consists of a 288-
amino-acid protein (32 kDa) encoded at the 3’end of the HIV pol gene, 
which contains three distinct domains: N-terminal, catalytic core, and the C-
terminal 19,230,244,245. The N-terminal domain (amino acids 1–49) is believed 
to be involved in protein multimerization and contains a histidine-histidine-
cystine-cystine (HHCC) motif that coordinates zinc binding 244,252-255. The 
central or catalytic core domain (amino acids 50–212) contains a highly 
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conserved triad of acidic residues D64, D116, and E152 (DDE motif) that 
are involved in catalysis 19,257,264. Mutation of any of these acidic residues 
has been shown to abolish HIV-1 IN activity 244,264. The C-terminal domain 
(amino acids 213–288), the least conserved of the three protein domains, 
binds the viral DNA ends and might also contribute to the binding of 
chromosomal DNA during integration 234,265,274,275.  
During the last 10 years, several IN inhibitors have been designed to block 
this critical process in the HIV replication cycle 17,226. However, progress in 
the development of IN inhibitors has been slow, given that most of these 
compounds have not met the minimum standards required to be defined as 
lead molecules in the search for clinically useful application, or turned out 
to be toxic in cell cultures 17,18. Only recently this situation has changed 
when the first IN inhibitor for clinical use, the MK-0518 (raltegravir), was 
validated and received the FDA approval 97. Although a second compound, 
GS-9137 (JTK-303, elvitegravir) is in clinical trials, new agents and 
therapeutic approaches must continue to be identified and developed to 
block this crucial step in HIV-1 replication 98,99. 
Over the recent years, gene therapy has been highly regarded as a new form 
of molecular medicine in treatment of HIV/AIDS, either as an alternative or 
as a complement to anti-retroviral chemotherapy 24-26. Within this context, 
intracellular antibodies (intrabodies) represent a new class of neutralizing 
molecules with potential use in gene therapy approaches 27-29. An intrabody 
consists of an antibody designed to be expressed intracellularly and directed 
to different subcellular compartments where they can exert their function 
more effectively 110,111. Intrabodies can be expressed in several forms 30.  
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The most commonly used format consists of a single-chain antibody (scFv) 
in which the variable domain of the heavy chain (VH) is connected to the 
light chain (VL) through a peptide linker. The specificity and affinity of the 
parent antibody is preserved in this process 110,111. The binding of an 
intrabody to its molecular target has the potential to block, suppress, alter or 
even enhance the process mediated by that molecule 31-33.  
A number of murine monoclonal antibodies (mAbs) directed against HIV-1 
IN has been raised and characterized by several groups 315-323. Some of these 
mAbs have already been cloned into scFv fragments and tested as 
intrabodies 320,321. Although some of these block HIV-1 replication, they are 
all derived from murine IgG molecules and were generated by hybridoma 
technology. The rabbit antibody repertoire has been used for decades in 
diagnostic applications in the form of polyclonal antibodies. Nowadays, it 
offers an attractive alternative to the murine antibody repertoire for the 
generation of therapeutic monoclonal antibodies 220. Combinatorial rabbit 
scFv libraries have the potential to display the entire immunological record 
of an individual, allowing the detection and recovery of any antibody ever 
made, irrespective of whether it is currently being produced. In addition, we 
have recently demonstrated that rabbit antibody fragments against viral 
proteins can be highly expressed in reducing environments of mammalian 
cells and consequently block efficiently viral protein functions 121,131,221.  
In the present study, we have for the first time immunized rabbits with HIV-
1 IN and developed a combinatorial scFv library against IN. We were able 
to identify 5 different scFv antibodies with high binding activity and 
specificity to IN. These scFvs bound simultaneously to the catalytic and C-
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terminus domains of IN. In addition, antibodies binding to these epitopes 
inhibited the strand transfer processing, whereas no effect was observed in 
the 3’end processing. Intrabody-expressing cells localized in either 
cytoplasm or nuclear compartments were highly resistant to HIV-1 
infection. Moreover, when HIV-1 particles where produced in the presence 
of anti-IN scFv, the expression of intrabodies did not affect virion 
production significantly. However, it markedly reduced the infectivity of 
progeny virions due to the incorporation of anti-IN scFvs into the viral 
particles. These findings provide proof-in-principle that rabbit anti-IN scFv 
intrabodies can be designed to block early and late stages of HIV-1 
replication. As a result, they might be useful agents for "intracellular 
immunization"- and used as new tools to study the structure and function of 
HIV-1 IN due to their epitope binding characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
Generation of anti-IN scFv intrabodies 
 
                                                         
 60 
2.2 Material and Methods 
2.2.1 Plasmids   
 
Plasmid coding for HIV-1NL4-3 was obtained from the AIDS Research and 
Reference Reagent Program. Plasmid pComb3X is derived from pComb3H 
324. Plasmid pCEP-INs was kindly provided by Dr. Zeger Debyser and 
contains an HIV-1 IN synthetic gene that was designed to be highly 
expressed in mammalian cells 325. The envelope plasmid pMD.G, was kindly 
provided by Dr. Didier Trono. Plasmid pcDNA3.1/Zeo(+) and pBR322 were 
obtained by Invitrogen. pMX-KRAB8FPBS2puro is a retroviral vector 
derived from pMX-puro, which comprises the 5' LTR and 3' LTR regions, 
lacks the complete gag, env, or pol genes and contains a puromycin 
selectable marker 326. The pMX-KRAB8FPBS2puro vector expresses a 
single bicistronic message for the translation of the 8FPBS2 zinc finger 
protein and additionally appends an HA-tag 327. Plasmid pNde675 has been 
previously described and is derived from pCR2.1 (Invitrogen) 328.  
 
2.2.2 Antibodies and cell culture  
The following antibodies were used for the present study: anti-M13-HRP 
mAb (Roche), anti-HA-HRP mAb (Roche), rhodamine-conjugated anti-HA 
mAb (Roche), Alexa-conjugated goat anti-rabbit immunoglobulin antibody 
(Pierce), anti-IN polyclonal antibody (#7375) and anti-p24 mAb (both from 
AIDS Research and Reference Reagent Program). 293T (American Type 
Culture Collection), Gag-Pol 293 cells (Clontech) and HeLa CD4 LTR-β-
Gal cells (AIDS Research and Reference Reagent Program) were 
                                                 Generation of anti-IN scFv intrabodies 
 
                                                         
                                                                   61 
maintained in DMEM and Jurkat cells were maintained in RPMI 1640 
medium. Media was supplemented with 10% fetal calf serum (FCS), 
antibiotics (100 units/ml penicillin and 100 µg/ml streptomycin) and 2 mM 
L-glutamine. Stable Jurkat clones expressing anti-IN scFv were maintained 
in the presence of puromycin (1 µg/ml). All cell cultures were maintained at 
37°C in 5% CO2. Tissue culture media and reagents were from 
BioWhitaker. 
 
2.2.3 Rabbit immunization 
 
Two New Zealand White rabbits were treated with 4 subcutaneous 
injections containing 200 µg of purified HIV-1 IN protein in a 1 ml 
emulsion of adjuvant (Ribi Immunochem Research, Hamilton, MT). The 
injections were administered in a 2-3 week intervals. Antisera from the 
immune animals was analyzed for binding to HIV-1 IN protein by ELISA 
using HRP-conjugated goat anti-rabbit Fc polyclonal antibodies as 
secondary antibodies (Pierce). Five days after the final boost, spleen and 
bone marrow from one leg were harvested and used for total RNA 
preparation with TRI-REAGENT from Molecular Research Center 
(Cincinnati, OH) according to the manufacturer’s protocol. 
 
2.2.4 cDNA synthesis, antibody library construction and phage display 
 
First-strand cDNA was synthesized using the Superscript Pre-amplification 
System with oligo(dT) priming (Life Technologies). Specific oligonucleotide 
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primers covering all known variable rabbit antibody family sequences were 
used to amplify separately VH and VL gene segments (Table 2.1) 324. 
  
Table 2.1 – Primers used to amplify chimeric rabbit scFv libraries.  
Primer  Sequence 5´to 3’ 
RSClambda1 
 
GGG CCC AGG CGG CCG AGC TCG TGC TGA CTC AGT CGC CCT C  
 
RJlambda0-BL 
 
 GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA GCC TGT GAC GGT CAG CTG GGT CCC  
 
RSCVK1   
 
 GGG CCC AGG CGG CCG AGC TCG TGM TGA CCC AGA CTC CA  
 
RSCVK2 
 
 GGG CCC AGG CGG CCG AGC TCG ATM TGA CCC AGA CTC CA 
RSCVK3 
 
 GGG CCC AGG CGG CCG AGC TCG TGA TGA CCC AGA CTG AA 
RKB9J0-BL 
 
 GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA TAG GAT CTC CAG CTC GGT CCC  
RKB9J10-BL  GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA TAG GAT CTC CAG CTC GGT CCC 
RSCVH1 
 
 GGT GGT TCC TCT AGA TCT TCC CAG TCG GTG GAG GAG TCC RGG  
 
RSCVH2 
 
 GGT GGT TCC TCT AGA TCT TCC CAG TCG GTG AAG GAG TCC GAG  
 
RSCVH3 
 
 GGT GGT TCC TCT AGA TCT TCC CAG TCG YTG GAG GAG TCC GGG 
 
RSCVH4  GGT GGT TCC TCT AGA TCT TCC CAG SAG CAG CTG RTG GAG TCC GG  
 
RSCG-B 
 
 CCT GGC CGG CCT GGC CAC TAG TGA CTG AYG GAG CCT TAG GTT 
GCC C  
 
RSC-F 
 
 GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC  
RSC-B 
 
 GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC TAG TG  
 
 
 
The purified variable regions products were then assembled into scFv 
format by overlapping PCR. An 18–amino acid linker fragment 
(SSGGGGSGGGGGGSSRSS) was used to connect the VL and VH 
fragments. The final DNA fragments encoding a library of scFv antibody 
fragments (VL–linker–VH) were gel-purified, digested with SfiI, and cloned 
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into the appropriately cut phagemid vector pComb3X. A schematic 
representation of the PCR steps is shown in Figure 2.1. pComb3X contains 
a suppressor stop codon and sequences encoding peptide tags for 
purification (6-His) and detection (HA). The recombinant phagemid was 
introduced into competent E. coli ER2538 cells by electroporation. The 
phage library displaying the scFv fragments was panned against 
immobilized HIV-1 IN antigen using a solid-phase protocol. For each round 
of selection, 1 µg of antigen in PBS was coated on triplicate wells of a 96-
well microtiter plate (Corning). The plates were coated overnight at 4°C and 
subsequently blocked with 3% BSA in PBS for 1 h at 37°C. The blocking 
reagent was then replaced by 50 µl of freshly prepared phage from the 
starting library. Plates were incubated at 37°C for 2 h. The unbound phages 
were discarded and the wells were washed with 0.5% Tween–PBS and 
incubated at room temperature for 5 min. The wells were washed 5 times in 
the first round of selection and 10, 15 and 15 times in the following 3 
rounds of selection, respectively. The bound phage were eluted by applying 
50 µl/well of 10 mg/ml trypsin and incubating at 37°C for 30 min. Eluted 
phage from triplicate wells were combined and directly added to fresh 
ER2538 bacterial culture for infection, phage amplification and titration. 
One hundred and fifty scFv phage-clones from the final output were 
randomly selected for ELISA to evaluate their binding activity against HIV-
1 IN.  HRP-conjugated anti-M13 mAb (Roche) was used for detection. All 
clones with a strong signal above background were further analyzed by 
DNA fingerprinting and sequencing. 
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Figure 2.1 Generation of scFv antibody fragments by PCR overlap extension for 
cloning into the pComb3x. In the first PCR round, the variable light chain regions (Vλ and 
Vκ) were amplified from rabbit cDNA by using specific VL primers (Table 2.1). Each sence 
primer has a 5’ sequence tail that contains an SfiI site and is recognized by the sense 
extension primer used in the third-round of PCR, each reverse primer has a linker sequence 
tail that is used in the overlap extension.  In the second PCR round the variable heavy chain 
Generation of anti-IN scFv intrabodies 
 
                                                         
 66 
regions (VH) are amplified from rabbit cDNA by using specific VH primers (Table 2.1). 
Each of the RCSVH sence primers is combined with the RCSG-B reverse primer, which 
recognizes the 5’ end of the rabbit CH1. The sence primers have a sequence tail 
corresponding to the linker sequence that is used in the overlap extension PCR. The reverse 
primer has a sequence tail corresponding to the linker sequence that is used in the overlap 
extension PCR. The reverse primer has a sequence tail containing an SfiI site, this tail is 
recognized by the reverse extension primer used in the second-round PCR. In the third PCR 
round each purified variable regions products are assembled into scFv format by 
overlapping PCR using the RSC-F and RSC-B. These primers recognize the sequence tails 
that were generated during the first and second round of PCR. The 800 bp PCR products 
have asymmetric SfiI sites on the 5’ and 3’ ends that are used for cloning into the pCom3x 
vector (Adapted from 324). 
 
2.2.5 Expression and purification of anti-IN antibody fragments 
To express and purify selected anti-IN scFvs, phagemid DNA was 
transformed into non-suppressor E. coli strain TOP10F. A fresh colony of 
each clone was grown at 37º C overnight in SB medium containing 100 
µg/ml of ampicillin. A 10 ml sample of cells was used to inoculate 1 liter of 
SB medium containing 100 µg/ml of ampicillin. Cells were grown at 37º C 
until A600nm= 0.9, induced by the addition of 0.5 mM IPTG and growth was 
continued for 18 hours. After induction, bacteria were harvested by 
centrifugation (4,000 × g, 4°C, and 15 min), resuspended in 50 ml 
equilibration buffer (20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole 
(pH 7.4)), supplemented with protease inhibitors (Roche), and lysed by 
sonication. Cell debris were removed by centrifugation (40,000 × g, 4° C, 30 
min), and the supernatant was filtered through a 0.2-µm syringe filter. All 
chromatographic steps were performed at 4 ºC. First, scFv extracts were 
                                                 Generation of anti-IN scFv intrabodies 
 
                                                         
                                                                   67 
purified by nickel chelate affinity chromatography using the C-terminal His-
tag. Bound proteins were eluted with a linear imidazole gradient (0-300 mM 
imidazole in 20 mM NaH2PO4, 0.5 M NaCl (pH 7.4)). The appropriate 
fractions from IMAC were pooled, dialyzed against 20 mM Tris (pH 8.0), 
50 mM NaCl, 1 mM EDTA and loaded onto a mono Q anion exchange 
column (Pharmacia), equilibrated in the same buffer. Elution from the anion 
exchange column was achieved with a 0 to 800 mM NaCl gradient. Pooled 
fractions of all antibody fragments were dialyzed against PBS. Protein 
purity was checked by non-reducing SDS-15% PAGE. Protein 
quantification was determined by the classic Bradford method.        
 
2.2.6 In vitro binding studies of anti-IN antibody fragments 
 
Relative binding affinities of purified anti-IN antibody fragments were 
determined via enzyme-linked immunosorbent assay (ELISA) after coating 
the wells with 500 ng of purified recombinant HIV-1 IN protein, HIV-1 
protease (PR) or BSA, overnight at 4ºC. Wells were blocked for one hour at 
37ºC with BSA 3% in PBS. Purified anti-IN scFvs were added to the wells 
for further 1 h incubation at 37ºC. After washing the wells with PBS, HRP-
conjugated anti-HA mAb (Roche) was used for detection. The results were 
measured by optical density at 405 nm and performed in triplicate. 
Specificity recognition of IN by anti-IN scFvs was next demonstrated by 
western-blot analysis. HIV-1 IN and HIV-1 PR proteins at several amounts 
were separated by PAGE and transferred to nitrocellulose membranes. After 
blocking, proteins were probed with each purified anti-IN scFv clones and 
then with HRP-conjugated anti-HA mAb (Roche), as a secondary antibody. 
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Proteins were visualized using the ECL system (Amersham Pharmacia). 
BM10 is an anti-LANA scFv and was used as an irrelevant control antibody 
in both assays 221. 
 
2.2.7 Mapping HIV-1 IN epitopes 
 
To explore the IN epitope, purified anti-IN antibody fragments were tested 
for binding to a set of linear 20-mer peptides representing the entire HIV-1 
IN sequence (AIDS Research and Reference Reagent Program). Briefly, 
covalink ELISA plates (Nunc) were coated overnight with 5 µg of each 
peptide. After blocking with 3% BSA in PBS, purified anti-IN ScFv were 
added to the wells and incubated 1 h. After washing the wells with low ionic 
buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 0.1% Triton X-100) or high 
ionic buffer (500 mM NaCl, 50 mM Tris, pH 7.5, 1% Triton X-100), HRP-
conjugated anti-HA mAb (Roche) was used for detection. All steps were 
performed at room temperature. The results were measured by optical 
density at 405 nm and performed in triplicate. BM10 was used as an 
irrelevant control antibody. 
 
2.2.8 DNA substrates for IN activity assays 
 
The 3'-end processing substrate consisted of the terminal 21 bp from the U5 
end of viral DNA was prepared by using the oligonucleotide RZ132 (5'-
GTGTGGAAAATCTCTAGCAGT-3') and AE118 (5'-
ACTGCTAGAGATTTTCCACA-3') 329. RZ132 was treated with alkaline 
phosphatase and 5’ end labeled with [γ-32P] ATP by T4 olynucleotidekinase. 
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The radiolabeled oligonucleotide was then annealed to AE118 and the 
unincorporated nucleotide was removed by centrifugation through a quick 
spin column (Millipore). The pre-cut DNA substrate for the strand transfer 
assay was prepared by NdeI digestion of pNde675 plasmid and resulted in a 
675bp DNA linear fragment flanked by 31bp of HIV-1NL4-3 U5 LTR and U3 
LTR sequences at each ends. The pre-cut DNA fragments were treated with 
alkaline phosphatase and then 5’ end labeled with [γ-32P] ATP by T4 
polynucleotidekinase. The target DNA used in the strand transfer integration 
assay was the supercoiled pBR322 (Invitrogen). 
 
2.2.9 IN activity assays   
 
All IN activity assays were performed essentially as described previously 
with minor modifications 328,329. For the 3'-end processing assay the reaction 
mixtures (25 µl final volume) were assembled by incubating 200 nM 
integrase on ice in 20 mM MOPS, pH 7.2, 0.1 mg/ml BSA, 7.5 mM MnCl2, 
10% glycerol and 10 mM 2-mercaptoeth. These components were 
preincubated on ice for 15 min with anti-IN ScFv at various IN/scFv ratios. 
Then, 20 nM oligonucleotide substrate was added. Samples were further 
incubated 1 h at 37ºC and reactions were quenched by adding 20 µl of 
sequencing gel loading dye (95% formamide, 10 mM EDTA, 0.03% 
bromophenol blue and 0.03% xylene cyanol). A 2.5 µl aliquot of each 
reaction mixture was subjected to electrophorese in a 20% denaturating 
polyacrylamide gel. Gels were dried, exposed to imaging plates and 
visualized and quantified with a Fuji BAS-2500 bio-imaging analyzer. For 
the strand-transfer assay reaction mixtures (25 µl final volume) were 
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assembled by incubating 80 nM integrase on ice in 20 mM HEPES, pH 7.5, 
12% DMSO, 5 mM DTT, 10% PEG-6000, 10 mM MgCl2, 20 mM ZnCl2 
and 100 mM NaCl. These components were preincubated on ice for 15 min 
with anti-IN ScFv at various IN/scFv ratios. After addition of 10 nM DNA 
pre-cut substrate, samples were further incubated on ice 30 min. Then 500 
ng target plasmid DNA pBR322 was added. After a further 30 min 
preincubation on ice, the reaction was initiated by transfering to 37ºC and 
incubation was continued for 90 min. The reactions were stopped by 
addition of 0.1% SDS, 10 mM EDTA and 5 µg of proteinase K. A 2.5 µl 
aliquot of each reaction mixture was subjected to electrophoresis in a 0.8% 
agarose gel in 1×TBE buffer. Gels were dried, exposed to imaging plates 
and visualized and quantified with a Fuji BAS-2500 bio-imaging analyzer.  
 
2.2.10 Expression of anti-IN antibody fragments in eukaryotic cells  
 
After expression studies in E. coli TOP10F and analysis of binding activities, 
genes encoding anti-IN scFv’s were transferred into pcDNA3.1/Zeo+ 
(Invitrogen) by NotI and XhoI digestion. A methionine initiation codon was 
added into all ScFv by PCR as well a sequence encoding the HA-tag 
sequence (YPYDVPDYA) at the C-terminus. The primers used for cloning 
in pcDNA3.1/Zeo+ were: Babe ScFv5 5’-
GGCATGGGGGCCCAGGCGGCCCAGCTC-3’ and Babe ScFv3 5’-
GCCACCACCCTCCTAAGAAGC-3’. Anti-IN ScFv were also cloned into 
pcDNA3.1/Zeo+ with a nuclear localization signal (NLS). The NLS sequence 
was added at the N-terminal end of each fragment by using the primers: 
Babe ScFv5NLS 5’-GGCATGGGGGCCCAGGCGGCCCAGCTC-3’ and 
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Babe ScFv3 5’-GCCACCACCCTCCTAAGAAGC-3’. To analyze the 
intrabodies expression in eukaryotic cells, 293T cells (1-2×106) were 
transfected by a standard calcium phosphate method with 5 µg of plasmids 
encoding the scFv of interest. Forty-eight hours post-transfection, 293T cells 
were washed with 5 ml of cold PBS. Cells were lysed in 1 ml 50 mM Tris 
(pH 8.0), 100 mM NaCl, 1% Nonidet P-40 containing protease inhibitors 
(Roche) for 60 min on ice. The lysates were cleared by centrifugation for 30 
min at 14,000×g, separated by 12% SDS-PAGE and transferred to 
nitrocellulose membrane. Western Blot was performed with HRP- 
conjugated anti-HA mAb.  
 
2.2.11 Immunofluorescence staining  
HeLa CD4 cells (0.5×106/well) transfected by calcium phosphate method 
with 4 µg of plasmids were fixed in PBS with 4% paraformaldehyde for 10 
min at room temperature, permeabilized with PBS plus 0.1 % Triton X-100 
for 5 min, and washed with PBS plus 2% fetal calf serum before staining. 
For IN analysis, fixed cells were incubated with HIV-1 anti-IN polyclonal 
antibody #7375 (1:40) for 90 min at 37°C, washed with PBS and then 
incubated with Alexa-conjugated goat anti-rabbit immunoglobulin antibody 
(1:200) for 30 min at 37°C. For immunostaining of scFv, direct 
immunofluorescence was performed with rhodamine-conjugated anti-HA 
mAb (5 µg/ml). For double immunofluorescence staining of intrabodies and 
IN protein, rhodamine-conjugated anti-HA mAb was used in combination 
with anti-IN polyclonal antibody #7375 and Alexa-conjugated goat anti-
rabbit immunoglobulin antibody at similar concentrations. Slides were 
Generation of anti-IN scFv intrabodies 
 
                                                         
 72 
mounted with DAPI (4,6 diamidino-2-phenylindole) Vectashield (Vector 
Labs, Burlingame, CA) to stain nuclei, and cells were visualized using an 
Olympus IX-50 inverted microscope, Ludl BioPoint filter wheels and a 12-
bit V-scan cool CCD (Photonic Science). Integrated control of filter wheel 
and image acquisition is achieved by Image-Pro Plus 4.0 and Scope-Pro 3.1 
(Media Cybernetics). Settings for image acquisition (camera exposure time, 
filters, time interval and storing modes) were determined by custom-made 
macros. Images were collected with Olympus 40x or 100x plan apo 
objectives (NAs= 0.95 and 1.4 respectively). 
2.2.12 One step viral replication analysis  
One step viral replication experiments were performed into HeLa CD4 
LTR-β-Gal cells. Briefly, HeLa CD4 LTR-β-Gal cells (1×106/well) were 
transfected by calcium phosphate method with 4 µg of plasmids encoding 
anti-IN ScFv. After 24 h of transfection, HIV-1NL4-3 at a multiplicity of 
infection (MOI) of 1.0 was used to infect cells for 5 h. Cells were washed 
with pre-warmed serum free medium and cultured for 48 h. The ability of 
anti-IN ScFv to inhibit early steps of replication was measured by 
quantification of the β-galactosidase activity in cell lysates, using a 
colorimetric assay based on the cleavage of chlorophenolred-β-
Dgalactopyranoside (CPRG) by β-galactosidase. HeLa CD4 LTR-β-Gal 
cells were washed with PBS and lysed with lysis buffer (50 mM Tris (pH 
8.0), 100 mM NaCl, 1 % Nonidet P-40), supplemented with protease 
inhibitors (Roche). After incubation for 30 min on ice, CPRG reaction 
buffer (6 mM in lysis buffer) was added to the cell lysates and incubated for 
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2 h at 37ºC. The results were measured by optical density at 570 nm. BM10 
was used as an irrelevant control antibody. 
2.2.13 Single round infectivity assay and western-blot analysis of anti-
IN scFv and IN packaging into viral particles 
To further evaluate the inhibition of HIV-1 infectivity by anti-IN ScFv, 
293T cells (1-2× 106/well) were cotransfected by calcium phosphate method 
with 8 µg of HIV-1NL4-3 and 4 µg of plasmids encoding anti-IN ScFv. Forty 
eight hours post-transfection, the viral supernatants were normalized for the 
same TCID50 and used to infect subconfluent HeLa CD4 LTR-β-Gal cells 
in 96-well plates. Forty eight hours after infection, the ability of anti-IN 
ScFv to inhibit HIV-1 infection was measured by quantification of the β-
galactosidase activity in cell lysates as described above. To analyze virion 
protein contents, the HIV-1 particles used in the infectivity assay were 
analyzed by Western Blot. Briefly, viral supernatants produced in the 
cotransfected 293T cells were harvested and cleared by low speed 
centrifugation. Virion particles were concentrated by ultracentrifugation and 
then separated on 15% acrylamide gels. For detection of scFv, proteins were 
probed with HRP-conjugated anti-HA mAb. For detection, of IN and p24, 
proteins were probed with anti-IN polyclonal antibody #7375 and anti-p24 
mAb, respectively. Subsequently, blots were probed with species-specific 
HRP-conjugated secondary antibodies.  
2.2.14 Generation of stable anti-IN-scFv-Jurkat cell clones 
pcDNA3.1-anti-IN-scFv plasmids were digested with SfiI, and the anti-IN 
scFv genes were cloned between the two SfiI sites of pMX-
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KRAB8FPBS2puro, replacing the KRAB8FPBS2 zinc finger gene. pMX-
anti-IN-scFv and pMD-G plasmids were co-transfected into the Gag-Pol-293 
packaging cell line (Clontech) using the standard calcium phosphate method. 
After 48 h of incubation, culture supernatants were used for transduction of 
Jurkat cells. After 3-4 weeks of selection in a gel matrix containing 
puromycin, stable anti-IN-scFv-Jurkat clones were isolated and analyzed for 
expression of anti-IN antibody fragments by western blot analysis with HRP-
conjugated anti-HA mAb. 
 
2.2.15 HIV-1 challenge of stable anti-IN-scFv-Jurkat cell clones  
Anti-IN-scFv-Jurkat clones were infected at a MOI of 0.1 to 0.5 for 6 h at 
37°C, washed, and then cultured for up to 20 days. To monitor infection, 
aliquots were taken from the cultures at the indicated time points and p24 
levels were determined using a HIV-1 p24 ELISA (Innovagen). Cellular 
proliferation and viability of infected cells were analyzed with tetrazolium 
salt WST-1 (Roche) according to the manufacturer's protocol. To further 
evaluate if HIV-1 viral replication could be inhibited during late stages, 
viral supernatants at day 12 were normalized by the same TCID50 and 
subjected to ELISA RT activity assay system (RetroSys™ RT Activity Kit) 
following by manufacturer’s instruction (Innovagen). 
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2.3 Results 
2.3.1 Selection of specific anti-IN antibody fragments  
  
Two pairs of rabbits from the New Zealand White strain were immunized 
and boosted four times with 200 µg of purified HIV-1 IN protein. ELISA 
analyses of the rabbit sera from both animals showed that the immunization 
along time resulted in a strong immune response against HIV-1 IN (Figure 
2.2). Rabbits were euthanized and bone marrow and spleen were extracted 
for total RNA preparation and cDNA synthesis. To generate the chimeric 
scFv library, specific oligonucleotide primers covering all known variable 
rabbit antibody family sequences were used to amplify VH and VL gene 
segments 324. The purified variable regions products were assembled into 
scFv format by overlapping PCR. The recombinant phagemid pComb3x was 
transformed into E. coli ER2538 cells to yield 8.3 × 107 individual clones. 
The phage library displaying the scFv fragments was then panned against 
immobilized HIV-1 IN protein using a solid-phase as described in Material 
and Methods section. 
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Figure 2.2 - Titration of serum antibodies A) - Rabbit # 7621 and B) - Rabbit # 7622. 
Antisera from the immunized animals was analyzed for binding to 200 ng of HIV-1 IN 
protein by ELISA using HRP-conjugated goat anti-rabbit Fc polyclonal antibody as 
secondary antibody (PIERCE). Serum titre is defined by the highest limiting dilution 
recognized by the antigen (1:10000).  
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From the final phage-display panning, 150 scFv phage-clones were 
randomly selected for ELISA to evaluate their binding activity against HIV-
1 IN (Figure 2.3). A total of 22 clones with higher-than-background signal 
were isolated and sequenced. We observed that 14 clones shown sequence 
variations in the CDR regions and therefore were chosen for further 
expression and binding characterization (data not shown).   
 
 
Figure 2.3 - Relative binding affinities of scFv phage-clones. A total of 150 scFv phage-
clones were randomly selected for ELISA to evaluate their binding activity against HIV-1 
IN. HRP-conjugated anti-M13 mAb was used as secondary antibody. Results were 
measured by optical density at 405 nm. A total of 22 clones with higher-than-background 
signal were isolated (shown with an arrow). 
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2.3.2 Relative binding affinity and specificity of anti-IN antibody           
          fragments 
 
To determine if the binding efficiency of recombinant scFvs to the HIV-1 
IN protein were correlate with those of scFv phage-clones, we expressed the 
different 14 clones obtained in the periplasm of the non-suppressor E. coli 
strain TOP10F. After 18 hours of IPTG induction, cells were lysed and the 
soluble fraction was subjected to immobilized metal affinity 
chromatography (IMAC) and anion exchange chromatography as described 
in Material and Methods section. All scFvs were highly expressed in the 
form of soluble proteins (Figure 2.4A) and typical yields of pure scFv ( > 95 
%) were in the range of 1 ± 0.1 mg/L of bacterial culture. Relative binding 
affinity and specificity of anti-IN scFv fragments were assessed by ELISA 
and Western Blotting. As shown in Figure 2.4B, all anti-IN scFv clones 
specifically bound to HIV-1 IN protein. In contrast, no binding to IN protein 
was observed with an irrelevant scFv (clone BM10) that specifically 
recognizes the latency-associated nuclear antigen-1 (LANA1) from Kaposi 
sarcoma–associated herpes virus 221. Moreover, experiments showed near 
background signals and lower non-specific binding of all anti-IN scFvs to 
HIV-1 protease protein (PR) and bovine serum albumin (BSA).  
 
 
 
 
 
 
 
                                                 Generation of anti-IN scFv intrabodies 
 
                                                         
                                                                   79 
A 
 
B 
 
Figure 2.4 - Expression and relative binding affinities of anti-IN scFv fragments.          
(A) E. coli TOP 10F bacteria expressing anti-IN scFvs after induction with 0.5 mM IPTG at 
37°C for 18 hours. Antibody fragments were extracted from the periplasmic space as 
described in Material and Methods. After separation on a 15% SDS-PAGE gel and blotting, 
antibody fragments were detected with HRP-conjugated anti-HA mAb (Roche). Molecular 
weight is indicated in kDa. (B) The anti-IN scFv fragments were used for evaluating 
relative binding affinities to 200 ng of HIV-1 IN, PR and BSA by ELISA. The anti-LANA1 
scFv (BM10) was used as an irrelevant control antibody. Results were measured by optical 
density at 405 nm. Data represents results of three independent experiments.  
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To further test binding specificity of scFv to IN protein, four scFv clones 
with high binding activity to IN (clones 104, 135, 142 and 144) and one that 
gave a weaker signal (clone 7) were chosen to carry out the immunoblotting 
assays. We have separated HIV-1 IN and PR proteins by SDS-PAGE and 
transferred to nitrocellulose membranes. After blocking, proteins were 
probed with purified anti-IN scFvs and then with HRP-conjugated anti-HA 
mAbs, as a secondary antibody. As an irrelevant control antibody we have 
used the anti-LANA1 scFv (BM10). As demonstrated in Figure 2.5, all anti-
IN scFvs specifically recognize the 32 kDa HIV-1 IN protein. As expected 
by our ELISA results, only the high binding clones could detect low 
concentrations of IN. Importantly, recombinant anti-IN scFv did not 
recognize HIV-1 PR and no bands were detected using the anti-LANA1 
scFv (BM10). Our ELISA and immunoblotting results showed that scFv 
clones 7, 104, 135, 142 and 144 specifically bound to HIV-1 IN and 
therefore were chosen for further antibody characterization and functional 
studies. 
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Figure 2.5 - Detection of antigens by western-blot. Purified HIV-1 IN protein at several 
amounts was separated by 15% SDS-PAGE and transferred to nitrocellulose membranes. 
For immunodetection, purified anti-IN scFv clones 7, 104, 135, 142 and 144 were used. 
HRP-conjugated anti-HA mAb was used as a secondary antibody. HIV-1 PR at 800 nM was 
used to test anti-IN specificity and anti-LANA1 scFv (BM10) was used as an irrelevant 
control antibody.  Molecular weight is indicated in kDa. 
 
2.3.3 Mapping HIV-1 IN epitopes 
 
We observed that the 5 selected anti-IN scFvs apparently recognized a 
continuous epitope(s) of IN, since they reacted with denatured IN on 
immunoblots. In order, to identify the epitopes recognized by the different 
antibodies, a set of 30 overlapping synthetic peptides covering the entire IN 
molecule were used. Each peptide contained 20 residues, with the first 10 
residues overlapping those found in the peptide immediately preceding it in 
the primary sequence. Interactions between the scFvs and the synthetic 
peptides were analyzed by ELISA as described in the Material and Methods 
section. We verified that the background signal was routinely quite low, that 
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no peptide binding was observed with anti-LANA1 scFv (clone BM10) and 
an unexpected pattern of peptide reactivity for the five anti-IN scFvs. As 
shown on Table 2.2, all anti-IN scFv clones bound to peptide 4338 (residues 
126 to 145), and peptide 4343 (residues 176 to 195) and also to two 
upstream peptides, 4346 and 4347 (residues 206 to 235). Since all clones 
bound simultaneously to three separate regions in the linear sequence of IN, 
we were concerned that unspecific peptide binding was occurring with anti-
IN scFv. Therefore, ELISA epitope mapping was repeated with a high ionic 
washing buffer (Material and Methods section). With these conditions, a 
small decrease in the relative antigen-binding affinity was observed (data 
not shown); although the same epitope binding patterns were maintained for 
all anti-IN scFv clones.  
 
Table 2.2 – Epitope mapping of anti-IN scFv.  To perform epitope mapping, purified anti-
IN scFv clones 7, 104, 135, 142 and 144 were tested for binding to a set of 30 overlapping 
synthetic peptides covering the entire HIV-1 IN protein sequence. Covalink ELISA plates 
were coated with 5 ug of each peptide and incubate overnight at 4ºC. The plates were then 
blocked with BSA and incubate with purified antibody fragments. After washing the wells 
with low ionic buffer or high ionic buffer (Material and Methods), HRP-conjugated anti-HA 
mAb was used for detection. The same binding pattern was observed in both washing 
conditions. The anti-LANA1 scFv (BM10) was used as an irrelevant control antibody. The 
black box highlights the scFv specific binding to the different IN peptide regions.  The + 
symbol means binding and the – symbol means no binding.     
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Therefore, we went to analyze if the three IN regions (residues 126-145, 
residues 176-195 and residues 206-235 – Figure 2.6A) were closely located 
in the folded IN structure and could therefore form a shared epitope. 
Although, the structure of full-length HIV-1 IN protein has not been 
determined, a crystal structure of the catalytic core and C-terminal is already 
available 251. Observation of this structure prompt us to the conclusion that 
the three epitope regions are close together in the folded structure and 
indeed form a cavity (Figure 2.6B). To our knowledge we believe that our 
scFv fragments constitute the first set of anti-IN antibodies that recognize 
and bind simultaneously to epitope regions in catalytic and C-terminus 
domains of IN. 
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Figure 2.6 – Schematic representation of HIV-1 IN and its interactions with anti-IN 
scFvs. (A) Linear model of HIV-1 IN protein and its domains recognized by anti-IN scFv 
clones 7, 104, 135, 142 and 144. The IN enzyme comprises the N-terminal domain (NTD, 
aa 1–49), catalytic core domain (CCD, aa 50–212) and C-terminal domain (CTD, aa 213–
288). The H and C residues within the NTD are additionally conserved among 
retrotransposon integrase proteins. The D and E residues in the CCD form the DDE motif. 
The nuclear localization signal (NLS) is localized in the C-Terminal domain. All anti-IN 
scFv tested recognize and bind simultaneously to residues 126 to 145 (peptide 4338), and 
residues 176 to 195 (peptide 4343) and also to the upstream residues 206 to 235 (peptides, 
4346 and 4347). (B) Model of the crystal structure of HIV-1 catalytic and C-terminal 
domains (PDB code 1EX4)251 showing the epitopes regions recognized by the anti-IN 
scFvs. The probable binding site of scFvs to HIV-1 IN is indicated by a white arrow.  
 
2.3.4 Anti-IN scFv strongly inhibit the strand transfer reaction  
Integration of retroviral DNA into the host chromosomal DNA involves two 
chemical steps. The newly synthesized bluntended viral DNA first 
undergoes 3´- end processing. In this reaction, two nucleotides are removed 
from each 3´- end. Next, the exposed hydroxyl groups attack a pair of 
phosphodiester bonds on opposite strands of the target DNA to complete the 
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strand transfer step. Both the 3´- processing and DNA strand transfer 
activities of HIV-1 IN can be recapitulated in vitro with DNA substrates that 
mimic the viral DNA ends. Therefore, to study the effects of our scFvs on 
the in vitro activities of IN, 3'-end processing and strand transfer assays 
were performed in the presence of our anti-IN scFv. As shown in Figure 
2.7A, none of the anti-IN scFvs tested interferes in the 3'-end processing 
reaction since we did not observed any inhibition in the -2 cleavage product 
from the 21-base pair oligonucleotide substrate that represents the viral U5 
end of viral DNA. In fact, not even a minimal inhibitory effect was observed 
when anti-IN scFv were added to IN at molar ratios of 1:4 (800nM). To 
evaluate the effect of each anti-IN scFv in the strand transfer reaction we 
have used a preprocessed DNA substrate. As shown in Figure 2.7B scFv 
104, 135, 142 and 144 clearly inhibited the strand transfer reaction as 
demonstrated by the decrease of the half-site and full-site (concerted) 
integration of the 32P-labeled preprocessed DNA substrate into the target 
DNA (pBR322).  Indeed, these four antibody fragments inhibited more than 
50% of the IN activity when present in the reaction in a ~twofold molar 
excess over IN (200 nM). 
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Figure 2.7 – Effect of anti-IN scFv binding on in vitro activities of HIV-1 IN. (A) Anti-
IN scFvs do no inhibit the 3´-end processing reaction of HIV-1 IN. IN at 200 nM was 
preincubated on ice with each scFv at various scFv/IN molar ratios. Radioactively labeled 
oligonucleotide substrate was added, and the reactions were allowed to proceed at 37ºC. 
Each reaction mixture was subjected to electrophorese in a 20% denaturating 
polyacrylamide gel. The position of the 21-base pair oligonucleotide substrate (S) and the -
2 cleavage product (P) are indicated. As shown no inhibition was observed in the 3´-end 
processing. (B) – Anti-IN scFvs strongly inhibit the strand transfer process of HIV-1 IN. 
Each purified scFv was preincubated with 80 nM IN at various scFv/IN molar ratios on ice. 
Radioactively labeled preprocessed DNA substrate and supercoiled target DNA (pBR322) 
were added and incubated as described in the Material and Methods section. Each reaction 
mixture was subjected to electrophoresis in a 0.8% agarose gel. Half-site integration 
involves the insertion of one LTR end per target, and full-site integration involves the 
concerted insertion of two LTR ends per target. The positions of the concerted integration 
product, the half-site product, and products resulting from integration of viral DNA 
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substrate into itself (Donor/Donor) are indicated. In both assays, anti-LANA1 scFv (BM10) 
was used as an irrelevant control antibody and gels were dried, exposed to imaging plates 
and visualized and quantified with a Fuji BAS-2500 bio-imaging analyzer.  
 
 
At higher concentrations (400 nM) scFv-104 and scFv-142 inhibited the 
reactions almost completely. On the other hand, scFv-7 had a weak 
inhibitory effect, and scFv anti-LANA1 had no detectable effect on the 
strand transfer activity of IN as expected. Therefore, our scFv 104, 135, 142 
and 144 shown to have an important inhibitory effect on the strand transfer 
reaction meaning that they might be efficiently used as intrabodies to block 
the integration process during the HIV-1 replication. 
 
2.3.5 Anti-IN scFv are efficiently expressed in eukaryotic cells and co-
localize with IN   
 
After analysis of inhibition of HIV-1 IN activity in vitro, genes encoding 
anti-IN scFv fragments with and without a nuclear localization signal (NLS) 
were transferred into pcDNA3.1/Zeo+. To evaluate the expression of our 
anti-IN scFv in eukaryotic cells, 293T cells (1-2x 106) were transfected by a 
standard calcium phosphate method with each scFv plasmid. The data in 
Figure 2.8A demonstrates that all anti-IN scFv clones are highly expressed. 
To understand better where they are localized we have performed an 
immunofluorescence assay in HeLa cells using the scFv-142 and scFv-142-
NLS. As shown in Figure 8B, scFv-142 is efficiently expressed in the 
cytoplasm and the scFv-142-NLS is expressed in the nucleus of eukaryotic 
cells. Therefore, these results demonstrate that our intrabodies can efficiently 
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be delivered to the destined compartment. We then evaluate the potential co-
localization of both antibody formats expressed together with the HIV-1 IN 
protein. As shown in Figure 8C, when the IN protein is expressed with clone 
scFv-142 or scFv-142-NLS, we can observe co-localization of IN and scFv 
in both cases in the nucleus. Since, HIV-1 IN protein has been reported to 
localize predominantly in cell nucleus, and to play a role in nuclear import of 
the HIV-1 pre-integration complex, we can speculate that IN NLS domain 
can efficiently cause re-location within the nucleus of anti-IN intrabodies.  
 
A
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C 
 
Figure 2.8 - Expression and co-localization of anti-IN intrabodies in eukaryotic cells.  
(A) Anti-IN intrabody expression vectors were transfected into 293T cells and after 48 hours 
cells were lysed and cleared by centrifugation. Proteins were separated by 15% SDS-PAGE 
and visualized by Western blot probed with HRP-conjugated anti-HA mAb. Mock lysates of 
293T cells were used as controls in Western Blot analysis. Molecular weight is indicated in 
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kDa. (C) Transfected HeLa cells expressing scFv-142 and scFv-142-NLS were stained with 
rhodamine-conjugated anti-HA mAb. ScFv is shown in red (rhodamine) and IN in green 
(Alexa). (B) Transfected HeLa cells expressing scFv-142 or scFv-142-NLS and HIV-1 IN 
protein were stained with rhodamine-conjugated anti-HA mAb and anti-IN polyclonal 
serum plus Alexa-conjugated goat anti-rabbit immunoglobulin antibody as described in 
Materials and Methods. ScFv is shown in red (rhodamine) and IN in green (Alexa). Overlay 
of scFv and IN panels results in a yellow signal at sites of co-localization. 
Immunofluorescence microscopy was performed with the imaging setup described in 
Material and Methods using the appropriate excitation and emission filters. 
2.3.6 HIV-1 replication can be inhibited by both cytoplasm and nucleus 
localized anti-IN scFv intrabodies    
 
To evaluate whether the expression of anti-IN scFv fragments in either 
cytoplasm or nucleus could prevent HIV-1 replication, a one step viral 
replication assay in HeLa CD4 LTR-β-Gal cells was performed. The results 
shown in Figure 2.9 represent the percentages of viral replication relatively 
to the value obtained for HIV-1NL4-3 infection of control HeLa CD4 LTR-β-
Gal cells (positive control, C+). As shown, both cytoplasmic and nuclear 
expressions of anti-IN scFv clones 104, 135, 142 and 144 inhibit the HIV-1 
viral replication to 70-80%. The, scFv-7 in turn had a less prominent on the 
reduction of viral replication (only ~20% of the wild-type). Expression of 
anti-LANA1 scFv (BM10) with or without NLS had no inhibitory effect on 
HIV-1 replication. The biological activities of anti-IN scFv are correlated 
directly with our data described above, indicating that those clones that 
showed the stronger relative binding affinities and strand transfer inhibition 
are those that present the most efficient anti-HIV-1 activities. All together, 
our data indicates that the expression of anti-IN scFvs in eukaryotic cells 
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specifically neutralize IN activity prior to integration and, thus, has an effect 
on the integration process itself. Therefore, our experiments clearly 
demonstrate that HIV-1 replication can be blocked at early stages of viral 
replication in cells due to expression of anti-IN scFv intrabodies.  
 
 
Figure 2.9 - Neutralization of IN function in one-cycle replication assay. Values 
represent the percentages of one cycle-replication in HeLa CD4 LTR-β-Gal cells relative to 
the value obtained for the wild-type. Cells were transfected with plasmids encoding anti-IN 
antibody fragments as described in Material and Methods. The ability of anti-IN antibody 
fragments to inhibit a single round of replication was measured by quantification of the β-
galactosidase activity in cell lysates, using a colorimetric assay based on the cleavage of 
chlorophenolred-β-Dgalactopyranoside (CPRG) by β-galactosidase as described in the 
Material and Methods. Anti-LANA1 scFv (BM10) was used as an irrelevant control 
antibody; C+, HIV-1NL4-3 infection of control HeLa CD4 LTR-β-Gal cells; C-, uninfected 
HeLa CD4 LTR-β-Gal cells. The results were measured by optical density at 570 nm and 
data are representative of three independent experiments. 
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2.3.7 Anti-IN scFv intrabodies inhibit HIV-1 infectivity and are 
incorporated in viral particles 
 
The three viral enzymes (reverse transcriptase, integrase and protease) are 
encoded within the HIV pol gene and translated as a polyprotein. The IN 
protein is then released from the polyprotein by the HIV protease during 
maturation of the virion. Therefore, if our anti-IN scFv intrabodies bind to 
the IN in the context of Gag-Pol polyprotein, problems in virion assembly or 
maturation might occur. Within this context, to evaluate if our anti-IN 
intrabodies could also inhibit the viral replication at late stages, 293T cells 
were cotransfected with pHIV-1NL4-3 and anti-IN scFv plasmids. The viral 
production was then analyzed by measurement of p24 amount in the culture 
supernatant by an HIV-1 p24 ELISA. We observed that the expression of 
any of the intrabodies into the cytoplasmic compartment did not affect 
significantly the virion production (data not shown). Resultant viruses were 
then normalized for the same TCID50 and used to infect HeLa CD4 LTR-β-
Gal cells, where the level of infectivity was measured by quantification of 
the β-galactosidase activity (CPRG assay). The results shown in Figure 2.10 
represent the percentages of viral infectivity relative to the value obtained 
for HIV-1NL4-3 infection of control HeLa CD4 LTR-β-Gal cells (positive 
control, C+). We observed that anti-IN scFv clone 104, 135, 142 and 144 
have a pronounced reduction of 85% to 60% in viral infectivity compared to 
wild-type virus. The scFv-7 had only a reduced effect in HIV-1 infectivity 
(only 10% less than the wild-type level). The irrelevant anti-LANA1 scFv 
(BM10) did not have any effect in HIV-1 infectivity demonstrating the 
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specificity of our anti-IN scFvs. Taken together, these results suggest that 
anti-IN intrabodies can also block late stages of HIV-1 replication.  
 
Figure 2.10 – Inhibition of HIV-1 infectivity in HeLa cells. A single cycle infectivity 
assay was performed with HIV-1 NL4-3 virions produced in the presence of anti-IN antibody 
fragments. Values represent the percentages of infectivity in HeLa CD4 LTR-β-Gal cells 
relative to the value obtained for the wild-type. The infectivity of the viruses normalized for 
p24 was measured in HeLa CD4 LTR-β-Gal cells by quantification of the β-galactosidase 
activity in cell lysates, using a colorimetric assay based on the cleavage of chlorophenolred-
β-Dgalactopyranoside (CPRG). BM10 was used as an irrelevant control antibody; C+, HIV-
1NL4-3 infection of control HeLa CD4 LTR-β-Gal cells; C-, uninfected HeLa CD4 LTR-β-Gal 
cells. The results were measured by optical density at 570 nm and data are representative of 
three independent experiments. 
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To determine whether these defects in viral infectivity could be attributed to 
assembly or maturation problems, immunoblots protein analysis was 
performed for each virion produced in the presence of anti-IN scFvs. As 
demonstrated in Figure 2.11, all samples contained at the same intensity a 
32 kDa IN band, showing that expression of anti-IN scFv intrabodies did not 
affect the incorporation of Gag-Pol polyprotein into the virion. In addition, 
we can also see that scFv 104, 135, 142 and 144 could be detected in 
virions. Indeed, clone 142 seems to be strongly incorporated. In contrast, 
scFv-7 and anti-LANA1 scFv (BM10) were not detectable in virions. 
Therefore, this result indicates that scFv-7 is not efficiently incorporated 
into virions, which might explain our results at levels of Figure 2.10. The 
data in Figure 2.11 also demonstrates that all scFvs were equally expressed 
in co-transfected 293T cells. Taken together all our results, we can speculate 
that when viral particles are produced in the presence of high yields of 
cytoplasmic anti-IN scFv intrabodies, they might be able to interact with the 
IN protein in the context of the Gag-Pol polyprotein and therefore be 
incorporated into the viral particles. As a consequence, infectivity of these 
virions will be presumably reduced since the incorporated anti-IN scFv 
fragment will neutralize the function of intravirion IN.    
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Figure 2.11 - Immunoblot analysis of anti-IN scFv and IN packaging within virions. 
Each viral supernatant of 293T cells co-transfected with HIV-1NL4-3 and antibody plasmids 
were collected, concentrated by ultracentrifugation and then separated on 15% SDS-PAGE 
gel. For detection of scFvs, proteins were probed with HRP-conjugated anti-HA mAb. For 
detection, of IN and p24, proteins were probed with anti-IN polyclonal antibody serum and 
anti-p24 mAb, respectively. Subsequently, blots were probed with species-specific HRP-
conjugated secondary antibodies. The scFv expression was also analyzed in the 293T co-
transfected cells (cell lysates).  
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2.3.8 Jurkat stably cells expressing anti-IN intrabodies are protected 
from HIV-1 infection  
 
The experiments described above examined the biological activity of anti-IN 
scFvs in a transient assay under conditions in which most virus transmission 
occurs by cell-to-cell spread. To study whether anti-IN scFv intrabodies 
might be able to inhibit IN function during several rounds of HIV-1 
replication, Jurkat cell lines expressing independently scFv intrabodies were 
developed. For this generation, retroviral vectors encoding anti-IN 
intrabodies were used to transduce Jurkat cells. As a control, a retroviral 
vector encoding the irrelevant anti-LANA1 (BM10) was also used.                   
As shown in Figure 2.12A, resultant Jurkat-scFv cell lines showed 
homogeneous and stable expression of intrabodies. To determine if the 
intracellular expression of anti-IN scFvs was able to prevent HIV-1 
replication in susceptible human T cells, Jurkat intrabody-expressing cell 
lines were challenged with the HIV-1NL4-3. Infectivity assays were performed 
with an MOI of 0.1-0.5 to mimic natural infections 330. The infected cell 
cultures were maintained for up to 20 days and to monitor infection, aliquots 
were taken at the indicated time points and HIV-1 p24 antigen levels were 
determined by ELISA. Parental non-transduced Jurkat cell lines supported 
vigorous replication of HIV-1 (positive control, C+), as shown by the initial 
increases in HIV-1 p24 antigen, which peaked at approximately day 12 
(Figure 2.12B). Importantly, in the case of Jurkat scFv-104, scFv-135, scFv-
142 and scFv-144, low levels of HIV-1 p24 antigen were observed in the 
supernatants. On days 6 to 18 post-infection, these cells showed 
approximately 60-80% inhibition of HIV-1 p24 antigen production 
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compared with the parental Jurkat cells. The anti-IN scFv-7 in turn 
demonstrated a more modest inhibitory effect on HIV-1 replication. In 
addition, expression of control anti-LANA1 scFv (BM10) in Jurkat cell lines 
had no significant inhibitory effect on HIV-1 replication, indicating that our 
anti-IN scFv are specific for IN inhibition. Previous studies have shown that 
intracellular antibody expression has no obvious negative effect on cell 
viability or proliferation. Nevertheless, we quantified cell proliferation and 
cell viability of infected scFv-Jurkat cells and compared them to non-
infected cells. The assay consists of a colorimetric assay based on the 
cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in 
viable cells (Roche). We observed that the kinetics of WST-1 metabolism in 
scFv-Jurkat cells infected with HIV had similar levels of proliferation in 
comparison with non-infected cell lines (data not shown). The inhibition 
results obtained here indicate that HIV-1 replication was dramatically 
reduced in Jurkat cells at early stages by expression of our anti-IN 
intrabodies. To further evaluate if HIV-1 viral replication could also be 
inhibited during late stages by our anti-IN scFv, the viruses resulting from 
infection were normalized by the same TCID50 and used to measure the RT 
activity in the virions as described in Material and Methods at day 12. As 
demonstrated in Figure 2.13, the virions released from Jurkat cells 
expressing scFv-anti-LANA (BM10) showed RT activities similar as the 
wild-type virions. In contrast, virions released from Jurkat cells expressing 
scFv-104, scFv-135, scFv-142 and scFv-144, showed a pronounced 
reduction in the RT activities compared to wild-type virus. A more reduced 
effect in RT activity was obtained with anti-IN scFv-7 (only 10% less than 
the wild-type level), as already expected. We can also see that scFv-142 has 
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the stronger activity in the inhibition of the HIV-1 RT activity. In 
conclusion, our data demonstrates that the scFv 104, 135, 142 and 144 
generated from immunized rabbits with HIV-1 IN can simultaneously block 
early and late stages of HIV-1 replication. 
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C
 
Figure 2.13 – HIV-1 challenge of stable anti-IN-scFv-Jurkat cell clones. (A). Western-
blot of cell lysates of stable Jurkat cell lines expressing anti-IN ScFv and anti-LANA1 scFv 
(clone BM10). Lysates of Jurkat cells not expressing scFv were also used in Western blot 
as negative controls (mock). (B) Stable Jurkat cell clones expressing anti-IN scFv 
intrabodies were infected with HIV-1NL4-3 at a MOI of 0.1 to 0.5. The cultures were 
maintained for up to 20 days, and to monitor infection aliquots were taken at the indicated 
time points to determine p24 levels by ELISA. BM10 was used as an irrelevant antibody; 
C+, HIVNL4-3 infected cells; C-, uninfected cells. The data is representative of two 
independent experiments. (C) RT activity levels were detected in viral supernatants at day 
12. Viral supernatants were normalized by the same TCID50 and subjected to ELISA RT 
activity assay system as described in Material and Methods. Values represent the 
percentages of virions RT activity relative to the value obtained for the wild-type. BM10 
was used as an irrelevant control antibody; C+, HIVNL4-3 virion RT activity; C-, uninfected 
supernatant RT activity. 
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2.4 Discussion  
 
Controlling HIV infection continues to be a major challenge in both 
underdeveloped and developed nations. Although the drug cocktails used in 
HAART have markedly changed the profile of progression to AIDS in HIV-
infected individuals, drug failures continue to occur as a consequence of 
viral resistance and other complications arising from a lifelong regimen of 
chemotherapy. Therefore, the development of new modes of inhibition is of 
paramount importance and has been the focus of recent research efforts. 
Within this context, gene therapy has captured the interest of a number of 
investigators as an attractive addition to conventional pharmacologic 
therapies since; alteration of the host cell could potentially confer permanent 
suppression of viral replication, after infection, or could provide protection 
against viral infection. We have explored this approach by developing 
intrabodies to the HIV-1 IN protein. IN catalyzes the integration of viral 
cDNA into the host chromosome. Moreover, there are no cellular homologs 
to IN and the reactions catalyzed by IN are unique. Thus, scFv-based 
strategies directed against IN may be an effective approach to inhibit this 
crucial step of the viral replication cycle.  
 
In the present study, we have for the first time immunized rabbits with HIV-
1 IN and developed a combinatorial scFv phage-library against IN. While 
the generation of rabbit monoclonal antibodies by hybridoma technology 
has also been reported 331, the phage display approach with its inherent 
linkage of phenotype and genotype provides ready access to antibody 
sequences and facilitates further in vitro optimizations such as humanization 
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or affinity maturation. Furthermore, with combinatorial scFv libraries we 
have the potential to display the entire immunological record of an 
individual, allowing the detection and recovery of any antibody ever made, 
irrespective of whether it is currently being produced.  
 
The results presented here shown that we were able to identify 5 new scFv 
intrabodies that specifically recognize and bind HIV-1 IN protein. These 
scFvs bound simultaneously to two epitope regions in the catalytic domain 
(amino acids 126-145 and 176-195) and to one upstream region in the C-
terminal domain (amino acids 206-235) of IN protein. To our knowledge the 
scFv fragments described in this work constitute the first set of anti-IN 
antibodies that recognize and bind simultaneously to three epitope regions 
in IN. As mentioned above, these epitope regions are close together in the 
folded IN structure and form a cavity. Therefore, it seems that with our 
combinatorial scFv library we were able to identify a panel of new anti-IN 
scFv fragments that can reach targets not easily accessible by conventional 
antibodies molecules, such as small pockets or canyons in the IN protein. 
Moreover, since our anti-IN intrabodies bind simultaneously to three 
epitope regions in the IN protein, the development of HIV-1 escape mutants 
will be minimized. Our results have also shown that strongly binding of 
anti-IN scFvs inhibit the strand transfer reaction when these epitopes are 
target, whereas no effect was observed in the 3’end processing. We can 
assume that these epitope regions of IN are essential to the strand transfer 
activity but not to the 3’end processing. Thus, the data obtained here can be 
used to better understand the intracellular function of IN and determine 
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which IN residues and protein domains can be effectively target to inhibit 
HIV-1 IN function. 
 
The expression of anti-IN scFvs in eukaryotic cells showed that our 
intrabodies could be correctly folded as soluble proteins and were efficiently 
delivered into the cytoplasm and nucleus compartments. We also showed 
that both anti-IN scFv formats co-localize with the IN in the nucleus, 
indicating that the IN NLS domain localized in the C-terminal region was 
not blocked by the intrabodies. Moreover, these results suggest that the IN 
must contain a strong NLS domain, as we were not able to trap the IN in 
cytoplasm when anti-IN scFv and IN are co-expressed. By using a single-
round viral assay, we demonstrated that HIV infectivity was strongly 
inhibited in cells transiently expressing anti-IN scFv-104, scFv-135, scFv-
142 and scFv-144 clones in either the cytoplasmic or nuclear compartments. 
These results demonstrated that the stronger anti-IN scFv binders 
specifically neutralize the IN activity prior to integration and, thus, have an 
effect on the integration process itself. Therefore, our scFv-strategy can be 
used to block early stages of viral replication, due to their capacity to 
interfere with the establishment of a provirus. Moreover, we also found that 
these intrabodies were able to interact with the IN protein in the context of 
the Gag-Pol polyprotein and could be incorporated into the viral particles. 
As a result, these virions were shown to be less infectious than the wild-type 
virus, meaning that our intrabodies can also interfere in late stages of viral 
replication.  
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To further analyze that our intrabodies were also able to block the IN 
function during multiple rounds of infection, we developed stable Jurkat cell 
lines expressing our anti-IN scFv. Results of these experiments extend 
previous findings that scFv intrabodies can be stably expressed and do not 
affect cell viability or proliferation. Second, we demonstrate that Jurkat 
stable cells expressing intrabodies were highly protected from HIV-1 
infectivty, indicating that anti-IN scFvs were capable to block the IN 
activity during multiple rounds of infection. Thirdly, we observed that those 
virions that escape and were produce in the presence of our intrabodies 
shown a pronounced reduction in the RT activities compared to wild-type 
virus. It has been shown that IN also plays an important role during the 
reverse-transcription steps of HIV-1 infection, possibly through physical 
interactions with RT 332,333. Indeed, in a recent study Zhu et al have shown 
that the C-terminal domain of wild-type HIV-1 IN strongly interacts with 
RT 334. Although the mechanism(s) of inhibition during late stages of viral 
replication are not totally uncovered in these studies, it is in our contention 
that the reduction in RT activity and consequently in the viral infectivity can be the 
result of an intravirion activity of our anti-IN scFvs.   
 
In summary, the present study strongly suggests that combinatorial rabbit 
scFv phage-libraries can be efficiently used to identify scFv with new 
epitope binding characteristics. Moreover, our data provide proof-in-
principle that rabbit anti-IN intrabodies can be designed to block early and 
late stages of HIV-1 replication. Thus, anti-IN intrabodies can be potential 
agents for HIV-1 gene therapy approaches and also constitute new tools to 
better understand the structure and function of HIV-1 IN. 
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Abstract  
 
Intracellular antibodies have particular promise in the area of functional 
genomics and in the long term, may even find an enormous broad 
therapeutic application in gene therapy setting. The scFv is usually viewed 
as the suitable format for intracellular expression in eukaryotic cells. 
However, in the reducing environment of the cytoplasm the intrachain 
disulfide bridges cannot form and only very soluble and stably expressed 
antibody fragments will be able to fold correctly in sufficient amounts to be 
active as intrabodies. Within this context, there is a strong interest in the 
ability to express functional antibodies in this environment. Recent 
approaches have shown that VH, VHH and camelized VH single-domain 
antibodies alone may be useful as intrabodies, with improved intracellular 
expression. In the present study, we now show that a rabbit VL domain can 
also be very potentially as intrabody. Our VL single-domain was derived 
from an anti-Vif scFv that was recently developed from immunized rabbits 
to HIV-1 Vif protein. The results demonstrate that our VL single-domain 
could be expressed soluble at high yields, preserve the antigen-binding 
activity and specificity in the absence of the parent VH domain and show 
favourable biophysical properties. The expression in eukaryotic cells also 
showed that rabbit VL single-domain could correctly be folded as soluble 
protein in the reducing environment and could strongly neutralize HIV-1 
infectivity. Therefore, the present study strongly suggests that rabbit VL 
domains have enormous value as intracellular antigen recognition units.  
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3.1 Introduction 
 
Over the last two decades, monoclonal antibodies (mAbs) have become the 
most powerful tools for basic research, diagnostics and therapy 103,105-107. 
Advances in recombinant DNA technology and protein engineering has 
made possible to manipulate the genes encoding antibodies and to express 
antibody binding fragments in eukaryotic cells 109. These intracellularly 
expressed antibodies, termed intrabodies, are typically formulated as single 
chain Fv (scFv) fragments which comprise immunoglobulin variable (V) 
domains of heavy (H) and light (L) chains held together by a short peptide 
linker 109-111. Intrabodies can be genetically fused with known intracellular 
protein trafficking signals and thereby be directed to different subcellular 
comportments 30. The binding of an intrabody to an intracellular target 
protein has the potential to block, suppress, alter or even enhance the 
process mediated by that molecule 31-33. This new approach have particular 
promise in the area of functional genomics and in the long term, may even 
find an enormous broad therapeutic application in gene therapy setting. The 
strong inhibiting potential of intracellular antibodies has been demonstrated 
in the field of cancer, HIV, transplantation, autoimmune and 
neurodegenerative diseases 121,131,133-140,144-147. 
 
The recombinant scFv molecule is usually viewed as the suitable format for 
intracellular expression in eukaryotic cells. However, in the reducing 
environment of the cytoplasm the intrachain disulfide bridges cannot form 
and only very soluble and stably expressed antibody fragments will be able 
to fold correctly in sufficient amounts to be active as intrabodies 29. 
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Moreover, the interaction of VH and VL single-domains by the interface is 
weak and may aggregate in the cytoplasm being targeted to proteosome 
degradation. Within this context, there is a strong interest in the ability to 
express functional antibodies in this environment and only recently several 
different approaches started to emerge with such requirements. These 
approaches include in vivo selections for intrabody-antigen interaction based 
on two hybrid screenings, and construction of antibody libraries using 
randomized CDRs on scFv frameworks that have been selected for high 
solubility and stability in an intracellular environment152-157,190. Recently, 
single-domain antibodies (dAbs) are becoming a major strategy to generate 
effective intrabodies.  
 
Single-domain antibodies are the smallest functional antigen-binding 
fragments of an antibody, consisting of only the variable heavy (VH) or 
variable light domain (VL) 126. Each single-domain contains only three of 
the six complementarity determining regions (CDRs) from an antibody. 
However, this can be sufficient for antigen binding specificity and high 
affinity, as seen in camelids 127. Members of this family have a class of 
antibodies which contain no light chains and have functional antigen 
binding regions consisting of a single unpaired heavy chain variable 
domain, referred to as VHH 127,128. Recent studies have shown that single-
domains antibodies can be easily produced as recombinant proteins in 
microbial cell culture and appear to be more soluble and stable 126,128.                       
In addition, these smaller antibody molecules might, reach targets not easily 
accessible by conventional antibodies molecules, such as enzyme active 
sites and canyons in viral and infectious disease biomarkers 126,129.          
VL single-domain as intrabodies                                                                                                             
 
                                                                                                                                                              
110 
 
Thus an antibody molecule can be easily reduced in size to a single 
functional variable domain and be used as an intrabody. 
 
The first study of a single-domain tested as intrabody was reported in 2003 
by Tanaka et al 130. In this work the authors, demonstrated that VH single-
domains could be highly expressed in mammalian cells and exhibited 
specific antigen recognition in vivo. Moreover, VH selected for binding to 
the RAS protein could inhibit RAS-dependent oncogenic transformation of 
NIH3T3 cells 130. We have also recently developed a minimal rabbit VH 
fragment with intrabody properties derived from an anti-Vif scFv that was 
engineered to mimic camelid antibody domains 121,131. These camelized VH 
single-domain intrabodies were highly expressed in reducing environments 
and exhibited a strong neutralization of HIV infectivity 121. Natural VHH 
antibodies have also been validated as intrabodies. In this case, Bax-specific 
VHH intrabodies were efficiently developed to prevent mitochondrial 
membrane potential collapse and apoptosis after oxidative stress in the host 
cells 132. Although the first attention was directed to VH and VHH, VL 
single-domains are also becoming of considerable interest as intrabodies. In 
a recent study using a yeast surface display to isolate a scFv against amino 
terminus huntingtin (htt) protein, the binding site of the highest affinity 
variant was mapped to just the VL domain 135. This was the first reported 
case where a scFv paratope mapped entirely to the VL domain. In addition, 
this human VL single-domain was markedly better expressed in the 
cytoplasm relative to its scFv counterpart and consequently effectively 
blocked aggregation off htt in a cellular model of Huntington’s disease. 
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In the present work, we show that rabbit VL single-domains can be 
efficiently used as intrabodies. The VL scaffold was derived from an anti-
Vif scFv that was recently developed from immunized rabbits to HIV-1 Vif 
protein and inhibited viral replication. Our results demonstrate that the anti-
Vif VL single-domain preserve the antigen-binding activity and specificity 
in the absence of the parent VH domain. In addition, the VL single-domain 
was highly expressed in microbial cell culture and show favourable 
biophysical properties. The expression in eukaryotic cells also showed that 
the rabbit VL single-domain was correctly folded as soluble protein in the 
reducing environment and could strongly neutralize HIV-1 infectivity. 
Therefore, the present study suggests that rabbit VL single-domains may 
have an enormous value as intracellular antigen recognition units.  
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3.2 Material and Methods 
3.2.1 Cloning of VL anti-Vif single-domain  
 
A fragment encoding the anti-Vif VL domain was generated by PCR from 
the pComb3X phagemid vector containing the anti-Vif scFv gene 
(pComb3X-4BL). The following primers were used: SDVL-F 5’-CCT GGC 
CGG CCT GGC C      GCCTGTGACGGTCAGCTGGGTCCC-3’and 
SDVL-R 5’-CCT GGC CGG CCT GGC C      
GCCTGTGACGGTCAGCTGGGTCCC-3’.The resulting PCR fragment 
was gel-purified, digested with the restriction endonuclease SfiI, and cloned 
into the phagemid vector pComb3X. The pComb3X plasmid contains a 
suppressor stop codon and sequences encoding peptide tags for purification 
(6-His) and detection (HA). After expression studies in E. coli TOP10F and 
analysis of binding activities, the VL single-domain gene was transferred 
into pcDNA3.1/Zeo+ (Invitrogen). The primers used for cloning in 
pCDNA3.1/Zeo+ were: Babe ScFv5 5’-
GGCATGGGGGCCCAGGCGGCCCAGCTC-3’ and Babe ScFv3 5’-
GCCACCACCCTCCTAAGAAGC-3’.  We introduced a sequence 
encoding the HA-tag sequence (YPYDVPDYA) at the C-terminus, followed 
by a stop codon. The PCR products were cloned by NotI and XhoI into 
pCDNA3.1/Zeo+. The Anti-Vif VL single-domain gene was also cloned into 
pHIVnPLAP-IRES-N+ in place of PLAP-IRES-nef. The primers used for 
cloning were VL-VH-NOT 5’– 
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ATAAGAATGCGGCCGCTAAACTATATGGGGGCCCAGGCGGCCGA
GCTC-3’ and 4ScFv-HIV-Xho 5’-
CCGCTCGAGCGGGCCACCACCCTCCTAAGAAGC -3’.  
 
3.2.2 Expression and purification of antibody fragments  
To express and purify anti-Vif antibody fragments from the bacteria 
periplasmic space, each phagemid DNA was transformed into non-
suppressor E. coli strain TOP10F. A fresh colony of each clone was grown 
at 30ºC overnight in SB medium containing 100 µg/ml of ampicillin. A 10 
ml sample of cells was used to inoculate 1 liter of SB medium containing 
100 µg/ml of ampicillin. Cells were grown at 30ºC until A600nm= 0.9, 
induced by the addition of 0.5 mM IPTG and growth was continued for 18 
hours. After induction, bacteria were harvested by centrifugation (4,000 × g, 
4°C, and 15 min), resuspended in 50 ml equilibration buffer (20 mM 
NaH2PO4, 0.5 M NaCl, 30 mM imidazole (pH 7.4)), supplemented with 
protease inhibitors (Roche), and lysed by sonication. Cell debris were 
removed by centrifugation (40,000 × g, 4° C, 30 min), and the supernatant 
was filtered through a 0.2-µm syringe filter. Each antibody fragment was 
purified by nickel chelate affinity chromatography making use of the C-
terminal 6His of pComb3X. Bound proteins were eluted with a linear 
imidazole gradient (0-300 mM imidazole in 20 mM NaH2PO4, 0.5 M NaCl 
(pH 7.4)). The appropriate fractions from IMAC were pooled, dialyzed 
against PBS and concentrated by Centricon columns (Millipore). Protein 
purity was checked by non-reducing SDS-15% PAGE. Protein 
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quantification was determined by measuring the optical density at 280 nm 
by the classic Bradford method.        
3.2.3 ELISA measurements 
To analyze relative antigen binding affinities of anti-Vif VL, VH, VHD and 
scFv 4BL antibody fragments, ELISA plates (Nunc) were coated with 100 
ng of purified recombinant HIV-1 Vif protein, thyroglobulin or BSA, 
overnight at 4º C. Wells were blocked for one hour at 37ºC with BSA 3% in 
PBS. Purified anti-Vif VL, VH, VHD and scFv 4BL were added to the wells 
for further incubation. After washing the wells with PBS, HRP-conjugated 
anti-HA mAb (Roche) was used for detection. The results were measured by 
optical density at 405 nm and performed in triplicate.  
 
3.2.3 Protein expression in reducing environment and alkylation with 
AMS 
 
To assess the effect of the reducing environment on anti-Vif VL, VHD and 
scFv 4BL folding in the periplasm of E. coli Top10F we used a similar 
method as described by Missiakas et al 335 and Martineu et al 336. Briefly, a 
fresh colony was grown at 30ºC overnight in SB medium containing 100 
µg/ml of ampicillin. A sample of 1 ml of cells was used to inoculate 10 ml 
of SB medium containing 100µg/ml of ampicillin. Cells were grown at 30ºC 
until A550nm = 0.9 and 5 mM DTT was added at the time of induction with 
0.5 mM IPTG. After 18 hours induction, density of bacteria culture was 
normalized. Cultures were centrifuged (4000g, 30 min, 4º C) and cell pellets 
were resuspended in PBS containing protease inhibitors (Roche). Soluble 
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periplasmic proteins were extracted with lysozyme and collected by 15 min 
centrifugation at 14,000g. To confirm the redox state of the proteins in the 
periplasmic extracts we analyzed the alkylation of samples using the 4-
acetamido-4’- maleimidylstilbene-2,2’- disulfonic acid (AMS) as described 
by Kobayashi et al 337 and Jurado et al 338. Briefly, a final concentration of 
DTT 100 mM was added and then each sample was first incubated for 10 
minutes on ice and then 10 minutes at 100º C. Samples were precipitated 
with TCA for one hour on ice followed by centrifugation at 14,000 g for 15 
min at 4ºC. Pellets were washed with ethanol 70%, air dried and 
resuspended in 40 µl of an alkylating cocktail (150 mM Tris-HCl (pH 7.5), 
2% (w/v) SDS, 15mM AMS). After one hour of incubation at 22º C, 40 µl 
of SDS-PAGE sample buffer (2x) lacking 2- mercaptoethanol were added to 
all samples. Periplasm extracts were analyzed by non-reducing 15% SDS-
PAGE and Western Blot with HRP conjugated anti-HA mAb (Roche). As a 
control, alkylation of samples with no addition of DTT was performed. 
 
3.2.4 Monitoring intrabody solubility by the antibody-CAT-fusion 
system  
 
To further evaluate the solubility of each antibody fragments in a reducing 
environment we adapted the protein-CAT fusion system developed by 
Maxwell et al to our intrabodies 339. First, each anti-Vif VH, VL, VHD and 
scFv 4BL genes were cloned into the BglII and XbaI cloning sites of the 
pCFN1. The pCFN1 vector was kindly provided by Dr Davidson. This 
plasmid includes a strong IPTG promoter (Ptrc), a strong translation start 
with an NcoI site at the initiator ATG codon, phage f1 and pBR322 origins 
VL single-domain as intrabodies                                                                                                             
 
                                                                                                                                                              
116 
 
of replication, the ampicillin resistance gene, and the lacI q gene. To 
evaluate protein solubility, chloramphenicol resistance analysis were 
performed by transforming JM101 cells with each antibody CAT-fusion 
clone. Briefly, each transformation mixture was inoculated into 5 ml SOC 
and incubated at 37ºC for 1 hour. Next 10 ml of SB medium with 3 µl of 
100 mg/ml ampicillin was added to each transformation. A total 15 ml of 
each culture was shaken for 1 hour at 37ºC. Subsequently 4.5 µl of 100 
mg/ml ampicillin was added and cultures shaken for one hour at 37ºC. Then, 
35 ml of SB medium with 35 µl of 100 mg/ml ampicillin was added and 
cultures grown overnight at 37ºC. The following day, 600 µl of each culture 
was used to inoculate 20 ml of SB medium containing 100 µg/ml ampicillin. 
Expression of CAT-fusion antibody fragments was induced by addition of 
0.5 mM IPTG when the optical density of cultures reached 0.9. After 2 
hours of induction, several dilutions of each clone were plated on agar plates 
containing 100 µg/ml ampicillin, 200 ug/ml IPTG and various 
concentrations of chloramphenicol. Plates were incubated at 37ºC for 16-20 
hours. The level of resistance was quantified as the highest level of 
chloramphenicol at which colonies appeared after the 37 ºC incubation 
period. 
 
3.2.5 Cell lines and Transfections 
293T cells were maintained in DMEM Medium and H9, H938 LTR-CAT 
and Jurkat cells were maintained in RPMI 1640 Medium. Media was 
supplemented with 10% fetal calf serum (FCS), antibiotics (100 units/ml 
penicillin and 100 µg/ml streptomycin) and 2 mM glutamine. All cell 
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cultures were maintained at 37°C in 5% CO2. Tissue culture media and 
reagents were from BioWhitaker. To produce large amounts of HIV-1 
particles, 4-5 x 106 293T cells were transfected by Fugene (Roche) 
according to the manufacturer's protocol with 2 µg of wild type HIV-1NL4-3, 
pHIV-1NL4-3∆vif or pHIVnPLAP-IRES-N expressing anti-Vif antibody 
fragments.  
 
3.2.6 Pulse - chase analysis 
 
For pulse-chase experiments, 293T cells (1-2x 106) were transfected by 
Fugene (Roche) with 2 µg of VL, VH, VHD and scFv pcDNA3.1 plasmids. 
Thirty six hours post-transfection, cells were incubated with 1 ml of 
methionine/cysteine-free medium for 2 hours at 37ºC and metabolically 
labelled with similar medium containing 100 µCi [35S] methionine/cysteine 
for 2 hours at 37ºC. After labelling, cells were washed 3 times with 1 ml 
DMEM supplemented with 40x excess methionine (1.2 mg /ml) and 20x 
excess cysteine (0.84 mg/ml) and incubated with the same medium for 
various time points. At each time point, cells were washed twice with cold 
PBS and lysed on ice for 1 hour with 400 µl lysis buffer containing protease 
inhibitors (Roche). Lysates were cleared by centrifugation and supernatant 
incubated overnight at 4ºC with anti-HA affinity matrix (Roche) and then 
immunoprecipitated proteins were separated by 15% SDS-PAGE. The gel 
was dried and subjected to autoradiography. 
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3.2.7 Replication complementation assay 
 
A transient complementation assay was performed as previously described 
to provide a quantitative measure of the ability of wild-type Vif protein to 
complement a single-round of HIV-1 replication in trans.51 Briefly, H938 
LTR-CAT cells (106) and Jurkat (106) cells were cotransfected by Fugene 
(Roche), with 2 µg of pSVCAT∆env∆Vif, 2 µg of pVSVG, 2 µg of 
pSVLVif and either plasmids encoding anti-Vif scFv 4BL, VH, VHD or VL 
antibody fragments. The ability of antibody fragments to inhibit a single 
round of infection was measured by assaying for chloramphenicol 
acetyltransferase (CAT) activity in the transfected culture 9 days after 
transfection. CAT assay was performed by the Quan-T-CAT system 
(Amersham Biociences). 
 
3.2.8 Cell-specific inhibition of HIV-1 replication  
 
HIV-1 recombinant virus stocks encoding VL, VH, VHD and scFv antibody 
fragments were prepared by transfection of 293T cells. Forty eight hours 
post-transfection, the viral supernatants were normalized for the same 
TCID50 and used to infect permissive cells (Jurkat) and nonpermissive cells 
(H9).  Cell cultures were maintained for up to 20 days and to monitor 
infection, aliquots were taken at the indicated time points to determine p24 
levels by HIV-1 ELISA (Innotest). Permissive and nonpermissive cells were 
infected with HIV-1NL4-3 and HIV-1NL4-3 ∆Vif as positive and negative 
controls, respectively. Cellular proliferation and viability of infected H9 and 
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Jurkat cells were analyzed with tetrazolium salt WST-1 (Roche) according 
to the manufacturer's protocol.  
 
3.2.9 Gel-Filtration 
 
Gel-filtration was performed using a Pharmacia FPLC system on a 
Superdex 200 HR 10/30 column. Samples containing variable concentration 
of VL single-domain were loaded in 100 µl of 50 mM sodium phosphate 
buffer (pH 7.4). The column was calibrated using molecular weight markers 
including bovine serum albumin (66 kDa), ovalbumin (45 kDa) and 
cytrochrome c (12.4 kDa). 
 
3.2.10 GdnHCl-induced Unfolding/Refolding Equilibrium 
 
The fluorescence spectrum of the VL single-domain was recorded at 25ºC 
with a Varian Cary/Eclipse fluorescence spectrophotometer. Unfolding 
transition curves were determined by reversible chemical denaturation of 
10µM solutions of the VL single-domain mixed together in PBS (pH 7.4) 
with variable concentration of guanidinium chloride (GdnHCl), after 
overnight incubation at 4ºC. Under these conditions, the unfolding transition 
is completely reversible, and unfolding and refolding curves are identical 
within experimental error. The fluorescence emission spectrum was 
recorded from 295 to 420 nm with an excitation wavelength of 280 nm. 
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3.3 Results  
 
3.3.1 Anti-Vif VL single-domain strongly inhibit HIV replication 
 
 
The human immunodeficiency virus type-1 (HIV-1) vif gene encodes a 23 
kDa protein that is essential for viral replication and spread in peripheral 
blood lymphocytes and primary macrophages, as well as in some 
established T-cell lines 20,21,300-304. We recently demonstrated that anti-Vif 
scFv intrabodies are an effective approach to inhibit this crucial step of the 
viral replication cycle 131. A specific anti-Vif scFv (clone 4BL) from 
immunized rabbits was shown to bind Vif intracellularly and inhibit viral 
replication. From this scFv scaffold, we then developed a minimal VH 
single-domain with intrabody properties that was engineered to mimic 
camelid antibody domains121. Non-specific binding of VH by its interface 
for the VL domain was prevented through amino acid mutations in 
framework 2 and 4 (V37F, G44E, L45R, W47G and W103R). These 
camelized VH single-domain intrabodies were highly expressed in reducing 
environments and exhibited a strong neutralization of HIV replication121. In 
the present study, we now evaluate if the anti-Vif VL single-domain can 
also be effective as an intrabody. To test this hypothesis two sets of HIV 
inhibition experiments were performed. The first experiment was performed 
by a transient trans-complementation assay in nonpermissive cells that 
require Vif function for HIV-1 replication. Briefly, nonpermissive H938 
LTR-CAT cells were cotransfected with pSVCAT∆env∆Vif, pVSVG, 
pSVL-Vif and pcDNA3.1-anti-Vif-VL as described in Material and 
Methods section. To compare the VL inhibition with the VH, scFv 4BL and 
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the camelized VH (VHD) intrabody, anti-Vif VH, scFv-4BL and VHD 
antibody fragments were also transfected in H938 LTR-CAT cells. The HIV-
1 virus particles produced in this assay result in only a single round of 
infection, as the packaged viral genome is defective for Env production. The 
efficiency of a single round of virus replication is quantitated by measuring 
the level of CAT enzyme activity in the infected cultures after 9 days, the 
minimum time for a detectable signal above background. As shown in 
Figure 3.1, in the absence of Vif, replication of vif-negative virus was ∼ 90-
fold lower than that of vif-positive virus. When anti-Vif scFv and VHD 
intrabodies are coexpressed in H938 cells the trans-complementation is 
reduced to 25% and 15% of the wild-type level, respectively. When the anti-
Vif VL single-domain was coexpressed a strong reduction was also 
observed in the trans-complementation (~85% of the wild-type level). In 
contrast, the anti-Vif VH single-domain caused a much less significant 
reduction in viral replication. As a control, permissive cells (Jurkat) that do 
not require Vif function to HIV replication were cotransfected with 
pSVCAT∆env∆Vif, pVSVG, pSVL-Vif and plasmids encoding anti-Vif 
fragments. In this case, no inhibitory effect was observed on HIV-1 
replication.  
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Figure 3.1 - Neutralization of Vif function in a trans-complementation assay. Values 
shown represent the percentages of replication-complementation in nonpermissive H938 
cells (White bars) and permissive Jurkat cells (Dark bars) relative to the value obtained for 
the wild-type. Cells were cotransfected with pSVCAT∆env∆Vif, pVSVG, psvlVif, and 
either anti-Vif VL, VH, VHD or scFv 4BL plasmids as described in Material and Methods. 
The ability of anti-Vif antibody fragments to inhibit a single round of infection was 
measured by assaying for chloramphenicol acetyltransferase (CAT) activity in the cell 
cultures 9 days after transfection. 
 
The trans-complementation assay examined the biological activity of anti-
Vif antibody fragments in a transient assay under conditions in which most 
virus transmission occurs by cell-to-cell spread. To evaluate the specificity 
of viral inhibition in several rounds of replication in nonpermissive and 
permissive cell lines a second experiment was performed with recombinant 
HIV-1 viruses expressing anti-Vif fragments in cis. These recombinant 
HIV-1 viruses were generated from pHIVnPLAP-IRES-N+, by replacing 
the human placental alkaline phosphatase (PLAP) gene by VL, VH, VHD 
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and scFv-4BL, generating pHIV-VL, pHIV-VH, pHIV-D and pHIV-4BL. 
Each plasmid was then transfected in 293T cells, and high titre supernatants 
of each virus was obtained. HIV-1 supernatants normalized for the same 
TCID50 were used to infect permissive cells (Jurkat) and nonpermissive 
cells (H9) at a multiplicity of infection of 0.1 and their ability to replicate in 
these cells was assessed by performing standard virus growth curves. The 
cell cultures were maintained for up to 20 days and to monitor infection, 
aliquots were taken at the indicated time points and HIV-1 p24 antigen 
levels were determined by ELISA. As shown in Figure 3.2, nonpermissive 
cells did not support the spread of HIV-D, HIV-4BL and HIV∆vif. When 
H9 nonpermissive cells were infected with HIV-VL virus the same pattern 
of virus replication inhibition was observed. In contrast, the permissive cell 
line Jurkat supported replication of all viruses used in this experiment. We 
have previous shown that intracellular antibody expression has no obvious 
negative effects on cell viability or proliferation. Nevertheless, we 
quantified cell proliferation and cell viability of infected permissive and 
nonpermissive cells compared with non-infected cells. The assay consists of 
a colorimetric assay based on the cleavage of the tetrazolium salt WST-1 by 
mitochondrial dehydrogenases in viable cells (Roche). The kinetics of 
WST-1 metabolism showed that H9 and Jurkat cells infected with HIV 
expressing anti-Vif antibody fragments have similar levels of proliferation 
compared with non-infected cell lines (Figure 3.2 C and D). The two 
inhibition assays described above clearly demonstrate that the anti-Vif VL 
single-domain intrabody strongly neutralize HIV replication. The VL single-
domain tested in this study derived directly from the anti-Vif scFv 4BL 
scaffold. Therefore, to further understand why this VL single-domain was 
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so effective as an intrabody in the absence of the parent VH domain and 
without any camelization process, several experiments were performed to 
characterize the VL domain in more detail. 
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Figure 3.2 - Cell-specific inhibition of HIV-1 replication in the presence of anti-Vif 
antibody fragments. Replication of HIV-1 encoding anti-Vif VL, VH, VHD and scFv 4BL 
antibody fragments was assessed in permissive and nonpermissive cells. Cell-specific 
inhibition was started with HIV-1NL4-3 encoding anti-Vif antibody fragments produced after 
transfection of 293T cell lines with full-length proviral DNA as described in Material and 
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Methods. (A) - Nonpermissive H9 cells were infected with HIV-VL, HIV-VH, HIV-VHD 
and HIV-4BL. (B) - Permissive Jurkat cells were infected with HIV-VL, HIV-VH, HIV-
VHD and HIV-4BL. Infection of H9 and Jurkat cells with wild-type HIV-1NL4-3   and with 
HIV-1NL4-3 ∆Vif were used as positive and negative controls, respectively. The cultures 
were maintained for up to 20 days, and to monitor infection aliquots were taken at the 
indicated time points to determine p24 levels by ELISA. The data are representative of two 
independent experiments. (C) - H9 cells proliferation kinetics with WST-1 reagent. (D) - 
Jurkat cells proliferation kinetics with WST-1 reagent. The results of cellular proliferation 
and viability were measured according to the manufacturer's protocol (Roche) by optical 
density at 405 nm.  
 
3.3.2 Expression and relative binding affinity of the anti -Vif VL single-
domain  
 
The aim of the first experiment was to compare the expression yields and 
the relative binding affinities of the anti-Vif VL with VH, VHD and scFv 
4BL antibody fragments. Briefly, to express each antibody in the bacteria 
periplasmic space, phagemid DNA´s were transformed into non-suppressor 
E. coli strain TOP10F. After IPTG induction, samples of bacteria were 
taken just prior to induction of protein expression (non-induced) and at 2, 4, 
6, 12 and 18 hours. Cells were normalized for the same OD600, lysed and 
then each soluble protein fraction was separated by 15% SDS-PAGE, 
transferred to nitrocellulose membrane and analyzed by Western Blot with 
HRP-conjugated anti-HA mAb. As shown in Figure 3.3A, all antibody 
fragments were expressed in the periplasm as soluble proteins. However, 
VHD and VL single-domains were clearly the two antibody fragments that 
showed the higher expression and purification yields. Purification yields of 
soluble protein from 1 liter bacterial culture were 0.6 ± 0.1 mg in the VH 
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construct, 2 ± 0.1 mg in scFv 4BL and 8 ± 0.1 mg in VL and VHD. The 
VHD was previously demonstrated to be highly expressed as a soluble 
protein due to the VH camelization process that was applied to mimic 
camelid antibody domains. In the case of the VL, no camelization process or 
protein engineering was applied. Therefore, it seems likely that the VL 
single-domain can be naturally expressed as soluble protein at high levels in 
the absence of the parent VH domain.  
 
To analyze and compare the binding activity of the isolated VL domain with 
VH, VHD and scFv 4BL antibody fragments, an ELISA was performed as 
described in the Material and Methods section. As shown in Figure 3.3B, the 
VL single-domain showed similar binding patterns to that of the VH and 
VHD. Moreover and as previous observed with VH121, the VL also displayed 
a ~ 50- fold lower relative affinity for Vif as compared to the parental anti-
Vif scFv. Control experiments showed near background signals and lower 
non-specific binding of all single-domains to bovine serum albumin (BSA) 
and thyroglobulin, similar to that of anti-Vif scFv. This suggests that the 
binding of VL and VH domains antibodies is mediated through the CDRs 
loops and is not mediated via some other part of the molecule, for example 
the putative hydrophobic surface which is normally covered by the 
corresponding paired VH or VL domain in conventional antibodies. 
Therefore, the decrease in the relative binding affinity of the VL single-
domain is not dramatic and still allows constant specific binding to HIV-1 
Vif protein as observed previously for the VH and VHD intrabodies 121.     
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Figure 3.4 - Expression and relative binding affinities of anti-Vif VL, VH VHD and 
scFv 4BL antibody fragments.  (A) E. coli TOP 10F bacteria expressing anti-Vif VL, VH, 
scFv 4BL and VHD at 2, 4, 6,12 and 18 hours after induction with 0.5 mM IPTG at 30°C. 
Antibody fragments were separated by 15% SDS-PAGE and visualized by Western blot 
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probed with HRP-conjugated anti-HA monoclonal antibody. Molecular weight is indicated 
in kDa. (B) The anti-Vif VL, VH, scFv 4BL and VHD antibody fragments were used for 
evaluating relative binding affinities to 100 ng of Vif protein, thyroglobulin and BSA by 
ELISA. Results were measured by optical density at 405 nm. Data represents results of 
three independent experiments; anti-Vif scFv 4BL was used as positive control. As shown, 
all single-domains have similar binding patterns to Vif antigen, but less than scFv 4BL. 
Background levels were detected using the control antigens BSA and thyroglobulin.  
 
 
3.3.3 Expression and redox state of anti-Vif antibody fragments in 
reducing environment 
 
Antibody domains carry a highly conserved internal disulfide bond, 
connecting both β-sheets of the β-sandwich structure 105. Functional 
antibody fragments that fold under reducing conditions or which no longer 
require cysteine residues (Cys) for folding, give a number of significant 
advantages as intrabodies. The aminoacid sequence of the light and heavy 
chain variable chain of the anti-Vif scFv 4BL is shown in Figure 3.4. The 
VL sequence of the scFv 4BL belongs to the Vκ1 family. Most rabbit light 
chains have an extra disulfide bridge that links the variable and constant 
domains in addition to the two conserved intrachain disulfide bridges. In the 
case of the anti-Vif VL single-domain we can observe that this additional 
Cys is present 218,219. Moreover, we can also detect two additional Cys 
present in the CDR3. The presences of Cys in CDRs are usually observed in 
camelid antibody fragments 127,128. However, in our laboratory we also 
observe that this characteristic is quite common with rabbit antibodies (data 
not shown). The VH sequence of the scFv 4BL belongs to the VH1 family 
and only the two constant intrachain disulfides bridges are present.   
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Figure 3.4 – Amino acid sequence of rabbit anti-Vif VL domain. The frameworks, 
CDRs and the amino acid numbering are as defined by Kabat et al. The Cys are underlined.   
 
 
In order to determine if our anti-Vif antibody fragments do not require the 
cysteine residues to be correctly folded in a reducing environment, 
production of VL, VH, VHD and scFv 4BL were induced in the periplasm 
and 5mM of reducing agent DTT was added to the growth medium at the 
time of induction 335,336. This concentration of DTT has been described to be 
sufficient for mimic the reducing environment of cytoplasm and not impair 
the growth rate of bacteria cells. To analyze the oxidation state of the Cys 
residues in anti-Vif antibody fragments, soluble periplasmic extracts were 
prepared as described in Material and Methods section and incubated with 
the 4-acetamido-4’-maleimidylstilbene-2, 2’- disulfonic acid (AMS) 337,338. 
AMS covalently binds to free thiol groups in proteins, increasing their 
molecular mass and preventing any further oxidation 338. Due to the low 
expression yields and high tendency for aggregation of VH domain, it was 
only possible to examine and determine the redox state for the VL, VHD 
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and scFv 4BL antibody fragments. As the data in Figure 3.5 demonstrates, 
in the reducing DTT environment of periplasm the VL, VHD and scFv 
fragments could correctly be fold as soluble proteins and were alkylated by 
AMS (reduced form). In contrast, antibody fragments expressed in non-
reducing environment were not alkylated by AMS indicating their oxidized 
form. Therefore, these data indicate that, in the reducing environment the 
VL, VHD and scFv antibody fragments can tolerate the loss of intra-domain 
disulfide bonds and be correctly folded as soluble protein in high yields.    
 
Figure 3.5 - Analysis of soluble fractions of E. coli expressing anti-Vif VL, VHD and 
scFv 4BL antibody fragments in reducing environment and alkylation with AMS. To 
mimic the reducing environment of the cytoplasm in the E. coli TOP 10 F bacteria 
periplasm, 5mM DTT was added to medium at the time of induction. The redox state of 
each antibody fragment was analyzed by AMS-alkylation. The alkylated (reduced, red) and 
nonalkylated (oxidized, oxd) forms of antibody fragments from periplasmic space were 
prepared as described in Material and Methods, separated by their different mobility in 
nonreducing 15% SDS-PAGE gel and visualized by Western blot probed with HRP-
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conjugated anti-HA mAb. The arrow labelled DTT indicates the presence (+) or the 
absence (-) of 5mM DTT in the growth medium. As shown, reduced and alkylated proteins 
are expressed at higher molecular weight compared to oxidized forms when DTT is present. 
All antibody fragments expressed with DTT are reduced in their cysteine residues. 
Molecular weight is indicated in kDa. 
 
3.3.4 Monitoring intrabody solubility by the antibody-CAT-fusion 
system  
 
In a recent study Maxwell et al developed a simple in vivo system for 
assessing protein solubility that involves expressing a fusion of a protein or 
protein domain of interest with chloramphenicol acetyltransferase (CAT), 
the enzyme responsible for conferring bacterial resistance to 
chloramphenicol 339. CAT is a highly soluble homotrimeric protein of 25 
kDa molecular weight that has been shown to maintain activity when fused 
to various other proteins. With this system the authors demonstrate that E. 
coli cells expressing fusions of an insoluble protein to CAT exhibit 
decreased resistance to chloramphenicol compared to fusions with soluble 
proteins 339. To test if this system could also be able to differentiate which 
anti-Vif intrabody presents the higher solubility in a reducing environment, 
the VH, VL, VHD and scFv 4BL genes were cloned into the pCFN1-CAT 
fusion vector (kindly provided by Dr. Maxwell). Each antibody-CAT-fusion 
plasmid was transformed into JM101 cells and protein expression was 
induced as described in Material and Methods section. At the end of the 
induction period cells were diluted and plated on agar plates at increasing 
chloramphenicol concentrations. The level of resistance was quantified as 
the highest level of chloramphenicol where colonies appear after an 
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overnight incubation at 37ºC. Cells without pCFN1-CAT plasmid (negative 
control) did not grow on chloramphenicol concentration above 10 µg/ml, 
whereas cells with pCFN1-CAT plasmid (positive control) grew without 
detectable differences at chloramphenicol concentration as high as 600 
µg/ml (Table 3.1). Cells transformed with the pCFN1-VH-CAT showed 
decreased growth even at 10 ug/ml and did not grow above 20 µg/ml 
chloramphenicol concentration. In contrast, cells transformed with the 
pCFN1-scFv4BL-CAT grew at 400 µg/ml chloramphenicol concentration 
and cells with either the pCFN1-VL-CAT or pCFN1-VHD-CAT constructs 
grew at 600 µg/ml chloramphenicol concentration.  
 
 
These results clearly demonstrate that the chloramphenicol resistances 
displayed by cells transformed by the pCFN1 derivates were affected by the 
solubility of each antibody fragment fused to CAT. As expected, the VH 
domain was shown to be highly insoluble and with high tendency for 
aggregation. On the other hand, the scFv, VHD and VL antibody fragments 
revealed to be highly soluble when expressed in a reducing environment. 
VL single-domain as intrabodies                                                                                                             
 
                                                                                                                                                              
134 
 
Moreover, we can observe that among these three antibody fragments, the 
VL and VHD were those who revealed to be more soluble and correctly 
folded. Within this context, the VL single-domain alone and without any 
camelization process appears to be as soluble and stable as the VHD. The 
results presented here clearly demonstrated that the CAT-fusion system can 
differentiate soluble from insoluble intrabodies when expressed under 
reducing conditions. As a result, this system might also be a useful approach 
for direct in vivo screening of soluble and stable intrabody fragments.  
 
3.3.5 Steady-state expression and turnover measurements  
 
In a previous study we demonstrated that the biological activities of the anti-
Vif VH antibody fragments were directly correlated with their intracellular 
solubility and stability 121. In addition, the steady-state level and long 
protein half-lifes of camelized VH were shown to be higher than the wild-
type VH and thus were far more effective in neutralization of the HIV-1 
replication. To further understand why the anti-Vif VL single-domain was 
so effective as an anti-HIV-1 intrabody, steady-state expression level and 
turnover rates were measured by pulse-chase experiments in 293T cells 
Figure 3.6 shows the pulse-chase analysis for the VH, VHD, VL and scFv 
4BL antibody fragments.  
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Figure 3.6 - Pulse-chase analysis of anti-Vif VH, VL, VHD and scFv 4BL in 
transfected 293T cells. At 36 hours following transfection, 293T cells were pulse-labeled 
in [35S]-methionine/cysteine for 2 hours at 37ºC and chased for various times with DMEM 
medium supplemented with 40x excess methionine (1.2 mg /ml) and 20x cysteine (0.84 
mg/ml). At each time point, cells were lysed in buffer with 50 mM Tris (pH 8.0), 100 mM 
NaCl, 1% Nonidet P-40 and immunoprecipitated with anti-HA affinity matrix (Roche). The 
proteins were separated by 15% SDS-PAGE and visualized by autoradiography. Lysates of 
293T cells not expressing antibody fragments at time 0 were used in Western blot as a 
negative control (C-). Chase times (in hours) are indicated on top. The amount of protein 
expressed at all time points was determined by optical density relative to the protein 
expressed at time 0.  
 
As previously demonstrated, the wild-type VH domain shows a lower 
steady-state level and a relatively short protein half-life (< 2 hours). With 
respect to the scFv, a high protein steady-state level was observed in the 
first time point. However, it was not possible to detect any scFv protein 
quantity after two hours of labelling. The scFv was, therefore, shown to be 
rapidly degraded and hence its protein half-life was demonstrated to be 
relatively short (< 1 hour). In contrast, the anti-Vif VHD and VL intrabodies 
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were found to be the most stable, showing the higher steady-state level and 
long protein half-life. Moreover, it should be noted that although the VHD 
single-domain showed a relatively higher steady-state accumulation at 8 
hours, its higher stability was only possible to achieve due to the 
camelization process that was applied. In contrast, the high VL intracellular 
stability was naturally obtained without any process of protein engineering. 
Given these results, it can be speculated that the underlying reason that 
makes the VL single-domain so effective as the VHD intrabody is its 
capacity to be highly soluble in a reducing environment.      
 
 
3.3.6 Equilibrium transition experiments of VL single-domain 
 
To confirm that in vivo protein results were consistent with in vitro protein 
stability data, the thermodynamic stability of the anti-Vif VL single-domain 
was examined by GdnHCl equilibrium denaturation experiments. The 
thermodynamic parameters were calculated using the six-parameter fit on 
the plot of concentration of GdnHCl versus fluorescence intensity, giving 
curves consistent with two-state behavior 340. As shown in Figure 3.7A, the 
VL domain started to unfold at 1.75 M GdnHCl, where VL is monomeric in 
solution as indicated by gel-filtration analysis (Figure 3.7B).  
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Figure 3.7 – (A) – GdnHCl denaturation of anti-Vif VL single-domain antibody. 
Unfolding transition curves were determined by reversible chemical denaturation of 10µM 
solutions of the VL single-domain mixed together in PBS (pH 7.4) with variable 
concentration of guanidinium chloride (GdnCl), after overnight incubation at 4ºC. The 
fluorescence emission spectrum was recorded from 295 to 420 nm with an excitation 
wavelength of 280 nm. (B) - Analytical gel filtration of anti-Vif VL single-domain in 50 
mM sodium phosphate buffer (pH 7.4) on a Superdex 200 HR 10/30 column at a 
concentration of 10µM. Arrows indicate elution time of molecular mass standards: bovine 
serum albumin (66 kDa), ovalbumin (45 kDa) and cytrochrome c (12.4 kDa). 
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Therefore, the transition is influenced only by the stability of the monomeric 
VL domain and is not affected by multimerization equilibria. The VL 
single-domain displayed an unfolding cooperativity (m value) of 18.8 kJ 
mol-1 M-1 and a free energy upon unfolding (∆GN-U) of 42.4 kJ mol-1. The 
range of the m value can be compared to that expected for proteins of this 
size (14–15 kDa), and indicate that the VL have the cooperativity expected 
for a two-state transition 340. Recently, Ewert et al published a study where 
the biophysical properties of human VL single-domains families were 
intensely characterized 341. In this study the authors shown that Vk3 were 
the most stable VL domain with a ∆GN-U of 34.5 kJ mol-1, followed by Vk1 
with 29.0 kJ mol-1 and Vk2 and Vλ1 with 24.8 kJ mol-1 and 23.7 kJ mol-1, 
respectively. The least stable VL domains were Vλ2 and Vλ3 with a ∆GN-U 
of 16.0 kJ mol-1 and 15.1 kJ mol-1. When we compare these results with the 
anti-Vif VL single-domain ∆GN-U of 42.4 kJ mol-1 we can clearly note that 
our rabbit VL scaffold was more stable than the human VL domains. 
Therefore, the in vitro thermodynamic data measured by GdnHCl 
equilibrium denaturation experiments also indicates the anti-Vif VL single-
domain is extremely stable. However, it was already shown by others that 
the disulphide bond significantly contributes to the stability of antibody 
domains. Since our goal is to evaluate why the VL single-domain is so 
effective as an intrabody, further studies are in progress to measure the VL 
∆GN-U under reducing conditions. In addition, VH, scFv and VHD 
thermodynamic stabilities are also being determined so we can compare all 
the anti-Vif intrabodies stability.  
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3.4 Discussion  
 
The recombinant single-chain antibody fragment (scFv) is usually viewed as 
the suitable format for intracellular expression in eukaryotic cells. The 
purpose of these antibody fragments is to bind a specific protein and thereby 
inhibit a biological response. However, in the reducing environment of the 
cytoplasm the intrachain disulfide bridges cannot form and only very 
soluble and stably expressed antibody fragments will be able to fold 
correctly in sufficient amounts to be active as intrabodies.21 Moreover, the 
interaction of single-domains VH and VL by the interface is weak and may 
aggregate in the cytoplasm being targeted to proteosome degradation.  
 
Recently, single-domain antibodies (dAbs) have been considered a 
promising scaffold structure for construction of intrabodies. Single-domain 
antibodies are the smallest functional antigen-binding fragments of an 
antibody, consisting of only the variable heavy (VH) or variable light 
domain (VL). The VH domain has been shown to significantly contribute to 
the formation of the antigen-binding site. However, the efficient expression 
of VH fragments is usually confronted with folding problems, low solubility 
and high tendency for aggregation caused by the exposure of the 
hydrophobic VH/VL interface upon removal of the VL domain. 
Nevertheless, these problems seem to have been overcome, or at least 
greatly reduced for some mouse and rabbit VH domains by methods of 
genetic engineering that confer the structural properties of the VHH domain 
of camelids. The strong inhibiting potential of several VH and VHH 
intrabodies has been demonstrated in the field of cancer, HIV autoimmune 
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and neurodegenerative diseases 121,130-132. In contrast, the VL-domain has 
not been extensively studied as an independent source for intrabodies 
construction. The study of Colby et al is to our knowledge, the only study 
that reports the construction of a human VL single-domain as an intrabody 
135.  
In a recent study we have developed a minimal scaffold VH fragment with 
intrabody properties derived from an anti-Vif single-chain antibody that was 
engineered to mimic camelid antibody domains 121. We found that 
camelization of a rabbit anti-Vif VH domain renders it more soluble and 
enables higher levels of intracellular expression. As a result, these 
camelized VH intrabodies revealed higher steady-state levels and long 
protein half-lifes and strongly neutralize the HIV-1 infectivity. In the 
present work, we now show that rabbit VL single-domains can also be 
efficiently used as intrabodies. Our results demonstrate that the anti-Vif VL 
single-domain was highly soluble and resistant to aggregation when 
expressed in E. coli. When, expressed under reduction conditions the VL 
single-domain was shown to tolerate the loss of intra-domain disulfide 
bonds and be correctly folded as soluble protein in high yields. Moreover, 
although there was a small decrease in the antigen-binding, VL scaffold was 
shown to preserve its specificity and activity. Therefore, the anti-Vif VL 
intrabody demonstrated to be so effective in the neutralization of HIV 
replication as the VHD. These results, together with observations by our 
group and others suggest once again that the protein turnover rate and the 
steady state accumulation are the most critical factors for the effectiveness 
of an intrabody 121, 221, 138, 140. At the end the concentration of intrabody 
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inside the cell and the affinity for the antigen will govern the extent of its 
binding and consequent neutralization of function.  
 
In conclusion, in the present study we now demonstrate that a rabbit VL 
single-domain antibody can be highly expressed as soluble protein in the 
absence of the parent VH domain and without any process of protein 
engineering. Since several other rabbit VL single-domains have already 
been characterized in our laboratory and shown to be extremely robust, we 
can consider that rabbit VL single-domains have also an enormous value as 
intracellular antigen recognition units.  
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4.0 Abstract   
Lentiviral vectors are among the most efficient tools for gene delivery into 
mammalian cells. A major goal of lentiviral gene delivery systems is to 
develop vectors that can efficiently target specific cell types. In the present 
work, we attempt to generate viral particles for targeting gene delivery. We 
have used CCR5-positive cells as the target for our strategy. Therefore, we 
developed a novel Sindbis pseudotyped lentiviral vector where the Sindbis 
receptor binding envelope protein was modified to directly encode a single-
chain antibody fragment (scFv) against the CCR5 chemokine receptor. We 
have generated two chimeric scFv-Sindbis envelopes varying the length of 
peptide linker that connect the heavy chain and light chain of anti-CCR5 
scFv. The two chimeric scFv-Sindbis envelopes were successfully 
incorporated into lentiviral-derived vectors and the resulting pseudotyped 
viral particles showed specific targeting to CCR5-expressing cells.  
However, our data demonstrate that the length of the peptide linker 
significantly affect the efficiency of infection. Pseudotyped viral particles, 
which display single-chain antibody fragments with longer peptide linkers, 
allowed higher titers of infection. The present study can be a model strategy 
for specific gene delivery mediated by lentiviral vectors pseudotyped with 
Sindbis envelope displaying scFv that recognize specific cellular surface 
proteins. Furthermore, this strategy has the potential to become a powerful 
approach for targeting gene delivery in anti-HIV gene therapy due to the 
important role of CCR5 expression in disease progression.         
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4.1 Introduction 
 
Recent approaches of gene therapy have been proposed and developed for 
overcoming inborn errors of metabolism as well as in the treatment of 
cancer and HIV infection 149,342. In a large number of trials, the tools of gene 
delivery consist of lentiviral vectors 206. One of the main challenges faced 
by lentiviral gene delivery systems is the development of vectors that can 
efficiently target specific cell types 200, 206. The most common approach 
developed to date, changes the tropism of envelope lentiviral receptor-
binding domain with a cell specific ligand, or a single-chain antibody 
fragment that recognizes and binds to specific cell surfaces molecules 199-208. 
Some of theses approaches have allowed some degree of cell-type-specific 
viral entry, however, the envelope alterations in most strategies also affect 
viron assembly and lead to low fusion activity and viral titers 205,209,343,344. 
Within this context, there is a strong interest for the ability to develop new 
and improved strategies allowing a lentiviral cell specific targeting. 
 
Recently, Morizono et al reported an approach to improve lentiviral 
targeting by exploring some properties of the Sindbis virus, a member of the 
Alphavirus genus 208. This virus can be produced at very high titers, shows 
high levels of expression and, unlike retroviruses, the fusogenic protein can 
fuse to cells independently of the receptor binding protein 202,208,345,346. The 
Sindbis virus encodes two transmembrane envelope proteins, E1 and E2 208.  
Although E1 and E2 form a heterodimer that function as a unit, the E1 
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domain is responsible for pH-dependent fusion and E2 for binding to 
receptor cells 208,346. Morizono et al demonstrated that lentiviral vectors can 
be pseudotyped with Sindbis virus envelope modified with a Fc interaction 
domain of protein A (ZZ domain), to bind a monoclonal antibody against a 
specific cell surface antigen. This strategy provides enrichment in terms of 
level of infection and specificity 208. Thus, these new vectors have received 
considerable attention for use as cell-specific targeting. In the present study, 
we aim to extend the utility and advantages of this new approach. For this 
purpose, we have generated a chimeric scFv-Sindbis pseudotyped lentiviral 
vector to be tested for specific gene delivery.  
 
The entry of human immunodeficiency virus (HIV) requires a specific 
interaction of the viral envelope glycoprotein and a cell receptor complex 
formed by CD4 and a chemokine receptor, CXCR4 or CCR5 48,49,347. HIV 
variants that use CXCR4 are typically detected at the later stages, and are 
associated with a rapid decline in CD4+ T cells and progression to AIDS 348-
350. In contrast, CCR5-tropic variants dominate the early stages of HIV 
infection and frequently persist during the entire course of the disease 
349,351,352. Therefore, CCR5-positive cells are the critical first targets in HIV 
infection and the CCR5 expression is key in disease progression 148,220. 
Hence, the CCR5 can be a useful molecule for gene therapy targeting.              
A single-chain antibody fragment (scFv) specific to human CCR5 has 
recently been developed and characterized in detail 148,220. We therefore 
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sought to apply this scFv for targeting specific cell types that express CCR5. 
With this objective, we modified the Sindbis envelope by inserting the ST6 
scFv into the Fc-binding position (ZZ domain) previously reported by 
Morizono et al. Our results confirm that the modified scFv-Sindbis virus 
envelope can pseudotype lentiviral-derived vectors and, most importantly, 
we show that it is possible to target lentiviral vectors specifically to cells 
that express CCR5 chemokine receptor. Furthermore, this strategy has the 
potential to become a powerful approach for targeting gene delivery in anti-
HIV gene therapy due to the important role of CCR5 expression in disease 
progression.         
 
           Cell specific lentiviral targeting by scFv 
 
 
 
 
 
 
 
 
 
 
149
4.2 Material and Methods  
 
4.2.1 Cloning and plasmids    
 
A recombinant anti-CCR5 specific single-chain antibody fragment (ST6) 
was kindly provided by Carlos Barbas III. This scFv was isolated from an 
immunized rabbit by using the phage display approach and has been 
characterized in detail 148,220. A DNA fragment encoding the ST6 scFv was 
generated by PCR amplification, using as template the phagemid 
pComb3X-ST6, which contains a gene encoding the anti-CCR5 scFv. The 
scFv was modified at 5’ and 3’ end with the following primers introducing 
the BstEII sites: ST6-BstEII-F 5’-
AGGAGGAGCAGGTAACCGGAGGCGGGGCCCAGGCGGCCGAGCT
C-3’ and ST6-BstEII-HA-B 5’- 
GGTGGTTTGGTGGTTACCCCACCTCCCAGAAGCGTAGTCCGGAAC
GTCGTACGGGGTACTGGCCGGCCTGGCCACTAGTG-3’. The 
resulting PCR fragment was gel-purified, digested with the restriction 
endonuclease BstEII, and cloned into the BstEII sites of the Sindbis virus 
envelope protein expression vector, pIntron Sindbis ZZ 208, generating the 
pIntron Sindbis-ST6SL. The pIntron Sindbis ZZ, kindly provided by Irvin S. 
Y. Chen, contains BstEII cloning site, inserted between the amino acids 71 
and 74 of E2 208. With this cloning step, we modified the Sindbis ZZ 
envelope by inserting the ST6 scFv into the Fc-binding domain (ZZ) of 
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pIntron Sindbis ZZ. Original VL and VH fragments of ST6 scFv are 
covalently linked with a peptide linker of seven aminoacids (GGSSRSS). 
We constructed also the ST6 scFv with a long peptide linker of 18 
aminoacids (SSGGGGSGGGGGGSSRSS). The following primers were 
used: RSC-F 5'-
GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3' 
and ST6linkerB 5’- 
CCCACCACCGCCCGAGCCACCGCCACCAGAGGAGGAAGATCTAG
AGGAACCACC ; RSC-B 5'-
GAGGAGGAGGAGGAGGAGCCTGGCCGGCCTGGCCACTAGTG-3' 
and ST6linkerF 5’-
TCCTCTGGTGGCGGTGGCTCGGGCGGTGGTGGGGGTGGTTCCTCT
AGATCTTCC.   The purified PCR products were assembled by another 
PCR using the following primers: RSC-F 5'-
GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3' 
and RSC-B 5'-
GAGGAGGAGGAGGAGGAGCCTGGCCGGCCTGGCCACTAGTG-3'. 
The resulting overlap-PCR product encodes the ST6 scFv in which the N-
terminal VL region is linked with the VH region through the 18-aa peptide 
linker named ST6LL scFv. The DNA fragment was gel-purified, digested 
with the restriction endonuclease SfiI, and cloned into the appropriately 
cutted vector pComb3X. This scFv cDNA was then modified at its 5’ and 3’ 
with the primers ST6-BstEII-F and ST6-BstEII-B to introduce the BstEII 
sites. The resulting digested PCR fragments were cloned into the BstEII 
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sites of the plasmid pIntron Sindbis ZZ, generating the pIntron Sindbis-
ST6LL. 
4.2.2 Expression and purification of anti-CCR5 single-chain antibody 
fragments 
 
To express and purify anti-CCR5 single-chain antibody fragments (ST6SL 
and ST6LL) from periplasmic space, phagemid DNA was transformed into 
the non-suppressor E. coli strain Top10F. A fresh colony of each scFv was 
grown at 37ºC overnight in SOB medium containing 100 µg/ml of 
ampicillin. A 5 ml sample of cells was used to inoculate 500 ml of SOB 
medium containing 100 µg/ml of ampicillin. Cells were grown at 37ºC until 
O.D600nm 0.9, induced by the addition of 0.5 mM IPTG and growth 
continued for 16 hours. After induction, cells were centrifuged for 30 min at 
4000×g and for cell disruption pellets were resuspended in 30 ml of 20 mM 
Tris-HCl buffer (pH 8.0), 0.7 M sucrose and supplemented with protease 
inhibitors (Roche). After one hour on ice, 5 ml of a 2 mg/ml lysozyme 
solution in 0.1 M EDTA (pH 8.0) was added. Cells were incubated for 30 
min on ice and the soluble periplasmic extract was collected by 15 min 
centrifugation at 14000×g. The periplasmic expressed scFv antibody 
fragments was purified by nickel chelate affinity chromatography using the 
C-terminal His6-tag. The eluted fraction was concentrated by Centricon 
columns (Millipore). Purified scFv were analyzed by SDS-PAGE followed 
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by Coomassie Blue staining and Western Blot with HRP-conjugated anti-
HA monoclonal antibody (Roche). Protein quantification was determined by 
measuring the optical density at 280 nm by the classic Bradford method.        
 
4.2.3 Cell lines  
 
293T, U87-CD4 and U87-CD4.CCR5 cells were maintained in Dulbecco´s 
Modified Eagles Medium. U87-CD4 and U87-CD4.CCR5 cells were 
obtained from the AIDS Research and Reference Reagent Program. Media 
was supplemented with 10% fetal calf serum (FCS), antibiotics (100 
units/ml penicillin and 100 µg/ml streptomycin) and 2 mM glutamine. 
Human PBMC from healthy HIV-seronegative donors were treated for 48 
hours with phytohemagglutinin (PHA) and then cultured in RPMI 1640 
medium supplemented with 20% FCS and 50 U of interleukin-2 per ml 
(Roche). All cell cultures were maintained in a humidified incubator at 37°C 
in 5% CO2. Tissue culture media and reagents were from BioWhitaker.  
4.2.4 Pseudotyped Viral Particles 
 
For generation of Sindbis pseudotyped lentiviral vectors expressing the 
luciferase reporter gene, a lentiviral plasmid HIV-Luc∆env and pIntron 
Sindbis-ST6SL or pIntron Sindbis-ST6LL were used. The HIV-Luc∆env 
vector was kindly provided by Irvin S. Y. Chen. The resulting pseudotyped 
viruses were named HIV-Luc∆env/Sindbis-ST6SL and HIV-
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Luc∆env/Sindbis-ST6LL. For generation of Sindbis pseudotyped lentiviral-
derived vectors expressing the enhanced green fluorescent protein (EGFP) 
reporter gene, pRRL.SIN-EGFP, plasmid expressing viral structural and 
enzymatic proteins, pCMVR8.9, and pIntron Sindbis-ST6SL or pIntron 
Sindbis-ST6LL, were used. The packaging plasmid pRRL.SIN-EGFP, and 
the vector plasmid pCMVR8.9 were kindly provided by Didier Trono. The 
resulting pseudotyped viruses were named HIVEGFP/Sindbis-ST6SL and 
HIVEGFP/Sindbis-ST6LL. Vesicular stomatitis virus (VSV) and Sindbis 
ZZ envelope were also used as positive and negative controls, respectively. 
All viral particles were produced by cotransfection of 293T cells (5x106) 
with Fugene reagent according to the manufacturer's protocol (Roche). The 
virus-containing supernatant was collected 48 hours post-transfection, 
normalized by p24 antigen levels and used immediately or frozen at –70ºC 
for later use. 
4.2.5 Infection assays  
 
For infection assays, cells were seeded in 6-well plates at density of 1x106 
cells/well. After 24 hours, cells were infected overnight with 1 ml of 
pseudotyped lentiviral vectors normalized for the same p24 antigen levels 
(300 pg/ml), expressing the luciferase reporter gene (HIV-Luc∆env) or 
expressing the enhanced green fluorescent protein (EGFP) reporter gene 
(pRRL.SIN-EGFP). The medium was replaced and cell targeting was 
evaluated by luciferase assay in U87-CD4 and U87-CD4.CCR5 cells, and 
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by flow cytometry in U87-CD4, U87-CD4.CCR5, 293T and PBMC cells. 
Luciferase assay was performed 72 hours after infection, according to the 
manufacturer's protocol (Promega). In flow cytometry, cells were detached 
from wells at 96 hours after infection, washed with PBS and incubated for 1 
hour at 4ºC with BSA. Following two washing steps, cells were incubated 1 
hour at 4ºC with rabbit anti-human CCR5 monoclonal antibody. After two 
additional washing steps, cells were incubated 1 hour at 4ºC with 
rhodamine-conjugated anti-rabbit antibody and then analyzed by flow 
cytometry.  
4.2.6 Western Blot Analysis 
 
Supernatants from transfected 293T cells containing pseudotyped lentiviral-
derived vectors expressing EGFP (RRL.SIN-EGFP) reporter gene were 
harvested and concentrated by ultracentrifugation. The amount of virus was 
normalized by p24 antigen levels (70ng/sample). Pellets were resuspended 
in SDS-PAGE sample buffer, subjected to 10% SDS-PAGE and 
electroblotted onto nitrocellulose membranes. Western Blot was performed 
with a rabbit polyclonal antibody against the structural protein of Sindbis 
virus and HRP-conjugated anti-rabbit IgG antibody. The polyclonal anti-
Sindbis antibody was kindly provided by Pavel Osten and Sondra 
Schlesinger 355. Western Blot analysis was also performed with HRP-
conjugated mouse monoclonal antibody directed against the p24 antigen. 
Proteins were visualized by using the ECL system (Amersham Pharmacia 
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Biotech) according to the manufacture’s instructions. 
 
4.2.7 Binding assays 
 
To analyze if soluble anti-CCR5 ST6SL and ST6LL scFv recognize and 
bind specifically to CCR5 chemokine receptor, U87-CD4.CCR5 and U87-
CD4 cells were detached by non-enzymatic treatment with cell dissociation 
buffer (GIBCO) and distributed to polypropylene tubes (1x106 cells per 
sample). After incubation with BSA for 30 min at 4ºC, cells were washed 
with PBS and preincubated for 1 hour with purified ST6LL or ST6SL 
antibody fragments. Following another washing step with PBS, cells were 
incubated with anti-HA fluorescein isothiocyanate-conjugate antibody and 
then analyzed by flow cytometry (FACS). As positive control, cells were 
stained with rabbit anti-human CCR5 antibody followed by fluoresceine-
conjugated anti-rabbit IgG. 
 
4.2.8 Competition assay 
 
To test the specificity of viral infection with scFv-Sindbis envelope, 
competition assays were performed. Briefly, U87-CD4.CCR5 cells (1x106) 
were preincubated for 1 hour with increasing amounts of purified ST6SL 
and ST6LL antibody fragments before infection. Following two washing 
steps with DMEM medium, cells preincubated with ST6SL scFv were 
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infected overnight with 1 ml of HIV-Luc∆env/Sindbis-ST6SL and cells 
preincubated with ST6LL scFv were infected overnight with 1 ml HIV-
Luc∆env/Sindbis-ST6LL. Three days postinfection, cells were lysed and the 
supernatant analyzed for luciferase activity according to the manufacturer’s 
protocol (Promega). To control the assay, U87-CD4.CCR5 cells were 
preincubated with increasing amounts of ST6LL scFv antibodies before 
infection with HIV-Luc∆env/VSV and HIV-Luc∆env/Sindbis ZZ 
pseudotyped virus. 
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4.3 Results  
   
4.3.1 Construction of Sindbis pseudotyped lentiviral vectors displaying 
anti-CCR5 single-chain antibody fragments 
 
It was previously shown by Morizono et al that the envelope of Sindbis 
virus can pseudotype lentivirus-derived vectors 208. When Sindbis envelope 
was modified to contain the Fc-binding region of protein A (ZZ domain) 
between aminoacids 71 and 74 of the E2 protein, the pseudotyped vector 
significantly enhanced its specificity when used in combination with 
monoclonal antibodies that recognize and bind to specific cell surfaces 
antigens 208.  
 
In the present work, to develop lentiviral-derived vector particles with 
specificity of gene delivery for CCR5-expressing cells, we attempted to 
design a novel Sindbis pseudotyped vector where the Sindbis E2 receptor 
binding envelope protein was modified to directly encode a single-chain 
antibody fragment (scFv) against the CCR5 chemokine receptor (Figure 
4.1A). An anti-CCR5 recombinant antibody fragment (ST6) was developed 
and characterized in detail by Carlos Barbas III and co-workers 148,220. ST6 
specifically bound to the N-terminal extracellular domain of CCR5 (amino 
acids 16-18) and was originally derived from a Fab phage display library 
148,220.  To be applied as intrabody, the ST6 Fab was previously converted to 
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a single-chain fragment in which the VL and VH fragments were covalently 
linked with a peptide linker of seven amino acids (GGSSRSS) 148. 
Expression of ST6 with this short linker was reported to result in dimeric 
scFv domains 148.  
 
Figure 4.1 (A) - Schematic illustration for cell type-specific targeting with Sindbis 
pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies. (B) - 
Schematic representation of chimeric scFv-Sindbis envelope constructions developed 
in this study. The pIntron Sindbis ZZ was kindly provided by Irvin S.Y. Chen 208. The 
Sindbis envelope encodes two transmembrane envelope proteins, E1 and E2. E3 is a leader 
sequence for E2 protein and 6K is the leader for E1. The Sindbis envelope is initially 
synthesized as a polypeptide and then cleaved by cellular proteases to produce the E3, E2, 
6K and E1 proteins 208. The pIntron Sindbis ZZ plasmid contains the cytomegalovirus 
immediate early promoter, the intron II of the rabbit β-globin, the polyadenylation signal 
and a BstEII cloning site between aminoacids 71 and 74 of the E2 glycoprotein. A scFv 
(ST6) derived from a Fab phage display library obtained from immunized rabbits, which 
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recognizes the N-terminal extracellular domain of CCR5 chemokine receptor x, was cloned 
between the BstEII sites of the expression vector of Sindbis virus envelope. The VL and 
VH fragments of ST6SL are covalently linked with a peptide of seven aminoacids 
(GGSSRSS).  The VL and VH fragments of ST6LL are covalently linked with a long linker 
of 18 aminoacids (SSGGGGSGGGGGGSSRSS). 
 
The length of linker was crucial for the association state of the scFv 
molecule, as longer linkers favor monomeric molecules and short linkers 
favor dimers 324. ScFv with long and short linkers usually have different 
binding patterns and stabilities 131,353. Consequently, the display and 
conformation of ST6 anti-CCR5 scFv with short and long linkers on the 
Sindbis envelope can be different and influence the specificity of binding to 
the chemokine receptor. Therefore, to avoid conformation constraints we 
also constructed the ST6 scFv with a long peptide linker of 18 aminoacids 
(SSGGGGSGGGGGGSSRSS). To allow cell specific targeting, we 
modified the Sindbis envelope by inserting the anti-CCR5 ST6SL and 
ST6LL scFv into the Fc-binding domain (ZZ) between aminoacids 71 and 
74 of the E2 glycoprotein (Fig 4.1.B). The rationale for these two constructs 
was to determine whether the length of the linker influences the display of 
chimeric single-chain Sindbis envelope and/or infectivity of respective viral 
particles.  
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4.3.2 Production and incorporation of chimeric scFv-Sindbis envelope 
proteins into lentiviral particles  
 
To demonstrate that chimeric Sindbis-ST6SL and Sindbis-ST6LL envelope 
glycoproteins was successfully incorporated into the lentiviral-derived 
vector, immunoblot analysis was performed for each construct with a 
polyclonal antibody against the structural proteins of Sindbis virus 355. 
Briefly, 293T cells were transfected with pRRL.SIN-EGFP, pCMVR8.9 and 
pIntron Sindbis-ST6SL, pIntron Sindbis-ST6LL, pIntron Sindbis ZZ or 
pVSV. At 48 hours post-transfection, pseudotyped virions were harvested 
and concentrated by ultracentrifugation. The viral amount was normalized 
by p24 antigen levels (70 ng/sample) and pellets were analyzed by Western-
blot. As shown in Figure 4.2, the chimeric scFv-envelope glycoproteins 
showed a band near 97 kDa, confirming the expected size of E2 fused to 
anti-CCR5 scFv domain. The HIVEGFP/Sindbis ZZ virions showed a lower 
molecular weight band near 66 kDa which is the estimated molecular mass 
of the Sindbis ZZ chimeric glycoprotein. These results demonstrate that the 
chimeric scFv-Sindbis envelope proteins can be expressed, processed and 
incorporated into lentiviral-derived vectors.  
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Figure 4.2 - Detection of lentiviral particles pseudotyped with chimeric scFv-Sindbis 
envelope proteins. Supernatants from transiently transfected 293T cells were collected, 
ultracentrifuged and normalized for p24 antigen (70 ng/sample). Pellets were resuspended 
in SDS-PAGE sample buffer, subjected to 10% SDS-PAGE and electroblotted onto 
nitrocellulose membranes as described in Material and Methods. Western Blot was 
performed with rabbit polyclonal anti-Sindbis antibody and HRP-conjugated anti-rabbit 
IgG antibody. Western Blot analysis was also done with HRP-conjugated mouse 
monoclonal antibody directed against the p24 antigen. The molecular weight is shown in 
kDa.  
 
4.3.4 Targeting chimeric scFv-Sindbis pseudotyped lentiviral vectors to 
CCR5-expressing cells 
 
Three sets of experiments were performed to test the specificity of infection. 
First, the efficiency of cell targeting was analyzed with U87-CD4 and U87-
CD4.CCR5 cells by luciferase expression. U87-CD4.CCR5 is a U87-CD4 
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cell line expressing the CCR5 chemokine receptor (AIDS Research and 
Reference Reagent Program). Pseudotyped viral particles HIV-Luc∆env 
containing each of the chimeric envelope proteins (VSV, Sindbis ZZ, 
Sindbis-ST6SL or Sindbis-ST6LL) were incubated with target cells, and the 
efficiency of targeting of each construct were analyzed by luciferase 
activity. The results shown in Figure 4.3 represented the percentages of 
infection relative to the value obtained for the pseudotyped HIV-
Luc∆env/VSV vector. The HIV-Luc ∆env/Sindbis-ST6SL and HIV-
Luc∆env/Sindbis-ST6LL viral particles specifically infected U87-CD4 cells 
expressing the CCR5 chemokine receptor (Figure 4.3), but did not infect 
non-CCR5 expressing U87-CD4 cells. In contrast, the pseudotyped HIV-
Luc∆env vector displaying the Sindbis ZZ chimeric envelope was unable to 
infect CCR5-expressing cells at detectable levels. These results 
demonstrated that pseudotyped lentiviral-derived particles with Sindbis 
envelope containing anti-CCR5 scFv specifically infect CCR5-expressing 
cells. However, as the data in Figure 4.3 shows, the targeting of HIV-
Luc∆env/Sindbis-ST6SL to U87-CD4.CCR5 cells (14%) was lower than the 
HIV-Luc∆env/Sindbis-ST6LL (52%). Pseudotyped vectors were also used 
to infect other CCR5-expressing cell lines like P4R5 cells (AIDS Research 
and Reference Reagent Program). The infection efficiency of HIV-
Luc∆env/Sindbis-ST6SL and HIV-Luc∆env/Sindbis-ST6LL to P4 cell line 
expressing the CCR5 chemokine were similar to those obtained with U87-
CD4.CCR5 cells (data not shown). Therefore, these preliminary results 
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indicated that the linker length between the VH and VL domains may have a 
significant influence on the efficiency but not specificity of infection.  
 
 
Figure 4. 3 - Targeting of scFv-Sindbis pseudotyped lentiviral particles to U87-CD4, 
U87-CD4.CCR5. Supernatants of HIV-Luc∆env containing each of the chimeric envelope 
proteins (VSV, Sindbis ZZ, Sindbis-ST6SL or Sindbis-ST6LL) from producer cells were 
normalized for p24 antigen (300 pg/ml) and incubated overnight with the target cell line 
(1x106 cells), as described in Material and Methods. Efficiency of targeting for each 
pseudotyped vector was analyzed for luciferase activity 72 hours after infection according 
to the manufacturer's protocol (Promega). Values shown represent the percentages of 
infection relative to the value obtained for the pseudotyped VSV lentiviral vector. U87-
CD4.CCR5 is a U87-CD4 cell line expressing the CCR5 chemokine receptor (AIDS 
Research and Reference Reagent Program). As shown luciferase activity is only detected in 
CCR5-expressing cells infected with ST6SL and ST6LL chimeric Sindbis envelope virus. 
Data represents the results of two independent experiments. 
 
  Cell specific lentiviral targeting by scFv 
 
 
 
 
 
 
 
 
 
164
To quantify the efficiency of lentiviral targeting, U87-CD4.CCR5 and U87-
CD4 cells were transduced with the lentiviral-derived vector, pRRL.SIN-
EGFP. This vector has the enhanced green fluorescent protein (EGFP) as 
the reporter gene that allows detection and enumeration of transduced cells 
by flow cytometry 191,198,354. Therefore, specificity of gene delivery was 
quantified by FACS analysis for EGFP expression 96 hours after infection 
with pseudotyped lentiviral-derived vectors. As shown in Figure 4.4, 
HIVEGFP/Sindbis-ST6SL and HIVEGFP/Sindbis-ST6LL specifically 
infected CCR5-expressing cells. In contrast, no transduction was observed 
when U87-CD4.CCR5 was infected with pseudotyped HIVEGFP/Sindbis 
ZZ viral particles. Background levels of EGFP expression were detected in 
U87-CD4 cells transduced with these viruses. Virus titers in U87-
CD4.CCR5 were 3.4×105 EGFP transduction units/ml to 
HIVEGFP/Sindbis-ST6SL and 7.2×105 EGFP transduction units/ml to 
HIVEGFP/Sindbis-ST6LL. Consistent with our previous experiments, these 
results showed that targeting of CCR5-expressing cells was dependent of 
anti-CCR5 single-chain antibody display on Sindbis envelope. However, as 
indicated in Figure 4.4, the transduction levels obtained with Sindbis 
envelope displaying the ST6 with a longer linker (72%) was higher than that 
with Sindbis displaying the ST6 with the short linker (34%). 
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Figure 4.4 - High titers of scFv-Sindbis pseudotyped lentiviral particles are able to 
transduce CCR5-expressing cells. Lentiviral-derived vectors (1 ml) expressing EGFP and 
pseudotyped with VSV, Sindbis ZZ, Sindbis-ST6SL and Sindbis-ST6LL envelopes were 
normalized for p24 antigen (300 pg/ml) and incubated overnight with U87-CD4 cells and 
U87-CD4.CCR5 cells (1x106), as described in Materials and Methods. Four days after 
infection, cells were stained with rabbit anti-human CCR5 antibody plus rhodamine-
conjugated anti-rabbit IgG. Cells were analyzed for CCR5 staining and EGFP expression 
by flow cytometry. The viral titer was calculated according to the formula: transducing 
units (TU)/ml = number of cells counted before infection × percentage of transduced cells 
reported from flow cytometry analysis/ volume (ml) of viral supernatants. The percentage 
of transduced cells was calculated as the number of events in the upper right panel divided 
by the total number of events in the right and left upper panels. The titers obtained were 
3.4×105 EGFP transduction units/ml to HIVEGFP/Sindbis-ST6SL and 7.2×105 EGFP 
transduction units/ml to HIVEGFP/Sindbis-ST6LL. Data are representation of two 
independent experiments. 
 
Other groups and ours have reported that scFv with longer and short linkers 
usually lead to different antigen-binding properties and protein stabilities 
131,353. Therefore, to examine if ST6SL and ST6LL antibody fragments 
recognize and bind to CCR5 chemokine expressed at cell surface, a binding 
assay with purified soluble anti-CCR5 antibody fragments was performed. 
Briefly, U87-CD4 and U87-CD4.CCR5 cells were detached from flasks, 
blocked and incubated with purified ST6SL and ST6LL antibody fragments. 
Following a washing step, cells were incubated with anti-HA fluorescein 
isothiocyanate-conjugated antibody and analyzed by flow cytometry. The 
results shown in Figure 4.5, demonstrated that both anti-CCR5 scFv were 
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able to recognize CCR5 chemokine receptor at similar levels. The 
fluorescence intensities observed with each single-chain antibody fragment 
was comparable to those seen when an IgG anti-CCR5 was used as a CCR5-
specific probe (Figure 4.5). In contrast, no binding was detected when anti-
CCR5 scFv were used with U87-CD4 cells. These results suggested that 
soluble ST6SL and ST6LL have similar specificity for binding to CCR5-
expressing cells and do not shown influence of increased avidity of ST6SL. 
Although these experiments cannot rigorously establish a precise 
mechanism why Sindbis-ST6LL pseudotyped lentiviral derived vectors have 
higher titers, the most likely explanation was that the ST6LL scFv fused into 
the E2 protein of Sindbis envelope is able to undergo an optimal 
conformational for VH-VL paratopes interaction allowing superior binding 
to the native CCR5 chemokine receptor. 
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Figure 4.5 - Purified Anti-CCR5 scFv binds specifically to CCR5-expressing cells. 
U87-CD4.CCR5 and U87-CD4 cells (1x106 cells per sample) were incubate with soluble 
ST6LL or ST6SL purified antibody fragments. Following a washing step, cells were stained 
with anti-HA fluorescein isothiocyanate-conjugate antibody and analyzed by flow 
cytometry (FACS), as described in Material and Methods. As positive control for CCR5 
expression, cells were stained with rabbit anti-human CCR5 antibody followed by 
fluoresceine-conjugated anti-rabbit IgG. Data represents the results of two independent 
experiments. 
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As alphavirus vectors have been shown to infect cells from different species 
in vitro, the extent of infection of human cells for which Sindbis viruses 
have tropism requires further investigation with chimeric scFv-Sindbis 
lentivirus vectors 356,357. To assess the ability of Sindbis ZZ, Sindbis-ST6SL 
and Sindbis-ST6LL to mediate viral transduction to 293T cells, pseudotyped 
lentiviral vectors expressing EGFP were used and infection levels were 
evaluated. As shown in Figure 4.6, pseudotyped HIVEGFP viral particles 
containing each of the chimeric envelope proteins (Sindbis ZZ, Sindbis-
ST6SL or Sindbis-ST6LL) were unable to infect 293T cells at detectable 
levels. In contrast, when 293T cells were infected with VSV-pseudotyped 
lentiviral vector, 72% of cells were trasnduced. These results were 
consistent with those of Morizono et al., where a reduced infectivity was 
observed with Sindbis lentiviral vector 208. Therefore, this data suggest that 
lentiviral vectors pseudotyped with chimeric-Sindbis envelope are unable to 
target cells for which Sindbis virus have tropism. 
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Figure 4.6 - Targeting of pseudotyped lentiviral particles to 293T. Lentiviral-derived 
vectors (1 ml) expressing EGFP and pseudotyped with VSV, Sindbis ZZ, Sindbis-ST6SL or 
Sindbis-ST6LL envelopes were normalized for p24 levels (300 pg/ml) and incubated 
overnight with 293T cells (1x106), as described in Materials and Methods. Four days after 
infection, viral infectivity was evaluated by flow cytometry (FACS), as described in 
Materials and Methods. As shown, lentiviral infection in 293T cells was only observed with 
VSV pseudotyped vectors. 
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4.4.5 Specificity viral infection with chimeric scFv-Sindbis envelope 
  
To validate if the specificity of infection with scFv-Sindbis pseudotyped 
lentiviral vectors was mediated by the display of anti-CCR5 single-chain 
antibody fragments, competition experiments were performed with purified 
ST6SL and ST6LL scFv. We hypothesized that the addition of increasing 
amounts of anti-CCR5 scFv to the target cells would block the CCR5 
chemokine receptor, preventing viral infection. Briefly, U87-CD4.CCR5 
cells were preincubated before infection with increasing amounts of purified 
ST6SL or ST6LL antibody fragments. Following a washing step, cells 
preincubated with ST6SL scFv were infected with HIV-Luc∆env/Sindbis-
ST6SL and cells preincubated with ST6LL scFv were infected with HIV-
Luc∆env/Sindbis-ST6LL. As a control, cells preincubated with ST6LL 
antibody fragments were also infected with HIV-Luc∆env/VSV and HIV-
Luc∆env/Sindbis ZZ vectors. Three days postinfection, cells were lysed and 
luciferase activity was determined. The results shown in Figure 4.6 
demonstrate that increasing amounts of anti-CCR5 scFv added to the CCR5-
expressing cells before infection blocked infectivity of HIV-
Luc∆env/Sindbis-ST6SL and HIV-Luc∆env/Sindbis-ST6LL, respectively 
(Figure 4.7). No inhibition of infection was observed when those cells were 
preincubated with similar amounts of an irrelevant scFv (anti-Vif scFv) 
(data not shown). In contrast, no infection was observed when U87-CD4 
cells were preincubated with similar amounts of ST6SL or ST6LL scFv, 
  Cell specific lentiviral targeting by scFv 
 
 
 
 
 
 
 
 
 
172
reflecting the absence of target molecule for pseudotyped lentivirus (data 
not shown). As shown in Figure 4.7 the addition of ST6LL to U87-
CD4.CCR5 cells in any concentration did not inhibit infectivity of HIV-
Luc∆env/VSV. The data showed that blocking of viral infectivity was 
mediated by antibody-specific inhibitory effects. Therefore, the specific 
targeting of CCR5-expressing cells by chimeric scFv-Sindbis pseudotyped 
lentiviral vectors were mediated by the anti-CCR5 scFv display. 
 
Figure 4.7 - Competition assay shows the specificity of infection with Sindbis 
pseudotyped lentiviral particles displaying anti-CCR5 single-chain antibody 
fragments. U87-CD4.CCR5 cells (1x106) were preincubated with increasing amounts 
(µg/ml) of purified ST6SL and ST6LL antibody fragments before infection. Cells 
preincubated with ST6SL scFv were infected with HIV-Luc∆env/Sindbis-ST6SL and cells 
preincubated with ST6LL were infected with HIV-Luc∆env/Sindbis-ST6LL. Virus was 
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normalized for p24 antigen (300 pg/ml). Three days postinfection, cells were lysed and 
analyzed for luciferase activity according to the manufacture’s protocol (Promega). As a 
control, cells preincubated with increasing amounts of ST6LL antibodies were also infected 
with HIV-Luc∆env/VSV and HIV-Luc∆env/Sindbis ZZ pseudotyped vectors. Percentage of 
infectivity was calculated as the level of luciferase activity relative to the value obtained for 
pseudotyped VSV vector. As shown, viral infection with pseudotyped Sindbis envelope is 
inhibited by increasing concentrations of ST6SL and ST6LL scFv. No effect was observed 
with VSV pseudotyped vectors.  
 
4.4.6 Targeting of pseudotyped lentiviral vectors displaying anti-CCR5 
chimeric scFv-Sindbis envelope to primary lymphocytes   
 
To demonstrate that chimeric scFv-Sindbis pseudotyped lentiviral-derived 
vectors can specifically target a subpopulation of CCR5-positive cells, 
primary blood mononuclear cells (PBMC) were used. As PBMC consist of 
both CCR5-negative and CCR5-positive cell populations, this assay is 
optimal for testing our approach for targeting gene delivery. Briefly, 
stimulated PBMC cells (1x106) were transduced overnight with 
pseudotyped lentiviral-derived vectors expressing the EGFP reporter gene, 
as described in Materials and Methods. Four days after transduction, cells 
were stained with rabbit anti-human CCR5 antibody plus rhodamine 
conjugated anti-rabbit IgG. Cells were then analyzed for CCR5 staining and 
EGFP expression by flow cytometry (FACS). As the data in Figure 4.8 
demonstrate, the lentiviral vector that contains the VSV envelope 
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transduced both CCR5-negative and CCR5-positive cell populations with an 
efficiency of 40.6%. In contrast, lentiviral vectors pseudotyped with 
chimeric scFv-Sindbis resulted in a preferential infection of the CCR5-
positive cell population of PBMC. As expected, the level of transduction for 
the total of cells obtained with Sindbis envelope displaying the ST6LL 
(1.9%) was higher than that with SindbisST6SL (0.5%). As a control, the 
lentiviral-derived vector containing the Sindbis ZZ envelope was unable to 
infect either CCR5-negative or CCR5-positive cells. As a comparison, with 
VSV pseudotyped lentivirus the transduction levels obtained in CCR5-
positive cells with chimeric Sindbis-ST6LL envelope vectors were in 
average 48.7% of that of the amphotropic envelope lentivirus. This 
transduction efficiency was similar to that obtained with U87-CD4.CCR5 
cells. Therefore, these results indicated that lentiviral-derived pseudotyped 
with Sindbis envelope glycoproteins containing a single-chain antibody 
fragment (scFv) against CCR5 chemokine receptor can specifically target a 
CCR5-expressing primary population of cells.  
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Figure 4.8. ScFv-Sindbis envelope mediates gene transduction of a heterogenous 
primary cell population by a lentiviral-derived vector. Primary blood mononuclear cells 
(PBMC) (1x106 cells) were transduced overnight with pseudotyped lentiviral-derived 
vectors (1 ml) expressing EGFP, and normalized for p24 antigen as described in Material 
and Methods. The titers used for transduction were 3.4×105 EGFP transduction units/ml to 
HIVEGFP/Sindbis-ST6SL and 7.2×105 EGFP transduction units/ml to HIVEGFP/Sindbis-
ST6LL. Four days after infection, cells were stained with rabbit anti-human CCR5 antibody 
plus rhodamine-conjugated anti-rabbit IgG and analyzed for CCR5 staining and EGFP 
expression by flow cytometry (FACS). The percentage of EGFP-positive cells (viral 
transduction) in the CCR5 positive population was calculated as the number of events in the 
upper right quadrant divided by the total number of events in the four quadrants. The 
percentage of EGFP-positive cells was calculated by dividing the number of events in the 
lower right quadrant by the total number of events in all quadrants.  
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4.4 Discussion  
 
 A number of potential gene therapy strategies have been identified in the 
past few years. These strategies include intracellular antibodies, dominant 
negative viral proteins, intrakines, suicide genes, ribozymes, RNA decoys, 
antisense messenger RNAs and small interfering RNA (siRNA) molecules 
121,131,358. They represent the most rapidly developing areas in pre-clinical 
research. Lentiviral vectors are among the most efficient tools for gene 
delivery into mammalian cells 206. Nevertheless, some problems need to be 
solved before this approach becomes routinely adopted in clinic. Two of the 
most important problems of lentiviral gene delivery systems are the lack of 
selectivity of the existing vectors to the target cells and the low efficiency of 
gene transfer.  
 
Recently, many properties of alphavirus vectors have made them a desirable 
alternative to lentiviral vectors 362. Alphavirus can be produced at very high 
titers, show high levels of expression and, unlike retroviruses, the fusogenic 
protein can fuse to cells independently of the receptor binding protein 
208,346,362. However, as a lytic RNA virus, these vectors are not suitable for 
applications requiring stable transduction 208. Within this context, Morizono 
et al reported an approach to improve lentiviral targeting and viral titer by 
exploring some properties of the Sindbis virus envelope 208. In that work a 
Sindbis envelope pseudotyped lentiviral vector displaying the Fc-binding 
domain of protein A (ZZ domain) was constructed. When used in 
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combination with monoclonal antibodies to a specific cell surface antigen, 
the chimeric envelope provides enrichment in terms of specificity of 
infection and viral titers were relatively high and stable. Theorically this 
approach is applicable to any cellular membrane-receptor domain for which 
specific monoclonal antibodies are available. However, chimeric Sindbis-
ZZ pseudotyped lentiviral-derived vectors may not be a suitable strategy for 
in vivo applications where plasma antibodies are present. As monoclonal 
antibodies are not covalently linked to the Sindbis envelope, a percentage of 
free-ZZ domains will be available to bind autologous antibodies, resulting in 
non-specific transduction by the lentiviral vector. Furthermore, some level 
of in vivo competition may be envisioned between plasma antibodies and 
recombinant monoclonal antibodies used to target the ZZ-domain. Given 
these considerations there is a higher probability for the chimeric ZZ-
Sindbis envelope to non-specifically target other cellular receptors or reduce 
the transduction efficiency for the target cell. Therefore, to overcome these 
questions, we attempted to develop a novel pseudotyped lentiviral-derived 
vector where the Sindbis virus E2 protein was modified to directly encode a 
single-chain antibody fragment (scFv) against the CCR5 chemokine 
receptor. The results presented in this report demonstrate that Sindbis 
pseudotyped vectors that display single-chain antibody fragments against a 
cell surface receptor are competent for infection. As shown chimeric-
Sindbis envelope glycoproteins are expressed at virus surface reflecting a 
good incorporation. We also show that specific targeting into CCR5-
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expressing cells was mediated by the anti-CCR5 scFv display and viral titers 
were close to 106 EGFP transduction units/ml. The two chimeric scFv-
Sindbis pseudotyped viral particles could be produced at relatively high 
titers. However, our data indicate that infection levels obtained with Sindbis 
envelope displaying the ST6 with a longer linker was consistently higher 
than that with Sindbis envelope displaying the ST6 with a short linker. 
Although the precise mechanism for the high infectivity level of Sindbis-
ST6LL pseudotyped lentiviral-derived vectors was not determined, it is 
reasonable to assume that ST6LL scFv fused into the E2 protein of Sindbis 
envelope is able to undergo a conformational change that allows a better 
binding to the CCR5 receptor and, consequently, promote an increase in 
infectivity. An optimal interaction of VH and VL promoted by a flexible 
long linker may bring together the paratopes involved in CCR5 recognition 
359. Therefore, the affinity of the scFv for the receptor will be higher if both 
domains are closely localized in space. We hypothesize that a short-linker 
puts apart VH and VL domains reducing antibody affinity for the antigen 
and consequently the viral infectivity. It will be interesting in the future to 
see whether other aminoacid linkers will render chimeric scFv-Sindbis more 
effective for specific viral delivery. Besides the linker length, other 
variables may be envisioned to interfere with an optimal transduction by this 
strategy. An efficient expression and folding of the chimeric scFv-Sindbis 
envelope at virus surface are indispensable for the success of this strategy. 
In our case, ST6 was previously developed and optimized for CCR5 
recognition in eukaryotic cells 148,220. Therefore, an optimal expression and 
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folding of the scFv in mammalian cells will be essential for not disturbing 
the backbone of Sindbis envelope and the antigen-antibody interactions, 
which will be essential for an effective viral transduction. In addition, an 
improved expression and folding of scFv-Sindbis envelope would also 
facilitate incorporation into lentiviral particles improving the viral titers. 
Furthermore, the recognition epitope on a membrane antigen by the scFv 
must be localized in a protein domain that can result in a strong binding 
affinity. This will be important since differences in viral infectivities may 
result from different binding affinities of the scFv to the antigen. 
 
In conclusion, we show that the region between aminoacids 71 and 74 of E2 
can tolerate the insertion of single-chain antibody fragments. Thus, it should 
be possible to test whether other single-chain antibody fragments displayed 
on Sindbis envelope can be used for the development of a large variety of 
cell specific gene delivery vectors. This strategy once optimized may be 
considered for research purposes, like the identification of specific cellular 
receptors. Therefore, the present study can be considered a model strategy 
for specific viral gene delivery mediated by Sindbis envelope that displays 
single-chain antibody fragments recognizing specific cellular surface 
proteins. Furthermore, this strategy has the potential to become a powerful 
approach for targeting gene delivery in anti-HIV gene therapy due to the 
important role of CCR5 expression in disease progression.  
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5. General Conclusions and Future Perspectives 
Controlling HIV infection continues to be a major challenge in both 
underdeveloped and developed nations. Although the drug cocktails used in 
HAART have markedly changed the profile of progression to AIDS in HIV-
infected individuals, drug failures continue to occur as a consequence of 
viral resistance and other complications arising from a lifelong regimen of 
chemotherapy. As a result, there is an urgent need to identify and develop 
new drugs that can be effective against these highly resistant virus isolates. 
The importance of developing new antiretroviral drugs cannot be overstated. 
However, that HAART is lifelong and may be associated with cumulative 
toxicities underscores the need for new approaches. Given the increasing 
knowledge of mechanisms that allow control of HIV infection, several 
investigators are focusing their attention on gene therapy, either as a stand-
alone approach or as a supplement to pharmacological regimens. The 
specificity and affinity that can be obtained in intrabodies make these 
molecules effective modulators of viral or cellular targets. The binding of an 
intrabody to an intracellular target protein has the potential to block, 
suppress, alter or even enhance the process mediated by that molecule. 
Compared to other gene manipulation methods, such as gene knock-out or 
RNA-based technologies (ribozyme, antisense RNA or RNAi), intrabodies 
have the unique advantage of targeting proteins in different cellular 
compartments. Moreover, genes that have very high mRNA-turnover rates 
are very difficult to target effectively with RNAi, whereas intrabodies, 
which interact with the proteins directly, are unlikely to be affected by target 
dynamics. Because intrabodies act at the protein level, they will be of value 
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to map protein–protein interactions and model drug–target interactions. 
There is also the intriguing possibility of specifically blocking one function 
of a multi-epitope target by intrabody binding, while leaving intact the 
remaining functions or interactions of other domains on that target. Within 
this context, intracellular antibodies provide a powerful research tool that 
could potentially have many applications in the field of therapeutic 
molecules for gene therapy.  The strong inhibiting potential of intracellular 
antibodies in the context of HIV gene therapy was the focus of this 
dissertation thesis. 
In Chapter 1, we presented a general introduction to HIV-1 virus biology 
and HIV/AIDS treatment and describe in detail the intracellular 
immunization (intrabodies) approach and how it can be explored to 
neutralize the HIV-1 infection.  
In Chapter 2, we have explored the intracellular immunization approach by 
developing rabbit intrabodies to the HIV-1 IN protein. We choose the IN as 
a potential therapeutic target for our intracellular immunization strategy 
since IN is absolutely required for a stable and productive infection by HIV-
1. IN catalyzes the integration of viral cDNA into the host chromosome and 
it is highly conserved among HIV-1 clinical isolates. In addition, the 
reactions catalyzed by IN are unique and no human homologue known of IN 
exists. We identified five new IN-specific scFv antibodies derived from a 
rabbit immunized combinatorial scFv Phage-Library. Moreover, we 
demonstrated that these scFv were able to bind simultaneously to the 
catalytic and C-terminus domains of IN and block the strand transfer 
reaction. The identified scFv fragments constitute the first set of anti-IN 
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antibodies that show such epitope binding characteristics. We believe that 
combinatorial scFv libraries can be extremely effective to identify 
intrabodies that can bind simultaneously to different epitope regions, as well 
reaching targets not easily accessible by conventional antibodies molecules 
(e.g. small pockets or canyons in viral and infectious disease biomarkers). 
The results presented also demonstrate that intracellular expression of scFv 
which bind strongly to the catalytic and C-terminal domains results in 
resistance to productive HIV-1 infection. This inhibition of HIV-1 
replication was observed with scFv localized in either the cytoplasmic or 
nuclear compartment of the cell. The expression of our anti-IN scFv was 
shown to specifically neutralize the IN activity prior to integration and, thus 
it, appears to have an effect on the integration process itself. Further studies 
are in progress with real time PCR analysis to study in more detail where 
our intrabodies are interfering in the establishment of the provirus.                
The results presented in this Chapter also demonstrated that anti-IN 
intrabodies were able to be incorporated into the viral particles which reduce 
the RT activity and viral infectivity of virions. We believe that this effect is 
mainly due to the inhibition of the function of the intravirion IN. However, 
further studies are in progress to better understand why our intrabodies can 
block the viral replication during late stages. In summary, the results 
presented in Chapter 2 showed that combinatorial rabbit scFv phage-
libraries can be efficiently used to identify scFv with new epitope binding 
characteristics. Moreover, the data presented here provide proof-in-principle 
that rabbit anti-IN intrabodies can be designed to block early and late stages 
of HIV-1 replication and be used as new tools to study the structure and 
function of HIV-1 IN due to their epitope binding characteristics. 
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In Chapter 3, we showed for the first time that rabbit VL single-domains 
have also an enormous value as intracellular antigen recognition units. As 
already mentioned, the strong inhibiting potential of several VH and VHH 
intrabodies has been demonstrated in the field of cancer, HIV autoimmune 
and neurodegenerative diseases. In contrast, the VL-domain has not been 
extensively studied as an independent source for intrabodies construction. 
To our knowledge, the work developed by Colby et al is the only study that 
reports the construction of a human VL single-domain as an intrabody 135. 
Within this context, we evaluated the potential of rabbit VL single-domains 
as intrabodies in Chapter 3. The VL scaffold study presented here was 
derived from an anti-Vif scFv that was recently developed from immunized 
rabbits to HIV-1 Vif protein and inhibited viral replication. The results 
obtained demonstrated that the anti-Vif VL single-domain preserve the 
antigen-binding activity and specificity in the absence of the parent VH 
domain. In addition, the VL domain was independently folded, stable, 
highly soluble, monomeric, and expressed at high levels in bacteria. The 
expression in eukaryotic cells also showed that the rabbit VL single-domain 
was correctly folded as soluble protein in the reducing environment and 
could strongly neutralize HIV-1 infectivity. Thus, the VL intrabody was 
shown to be extremely robust in the absence of the parent VH domain and 
without any process of protein engineering. Further studies are in progress 
to use the anti-Vif VL scaffold to construct a large and highly diversified 
phage-displayed synthetic VL library. This library might be a valuable 
source of antibodies targeting size-restricted epitopes and antigens in 
obstructed locations where efficient penetration could be critical for 
successful treatment. In Chapter 3, we have also shown that the CAT-fusion 
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system differentiate soluble from insoluble intrabodies when expressed 
under reducing conditions. Future studies are also in progress to evaluate if 
this system can be a potentially useful approach for direct in vivo screening 
of soluble and stable intrabodies. 
 
 
Using HIV-1 as an example, we demonstrate in Chapter 2 and 3 the broad 
versatility of intrabodies to inhibit different stages of the viral life cycle by 
targeting the IN and the Vif protein of the virus. However, several potential 
problems may limit the use of intrabodies in the clinical setting for the 
treatment of HIV-1 and AIDS. One problem that is shared with some of the 
gene-based therapies is the immunogenicity that the intrabody could elicit. 
As previously demonstrated, rabbit antibodies can be converted to 
humanized antibodies that retain both high specificity and affinity for the 
antigen 220. Therefore, the use of humanized antibodies from immunized rabbits 
should minimize the issue of immune recognition, but this will have to be 
determined in a human clinical trial. A second potential problem is the 
development of HIV-1 escape mutants, previously mentioned. A way to 
minimize the development of HIV-1 escape mutants would be to choose 
conserved epitopes needed for virus survival or to have an intrabody that 
could bind simultaneously to more than one epitope in the target antigen. 
Since, our anti-IN scFv intrabodies binds simultaneously to three epitope 
regions in the IN protein, the development of HIV-1 escape mutants should 
be minimized. An alternative approach is the use of combination targets, 
two intrabodies targeting different target/stages of the viral life cycle. For 
example, a bicistronic expression vector, capable of expressing two different 
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genes simultaneously, would allow different combinations of intrabodies to 
be tested for their combined or synergistic inhibition of HIV-1 replication. 
In our case, escape mutants should be minimized if a vector that could 
express simultaneously anti-IN and anti-Vif intrabodies is used. A third 
problem, also shared with other gene-based therapies, is the efficiency of 
gene delivery. The development of a gene-transfer system capable of 
delivering the intrabody gene into a sufficient number of a specific cell type 
is needed. Currently, lentivirus vectors are the main gene delivery tool used 
to obtain high transduction efficiency and long-term expression of 
intrabodies. However, one of the main challenges faced by lentiviral gene 
delivery systems is the development of vectors that can efficiently target specific 
cell types. 
 
In Chapter 4, we presented a study to generate lentiviral-derived particles 
with specificity of gene delivery for CCR5-expressing cells. For this 
purpose, we developed a novel Sindbis pseudotyped lentiviral vector where 
the Sindbis receptor binding envelope protein was modified to directly 
encode a scFv against the CCR5 chemokine receptor. Targeting into specific 
cells was mediated by the anti-CCR5 scFv display and viral titers were close 
to 106 EGFP transduction units/ml. Our data demonstrate that the length of 
the peptide linker that connects the heavy chain and light chain of anti-
CCR5 scFv significantly affects the efficiency of infection. Infection levels 
obtained with Sindbis envelope displaying a scFv with a longer linker were 
consistently higher than that with Sindbis envelope displaying a scFv with a 
short linker. The present study can be a model strategy for specific gene 
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delivery mediated by lentiviral vectors pseudotyped with Sindbis envelope 
displaying scFv that recognize specific cellular surface proteins.  
 
In conclusion, the results from this thesis provide proof-in-principle that 
rabbit anti-IN and anti-Vif intrabodies may be potentially useful agents for 
HIV-1 gene therapy approaches. Furthermore, we also show that the gene 
delivery strategy presented herein has the potential to become a powerful 
approach for targeting gene delivery in anti-HIV gene therapy due to the 
important role of CCR5 expression in disease progression.  Furthermore, 
using HIV-1 as an infection model, the intracellular immunization 
technology may also be applied to many other suitable infectious diseases. 
Such opportunities can be usefully expanded to other viral infections such as 
HIV-2, herpes and hepatitis group viruses. It seems certain that within the 
next decade gene therapy for both the treatment and prevention of infectious 
diseases will be an encouraging much needed alternative therapy. 
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